Yago L. Nieto, M.D., Ph.D

Peer-Reviewed Articles

1. Marcoux, C, Milton, D, Tanner, MR, Bashir, Q, Srour, S, Saini, N, Lin, P, Patel, A, Khan, HN, Ramdial, JL, Nieto, Y, Tang, G, Haider, A, Aljawai, YM, Kebriaei, P, Lee, HC, Ye, JC, Patel, K, Thomas, SK, Orlowski, R, Champlin, RE, Shpall, E, Qazilbash, MH, Pasvolsky, O. Outcomes of Patients With Multiple Myeloma With deletion 1p Following Autologous Stem Cell Transplant. Transplantation and Cellular Therapy 31(10):804.e1-804.e9, 2025. e-Pub 2025. PMID: 40752590.
2. Gauthier, J, Ahn, KW, Patel, J, Lian, Q, Badawy, SM, Cairo, MS, Delgado, J, Grover, NS, Haverkos, B, De Lima, M, Malone, AK, Mussetti, A, Nieto, Y, Pawarode, A, Pearson, LK, Solh, MM, Sureda, A, Tun, AM, Wudhikarn, K, Yamshon, S, Shadman, M, Turtle, CJ, Hamadani, M, Herrera, AF. CD19 CAR T-Cell Therapy for Primary Mediastinal Large B-Cell Lymphoma. American journal of hematology 100(10):1792-1802, 2025. e-Pub 2025. PMID: 40785644.
3. Nieto Y, Rezvani K. Harnessing engineered NK cells for refractory CD30+ lymphoma. Mol Ther 33(7):2981-2983, 2025. e-Pub 2025. PMID: 40562028.
4. Kawedia JD, Handy VW, Myers AL, Gulbis AM, Mehta R, Champlin RE, Shpall EJ, Nieto Y, Andersson BS, Popat UR. Seizure Prophylaxis and its Impact on Busulfan Pharmacokinetics and Dosing in a Novel Timed Sequential Protocol: MD Anderson Experience. Transplant Cell Ther 31(9):709.e1-709.e10, 2025. e-Pub 2025. PMID: 40514011.
5. Pasvolsky, O, Abid, MB, Milton, D, Tanner, MR, Bashir, Q, Srour, S, Saini, N, Jatoi, A, Khan, HN, Lin, P, Ramdial, JL, Nieto, Y, Tang, G, Siddiqui, U, Aljawai, YM, Kebriaei, P, Lee, HC, Patel, K, Gaballa, MM, Thomas, SK, Orlowski, R, Champlin, RE, Shpall, E, Qazilbash, MH. Outcomes of patients with multiple myeloma undergoing autologous transplant with suboptimal pretransplant response. British Journal of Haematology 206(6):1730-1736, 2025. e-Pub 2025. PMID: 40159289.
6. Nieto Y, Banerjee P, Kaur I, Basar R, Li Y, Daher M, Rafei H, Kerbauy LN, Kaplan M, Marin D, Griffin L, Barnett M, Bassett R, Uprety N, Shrestha R, Silva FR, Islam S, Ganesh C, Borneo Z, Ramdial J, Ramirez A, Hosing C, Alousi A, Popat U, Qazilbash M, Ahmed S, Iyer S, Sainz TP, Vega F, Fowlkes NW, Alexis K, Emig M, Harstrick A, Overesch A, Shpall EJ, Rezvani K. Allogeneic NK cells with a bispecific innate cell engager in refractory relapsed lymphoma: a phase 1 trial. Nat Med 31(6):1987-1993, 2025. e-Pub 2025. PMID: 40186077.
7. Pasvolsky O, Marcoux C, Milton DR, Rafaeli N, Tanner MR, Bashir Q, Srour S, Saini N, Lin P, Ramdial J, Nieto Y, Tang G, Mohamedi AH, Deen AF, Aljawai Y, Lee HC, Patel KK, Becnel MR, Kebriaei P, Thomas SK, Orlowski RZ, Champlin R, Shpall EJ, Qazilbash MH. Outcomes of Multiple Myeloma Patients With Prior Solid Tumors Undergoing Autologous Transplantation. Transplant Cell Ther 31(8):565.e1-565.e9, 2025. e-Pub 2025. PMID: 40383197.
8. Nieto, Y, Ramdial, JL, Valdez, B, Thall, PF, Bassett Jr, R, Barnett, M, Srour, S, Hosing, C, Alousi, AM, Qazilbash, MH, Popat, UR, Gulbis, A, Shigle, TL, Ahmed, S, Pacheco, MG, Champlin, RE, Shpall, E, Andersson, BS. Enhancement of High-Dose Chemotherapy and Autologous SCT with the PARP Inhibitor Olaparib for Refractory Lymphoma. Clinical Cancer Research 31(6):975-982, 2025. e-Pub 2025. PMID: 39804167.
9. Pasvolsky, O, Marcoux, C, Wang, Z, Milton, D, Pal, B, Tanner, MR, Bashir, Q, Srour, S, Saini, N, Lin, P, Ramdial, JL, Nieto, Y, Tang, G, Syed, N, Aljawai, YM, Lee, HC, Patel, K, Becnel, M, Ye, JC, Kebriaei, P, Thomas, SK, Orlowski, R, Champlin, RE, Shpall, E, Qazilbash, MH. Outcomes of Standard-Risk Multiple Myeloma Patients Who Undergo Upfront Autologous Hematopoietic Stem Cell Transplantation. Transplantation and Cellular Therapy 31(3):166.e1-166.e9, 2025. e-Pub 2025. PMID: 39746546.
10. Bashir, Q, Konopleva, M, Abueg, G, Ramdial, JL, Hosing, C, Srour, S, Alousi, AM, Popat, UR, Nieto, Y, Al-Atrash, G, Champlin, RE, Shpall, E, Qazilbash, MH, Pemmaraju, N. Tagraxofusp maintenance post-hematopoietic stem cell transplantation provides long-term survival and manageable safety for a patient with blastic plasmacytoid dendritic cell neoplasm. Leukemia Research Reports 24, 2025. e-Pub 2025. PMID: 40612021.
11. Marcoux, C, Pasvolsky, O, Milton, D, Tanner, MR, Bashir, Q, Srour, S, Saini, N, Lin, P, Ramdial, JL, Nieto, Y, Tang, G, Lee, HC, Patel, K, Kebriaei, P, Ahmed, A, Aljawai, YM, Thomas, SK, Orlowski, R, Shpall, EJ, Champlin, RE, Qazilbash, MH. Real-World Outcomes of Upfront Autologous Hematopoietic Stem Cell Transplantation in Patients With Newly Diagnosed Multiple Myeloma With Deletion 17p. Transplantation and Cellular Therapy 31(1):12.e1-12.e10, 2025. e-Pub 2025. PMID: 39448031.
12. Xiang, JJ, Campbell, M, Tu, S, Araujo, JC, Nieto, Y, Lin, JK, Xiao, L, Shah, AY, Wang, J. Doxorubicin, Paclitaxel, and Cisplatin (ATP) for Relapsed/Refractory Germ Cell Tumors. Clinical Genitourinary Cancer 22(6), 2024. e-Pub 2024. PMID: 39532049.
13. Ramdial, JL, Lin, R, Thall, PF, Valdez, B, Hosing, C, Srour, S, Popat, U, Qazilbash, MH, Alousi, AM, Barnett, M, Gulbis, A, Shigle, TL, Shpall, EJ, Andersson, BS, Nieto, Y. High activity of the new myeloablative regimen of gemcitabine/clofarabine/busulfan for allogeneic transplant for aggressive lymphomas. Bone marrow transplantation 59(12):1754-1762, 2024. e-Pub 2024. PMID: 39341929.
14. Pasvolsky, O, Marcoux, C, Milton, D, Pal, B, Tanner, MR, Bashir, Q, Srour, S, Lee, J, Saini, N, Lin, P, Ramdial, JL, Nieto, Y, Tang, G, Aljawai, YM, Kebriaei, P, Becnel, M, Lee, HC, Patel, K, Thomas, SK, Orlowski, R, Shpall, EJ, Champlin, RE, Qazilbash, MH. Optimal infused CD34+ cell dose in multiple myeloma patients undergoing upfront autologous hematopoietic stem cell transplantation. Blood cancer journal 14(1), 2024. e-Pub 2024. PMID: 39482325.
15. Pasvolsky O, Wang Z, Milton D, Tanner MR, Bashir Q, Srour S, Saini N, Lin P, Ramdial JL, Nieto Y, Tang G, Kebriaei P, Aljawai YM, Khan HN, Lee HC, Ye JC, Patel K, Thomas SK, Orlowski R, Shpall E, Champlin RE, Qazilbash MH. Multiple myeloma patients with a long remission after autologous hematopoietic stem cell transplantation. Blood cancer journal 14(1), 2024. e-Pub 2024. PMID: 38760362.
16. Pasvolsky O, Marcoux C, Dai J, Milton D, Tanner MR, Syed N, Bashir Q, Srour S, Saini N, Lin P, Ramdial JL, Nieto Y, Tang G, Aljawai YM, Lee HC, Gaballa MM, Patel K, Kebriaei P, Thomas SK, Orlowski R, Shpall E, Champlin RE, Qazilbash MH. Trends in Outcomes After Upfront Autologous Transplant for Multiple Myeloma Over Three Decades. Transplantation and Cellular Therapy 30(8):772.e1-772.e11, 2024. e-Pub 2024. PMID: 38852784.
17. Alzahrani K, Pasvolsky O, Wang Z, Milton D, Tanner MR, Bashir Q, Srour S, Saini N, Lin P, Ramdial JL, Nieto Y, Lee HC, Patel K, Manasanch EE, Kebriaei P, Thomas SK, Weber DM, Orlowski R, Shpall E, Champlin RE, Qazilbash MH. Impact of revised International Staging System 2 risk stratification on outcomes of patients with multiple myeloma receiving autologous haematopoietic stem cell transplantation. British Journal of Haematology 204(5):1944-1952, 2024. e-Pub 2024. PMID: 38448009.
18. Ahmed S, Bashir Q, Bassett Jr R, Ullah F, Aung FM, Valdez B, Alousi AM, Hosing C, Kebriaei P, Khouri IF, Marin D, Nieto Y, Olson AL, Oran B, Qazilbash MH, Rezvani K, Mehta RS, Shpall E, Ciurea SO, Andersson BS, Champlin RE, Popat UR. Eltrombopag improves platelet engraftment after haploidentical bone marrow transplantation. American journal of hematology 99(4):562-569, 2024. e-Pub 2024. PMID: 38314663.
19. Marcoux C, Saliba RM, Wallis W, Khazal SJ, Ragoonanan D, Rondon G, Tewari P, Popat UR, Oran B, Olson AL, Bashir Q, Qazilbash MH, Alousi AM, Hosing C, Nieto Y, Al-Atrash G, Marin D, Rezvani K, Khouri IF, Srour S, Champlin RE, Shpall E, Kebriaei P. Incidence and risk factors of early onset VOD/SOS differ in younger vs older adults after stem cell transplantation. Blood Advances 8(5):1128-1136, 2024. e-Pub 2024. PMID: 38266155.
20. Marin D, Li Y, Basar R, Rafei H, Daher M, Dou J, Mohanty V, Dede M, Nieto Y, Uprety N, Acharya S, Liu E, Wilson JM, Banerjee PP, Macapinlac HA, Ganesh C, Thall PF, Bassett Jr R, Ammari M, Rao SS, Cao K, Shanley M, Kaplan M, Hosing C, Kebriaei P, Nastoupil L, Flowers CR, Moseley SM, Lin P, Ang O, Popat UR, Qazilbash MH, Champlin RE, Chen K, Shpall E, Rezvani K. Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19+ B cell tumors. Nature medicine 30(3):772-784, 2024. e-Pub 2024. PMID: 38238616.
21. Nieto Y, Yang Z, Valdez BC, Kundu S, Bashir Q, Ramdial J, Srour S, Qazilbash M. Safety and efficacy of a new high-dose regimen of panobinostat, gemcitabine, busulfan, and melphalan for 1st or 2nd salvage ASCT for refractory/relapsed or high-risk myeloma: Matched-pair comparisons with concurrent control cohorts. Am J Hematol 99(2):245-253, 2024. e-Pub 2024. PMID: 38100199.
22. Nieto Y, Banerjee P, Kaur I, Kim KH, Fang D, Thall PF, Griffin L, Barnett M, Basar R, Hosing C, Ramdial J, Srour S, Daher M, Marin D, Jiang X, Chen K, Champlin R, Shpall EJ, Rezvani K. Ex vivo-expanded cord blood NK cells combined with Rituximab and high-dose chemotherapy and Autologous SCT for B-NHL. Transplant Cell Ther 30(2):203.e1-209.e9, 2024. e-Pub 2024. PMID: 38042257.
23. Pasvolsky O, Ghanem S, Milton DR, Rauf M, Tanner MR, Bashir Q, Srour S, Saini N, Lin P, Ramdial J, Nieto Y, Tang G, Aljawai Y, Khan HN, Kebriaei P, Lee HC, Patel KK, Thomas SK, Weber DM, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH. Outcomes of patients with multiple myeloma and 1q gain/amplification receiving autologous hematopoietic stem cell transplant: the MD Anderson cancer center experience. Blood cancer journal 14(1):4, 2024. e-Pub 2024. PMID: 38199987.
24. Valdez, B, Tsimberidou, AM, Yuan, B, Nieto, Y, Baysal, M, Chakraborty, A, Andersen, C, Andersson, BS. Synergistic cytotoxicity of histone deacetylase and poly-ADP ribose polymerase inhibitors and decitabine in pancreatic cancer cells. Oncotarget 15(1):361-373, 2024. e-Pub 2024. PMID: 38829622.
25. Valdez, B, Yuan, B, Murray, D, Ramdial, JL, Popat, UR, Nieto, Y, Andersson, BS. ABT199/venetoclax synergism with thiotepa enhances the cytotoxicity of fludarabine, cladribine and busulfan in AML cells. Oncotarget 15:220-231, 2024. e-Pub 2024. PMID: 38484153.
26. Mamlouk O, Strati P, Feng L, Sun R, Ayers A, Steiner RE, Nair R, Flowers C, Ramdial JL, Saini N, Srour SA, Champlin RE, Kebriaei P, Nastoupil LJ, Rodriguez MA, Shpall EJ, Nieto Y, Westin J, Neelapu SS, Mandayam S, Ahmed S. Real-world analysis of safety and efficacy of CAR T-cell therapy in lymphoma patients with decreased kidney function. Br J Haematol 1(1):e11-e16, 2024. e-Pub 2024. PMID: 37822075.
27. Pasvolsky, O, Ghanem, S, Milton, D, Rauf, M, Tanner, MR, Bashir, Q, Srour, S, Saini, N, Lin, P, Ramdial, JL, Nieto, Y, Tang, G, Aljawai, YM, Khan, HN, Kebriaei, P, Lee, HC, Patel, K, Thomas, SK, Weber, DM, Orlowski, R, Shpall, E, Champlin, RE, Qazilbash, MH. Outcomes of patients with multiple myeloma and 1q gain/amplification receiving autologous hematopoietic stem cell transplant. Blood/ASH Annual Abstract 14(1), 2024. e-Pub 2024. PMID: 38199987.
28. Pasvolsky O, Pasyar S, Bassett RL, Khan HN, Tanner MR, Bashir Q, Srour S, Saini N, Lin P, Ramdial J, Nieto Y, Lee HC, Patel KK, Kebriaei P, Thomas SK, Weber DM, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH. Impact of pretransplant minimal residual disease in patients with multiple myeloma and a very good partial response or better receiving autologous hematopoietic stem cell transplantation. Cancer 130(9):1663-1672, 2023. e-Pub 2023. PMID: 38127583.
29. Pasvolsky O, Ghanem S, Milton DR, Masood A, Tanner MR, Bashir Q, Srour S, Saini N, Lin P, Ramdial J, Nieto Y, Lee HC, Patel KK, Kebriaei P, Thomas SK, Weber DM, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH. Outcomes of Autologous Stem Cell Transplantation in Patients with Ultra-High-Risk Multiple Myeloma. Transplant Cell Ther 29(12):757-762, 2023. e-Pub 2023. PMID: 37673125.
30. Pasvolsky O, Bassett RL, Ghanem S, Cuglievan B, Tewari P, Hosing C, Srour S, Ramdial J, Mahadeo KM, Khazal S, Petropoulos D, Popat U, Qazilbash M, Kebriaei P, Champlin R, Shpall EJ, Nieto Y. Characteristics and outcomes of children, adolescents and young adults with relapsed/refractory non-hodgkin lymphoma undergoing autologous stem cell transplant. BMC Cancer 23(1):1258, 2023. e-Pub 2023. PMID: 38124057.
31. Alkhaldi H, Reinhardt A, Barnett M, Kundu S, Hosing C, Ramdial J, Saini N, Srour S, Alousi A, Kebriaei P, Popat U, Qazilbash M, Champlin R, Shpall EJ, Gulbis A, Shigle TL, Dabaja B, Pinnix C, Ahmed S, Steiner R, Andersson BS, Nieto Y. High-dose chemotherapy and autologous stem-cell transplant for relapsed or refractory primary mediastinal B-Cell lymphoma. Transplant Cell Therapy 29(11):690-694, 2023. e-Pub 2023. PMID: 37607645.
32. Popat UR, Pasvolsky O, Bassett R, Mehta RS, Olson AL, Chen J, Alousi AM, Al-Atrash G, Bashir Q, Gulbis AM, Hosing CM, Im JS, Kebriaei P, Khouri IF, Marin DC, Nieto Y, Oran B, Saini NY, Shigle TL, Srour SA, Ramdial JL, Rezvani K, Qazilbash MH, Andersson BS, Champlin RE, Shpall EJ. Myeloablative Fractionated Busulfan for Allogeneic Stem Cell Transplant in Older Patients or Patients with Comorbidities. Blood Adv 7(20):6196-6205, 2023. e-Pub 2023. PMID: 37611156.
33. Pasvolsky O, Milton DR, Masood A, Sami SS, Tanner MR, Bashir Q, Srour S, Saini N, Lin P, Ramdial J, Nieto Y, Saeed A, Lee HC, Patel KK, Kebriaei P, Thomas SK, Weber DM, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH. Single-agent lenalidomide maintenance after upfront autologous stem cell transplant for newly diagnosed multiple myeloma: The MD Anderson experience. Am J Hematol 98(10):1571-1578, 2023. e-Pub 2023. PMID: 37461327.
34. Merryman RW, Redd RA, Taranto E, Ahmed G, Jeter E, McHugh KM, Brown JR, Crombie JL, Davids MS, Fisher DC, Freedman AS, Jacobsen ED, Jacobson CA, Kim AI, LaCasce AS, Ng SY, Odejide OO, Parry EM, Jacene H, Park H, Dahi PB, Nieto Y, Joyce R, Chen YB, Shipp MA, Herrera AF, Armand P. Minimal residual disease in patients with diffuse large B-cell lymphoma undergoing autologous stem cell transplantation. Blood Adv 7(17):4748-4757, 2023. e-Pub 2023. PMID: 36399518.
35. Merrill MH, Dahi PB, Redd RA, McDonough M, Chen YB, DeFilipp Z, Herrera AF, Fisher DC, LaCasce AS, Odejide OO, Ng SY, Jacobson CA, Merryman RW, Kim AI, Nieto Y, Sauter CS, Shah GL, Zain J, Armand P, Jacobsen ED. A Phase 2 Study of pembrolizumab after Autologous Stem Cell Transplantation in Patients with T-Cell non-Hodgkin Lymphoma. Blood 142(7):621-628, 2023. e-Pub 2023. PMID: 37319432.
36. Pasvolsky O, Marcoux C, Milton DR, Tanner MR, Bashir Q, Srour S, Saini N, Lin P, Ramdial J, Nieto Y, Lee HC, Patel KK, Kebriaei P, Tewari P, Crawford-Suber L, Thomas SK, Weber DM, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH. Outcomes of young adults (aged = 40 years) with newly diagnosed multiple myeloma after up-front autologous stem cell transplant. Br J Haematol 202(4):866-873, 2023. e-Pub 2023. PMID: 37376789.
37. Marques-Piubelli ML, Kim DH, Medeiros LJ, Lu W, Khan K, Gomez-Bolanos LI, Rodriguez S, Parra ER, Ok CY, Aradhya A, Solis LM, Nieto YL, Steiner R, Ahmed S, Vega F. CD30 expression is frequently decreased in relapsed classic Hodgkin lymphoma after anti-CD30 CAR T-cell therapy. Histopathology 83(1):143-148, 2023. e-Pub 2023. PMID: 36994939.
38. Ragon BK, Shah MV, D'Souza A, Estrada-Merly N, Gowda L, George G, DeLima M, Hashmi S, Kharfan-Dabaja MA, Majhail NS, Banerjee R, Saad A, Hildebrandt GC, Mian H, Abid MB, Battiwalla M, Lekakis LJ, Patel SS, Murthy HS, Nieto Y, Strouse CS, Badawy SM, Al Hadidi SA, Dholaria B, Aljurf M, Vesole DH, Lee CH, Pawarode A, Gergis U, Miller KC, Holmberg LA, Afrough A, Solh MM, Munshi P, Nishihori T, Anderson LD, Wirk B, Kaur G, Qazilbash MH, Shah N, Kumar SK, Usmani SZ. Impact of Second Primary Malignancy Post-Autologous Transplantation on Outcomes of Multiple Myeloma: A CIBMTR Analysis. Blood Adv 7(12):2746-2757, 2023. e-Pub 2023. PMID: 36827681.
39. Ramdial J, Chan KH, Sanchez Petitto G, Valdez B, Andersson BS, Nieto Y. Intravenous Busulfan, Dimethylacetamide and neurotoxicity after high-dose pretransplant conditioning chemotherapy. Bone Marrow Transplant 58(6):635-638, 2023. e-Pub 2023. PMID: 36966213.
40. Ramdial JL, Valdez BC, Andersson BS, Nieto Y. Romidepsin antagonism with CHOEP. Leukemia 37(5):1160-1161, 2023. e-Pub 2023. PMID: 36906714.
41. Pasvolsky O, Milton DR, Rauf M, Ghanem S, Masood A, Mohamedi AH, Tanner MR, Bashir Q, Srour S, Saini N, Lin P, Ramdial J, Nieto Y, Tang G, Lee HC, Patel KK, Kebriaei P, Thomas SK, Weber DM, Orlowski RZ, Rezvani K, Champlin R, Shpall EJ, Lin P, Qazilbash MH. Impact of clonal plasma cells in autografts on outcomes in high-risk multiple myeloma patients. Blood Cancer J 13(1):68, 2023. e-Pub 2023. PMID: 37137874.
42. Afrough A, Alsfeld LC, Milton DR, Delgado R, Popat UR, Nieto Y, Kebriaei P, Oran B, Saini N, Srour S, Hosing C, Cheema FH, Ahmed S, Manasanch EE, Lee HC, Kaufman GP, Patel KK, Weber DM, Orlowski RZ, Pinnix CC, Dabaja BS, Thomas SK, Champlin RE, Shpall EJ, Qazilbash MH, Bashir Q. Long-term outcomes of allogeneic hematopoietic cell transplantation in patients with newly diagnosed multiple myeloma. Transplant Cell Ther 29(4):264.e1-264.e9, 2023. e-Pub 2023. PMID: 35605883.
43. Pasvolsky O, Gaballa MR, Milton DR, Masood A, Sami SS, Tanner MR, Bashir Q, Srour S, Saini N, Ramdial J, Nieto Y, Tang G, Lin P, Lee HC, Patel KK, Kebriaei P, Thomas SK, Weber DM, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH. Autologous Stem Cell Transplantation for Patients with Multiple Myeloma with Translocation (4;14): The MD Anderson Cancer Center Experience: Transplant in t(4;14) MM. Transplant Cell Ther 29(4):260.e1-260.e6, 2023. e-Pub 2023. PMID: 36646323.
44. Mehta RS, Cao K, Saliba RM, Al-Atrash G, Alousi AM, Lontos K, Marcoux C, Carmazzi Y, Rondon G, Bashir Q, Hosing CM, Kebriaei P, Khouri I, Marin D, Nieto Y, Oran B, Popat UR, Qazilbash MH, Ramdial J, Rezvani K, Champlin RE, Shpall EJ. HLA Factors versus Non-HLA Factors for Haploidentical Donor Selection. Transplant Cell Ther 29(3):189-198, 2023. e-Pub 2023. PMID: 36470579.
45. Saad A, Loren A, Bolaños-Meade J, Chen G, Couriel D, Di Stasi A, El-Jawahri A, Elmariah H, Farag S, Gundabolu K, Gutman J, Ho V, Hoeg R, Horwitz M, Hsu J, Kassim A, Kharfan Dabaja M, Magenau J, Martin T, Mielcarek M, Moreira J, Nakamura R, Nieto Y, Ninos C, Oliai C, Patel S, Randolph B, Schroeder M, Tzachanis D, Varshavsky-Yanovsky AN, Vusirikala M, Algieri F, Pluchino LA. NCCN Guidelines® Insights: Hematopoietic Cell Transplantation, Version 3.2022. J Natl Compr Canc Netw 21(2):108-115, 2023. e-Pub 2023. PMID: 36791762.
46. Nieto Y, Pasvolsky O, Bassett R, Ghanem S, Cuglievan B, Tewari P, Hosing C, Sr S, Ramdial J, Mahadeo K, Khazal S, Petropoulos D, Popat U, Qazilbash M, Kebriaei P, Champlin R, Shpall E. Characteristics and Outcomes of Children, Adolescents and Young Adults with Relapsed/Refractory Non-Hodgkin Lymphoma Undergoing Autologous Stem Cell Transplant. Res Sq, 2023. e-Pub 2023. PMID: 36798261.
47. Zurko J, Ramdial J, Shadman M, Ahmed S, Szabo A, Iovino L, Tomas AA, Sauter C, Perales MA, Shah NN, Acharya UH, Jacobson C, Soiffer RJ, Wang T, Komanduri KV, Jaglowski S, Kittai AS, Denlinger N, Iqbal M, Kharfan-Dabaja MA, Ayala E, Chavez J, Jain M, Locke FL, Samara Y, Budde LE, Mei MG, Pia AD, Feldman T, Ahmed N, Jacobs R, Ghosh N, Dholaria B, Oluwole OO, Hess B, Hassan A, Kenkre VP, Reagan P, Awan F, Nieto Y, Hamadani M, Herrera AF. Allogeneic transplant following CAR T-cell therapy for large B-cell lymphoma. Haematologica 108(1):98-109, 2023. e-Pub 2023. PMID: 35833303.
48. Cherng HJ, Xu G, Feng L, Steiner R, Fayad L, Strati P, Nair R, Nastoupil LJ, Lee HJ, Neelapu SS, Flowers CR, Rodriguez M, Wang M, Hagemeister F, Pinnix CC, Ramdial J, Srour S, Nieto Y, Rezvani K, Champlin R, Kebriaei P, Westin J, Macapinlac HA, Shpall E, Ahmed S. Positron emission tomography derived metrics in relapsed or refractory large B-cell lymphoma with residual disease before autologous stem cell transplant. Br J Haematol 200(1):35-44, 2023. e-Pub 2023. PMID: 36068929.
49. Valdez BC, Yuan B, Murray D, Ramdial JL, Nieto Y, Popat U, Tang X, Andersson BS. Synergistic cytotoxicity of fludarabine, clofarabine, busulfan, vorinostat and olaparib in AML cells. Front Oncol 13:1287444, 2023. e-Pub 2023. PMID: 38074694.
50. Herrera AF, Chen L, Nieto Y, Holmberg L, Johnston P, Mei M, Popplewell L, Armenian S, Cao T, Farol L, Sahebi F, Spielberger R, Chen R, Nademanee A, Puverel S, Nwangwu M, Lee P, Song J, Skarbnik A, Kennedy N, Peters L, Rosen ST, Kwak LW, Forman SJ, Feldman T. Brentuximab vedotin plus nivolumab after autologous haematopoietic stem-cell transplantation for adult patients with high-risk classic Hodgkin lymphoma: a multicentre, phase 2 trial. Lancet Haematol 10(1):e14-e23, 2023. e-Pub 2023. PMID: 36403579.
51. Pasvolsky O, Milton DR, Rauf M, Tanner MR, Bashir Q, Srour S, Tang G, Saini N, Ramdial J, Masood A, Nieto Y, Lee HC, Patel KK, Kebriaei P, Thomas SK, Weber DM, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH. Lenalidomide-Based Maintenance after Autologous Hematopoietic Stem Cell Transplantation for Patients with High-Risk Multiple Myeloma. Transplant Cell Ther 28(11):752.e1-752.e6, 2022. e-Pub 2022. PMID: 35940528.
52. Roldan CJ, Huh B, Song J, Nieto Y, Osei J, Chai T, Nouri K, Koyyalagunta L, Bruera E. Methylene blue for intractable pain from oral mucositis related to cancer treatment: a randomized phase 2 clinical trial. BMC Med 20(1):377, 2022. e-Pub 2022. PMID: 36324139.
53. Mehta RS, Saliba RM, Rondon G, Al-Atrash G, Bashir Q, Hosing CM, Kebriaei P, Khouri I, Nieto Y, Oran B, Popat UR, Qazilbash MH, Ramdial J, Srour SA, Champlin RE, Rezvani K, Shpall EJ, Alousi AM. Post-Transplantation Cyclophosphamide vs Tacrolimus and Methotrexate Graft-versus-Host Disease Prophylaxis For HLA-Matched Donor Transplantation. Transplant Cell Ther 28(10):695.e1-695.e10, 2022. e-Pub 2022. PMID: 35902049.
54. Pasvolsky, O, Milton, D, Rauf, M, Ghanem, S, Masood, A, Mohamedi, A, Tanner, MR, Bashir, Q, Srour, S, Saini, N, Ramdial, JL, Nieto, Y, Tang, G, Lee, HC, Patel, K, Kebriaei, P, Thomas, SK, Weber, DM, Orlowski, R, Shpall, E, Champlin, RE, Lin, P, Qazilbash, MH. MM-403 Impact of Clonal Plasma Cells in Autografts on the Outcome of High-Risk Multiple Myeloma Patients Undergoing Autologous Hematopoietic Stem Cell Transplant. Clinical Lymphoma, Myeloma and Leukemia 22(Supplement 2):S421-S422, 2022. e-Pub 2022. PMID: 36164172.
55. Valdez BC, Nieto Y, Yuan B, Murray D, Andersson BS. HDAC inhibitors suppress protein poly(ADP-ribosyl)ation and DNA repair protein levels and phosphorylation status in hematologic cancer cells: implications for their use in combination with PARP inhibitors and chemotherapeutic drugs. Oncotarget 13(1):1122-1135, 2022. e-Pub 2022. PMID: 36243940.
56. Mehta RS, Saliba RM, Hayase E, Jenq RR, Abraham S, Rashid A, Rondon G, Al-Atrash G, Bashir Q, Hosing CM, Kebriaei P, Khouri I, Marin D, Nieto Y, Olson A, Oran B, Popat UR, Qazilbash MH, Ramdial J, Srour S, Champlin RE, Rezvani K, Shpall EJ, Alousi AM. Mycophenolate Mofetil: A Friend or a Foe with PTCy and Tacrolimus Prophylaxis in HLA-Matched donors?. Transplant Cell Ther 28(8):500.e1-500.e10, 2022. e-Pub 2022. PMID: 35662592.
57. Alatrash G, Saberian C, Bassett R, Thall PF, Ledesma C, Lu Y, Daher M, Valdez BC, Kawedia J, Popat U, Mehta R, Oran B, Nieto Y, Olson A, Anderlini P, Marin D, Hosing C, Alousi AM, Shpall EJ, Rondon G, Chen J, Qazilbash M, Champlin RE, Andersson BS, Kebriaei P. Vorinostat combined with Busulfan, Fludarabine, and Clofarabine Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Leukemia: Long-term Study Outcomes. Transplant Cell Ther 28(8):501.e1-501.e7, 2022. e-Pub 2022. PMID: 35618218.
58. Andersson BS, Thall PF, Ma J, Valdez BC, Bassett R, Chen J, Ahmed S, Alousi A, Bashir Q, Ciurea S, Gulbis A, Cool R, Kawedia J, Hosing C, Kebriaei P, Kornblau S, Myers A, Oran B, Rezvani K, Shah N, Shpall E, Parmar S, Popat UR, Nieto Y, Champlin RE. A randomized phase III study of pretransplant conditioning for AML/MDS with fludarabine and once daily IV busulfan?±?clofarabine in allogeneic stem cell transplantation. Bone Marrow Transplant 57(8):1295-1303, 2022. e-Pub 2022. PMID: 35610308.
59. Gaballa MR, Ma J, Rauf M, Bassett R, Pasvolsky O, Tanner MR, Bashir Q, Srour SA, Saini N, Ramdial J, Nieto Y, Murphy R, Rezvani K, Tang G, Lin P, Lee HC, Patel KK, Ullah MR, Kaufman GP, Manasanch EE, Kebriaei P, Thomas SK, Weber DM, Shpall EJ, Champlin RE, Orlowski RZ, Qazilbash MH. KRD vs. VRD as induction before autologous hematopoietic progenitor cell transplantation for high-risk multiple myeloma. Bone Marrow Transplant 57(7):1142-1149, 2022. e-Pub 2022. PMID: 35523847.
60. Mehta RS, Saliba RM, Ghanem S, Alousi AM, Rondon G, Anderlini P, Al-Atrash G, Bashir Q, Hosing CM, Im JS, Kebriaei P, Khouri I, Marin D, Nieto Y, Olson A, Oran B, Popat UR, Qazilbash MH, Ramdial J, Saini N, Srour SA, Champlin RE, Rezvani K, Shpall EJ. Haploidentical versus Matched Unrelated versus Matched Sibling Donor Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide. Transplant Cell Ther 28(7):395.e1-395.e11, 2022. e-Pub 2022. PMID: 35513252.
61. Yalniz FF, Greenbaum U, Pasvolsky O, Milton DR, Kanagal-Shamanna R, Ramdial J, Srour S, Mehta R, Alousi A, Popat UR, Nieto Y, Kebriaei P, Al-Atrash G, Oran B, Hosing C, Ahmed S, Champlin RE, Shpall EJ, Qazilbash MH, Bashir Q. Characteristics and Outcomes of Patients With Multiple Myeloma Who Developed Therapy-Related Acute Myeloid Leukemia and Myelodysplastic Syndrome After Autologous Cell Transplantation. Transplant Cell Therapy 30(2):205.e1-205.e12, 2022. e-Pub 2022. PMID: 37437764.
62. Valdez BC, Yuan B, Murray D, Nieto Y, Popat U, Andersson BS. Enhanced cytotoxicity of bisantrene when combined with venetoclax, panobinostat, decitabine and olaparib in acute myeloid leukemia cells. Leuk Lymphoma 63(7):1634-1644, 2022. e-Pub 2022. PMID: 35188042.
63. Akin S, Hosing C, Khouri IF, Ahmed S, Alousi A, Fowler NH, Joseph J, Truxillo J, Ramdial J, Maadani F, Rondon G, Daher M, Im JS, Steiner RE, Westin JR, Iyer SP, Dabaja BS, Anderlini P, Popat UR, Qazilbash MH, Flowers CR, Shpall EJ, Champlin RE, Nieto Y, Srour SA. Autologous Stem Cell Transplantation for Large B-cell Lymphoma with Secondary Central Nervous System Involvement. Blood Adv 6(7):2267-2274, 2022. e-Pub 2022. PMID: 35008100.
64. Nieto Y, Gruschkus S, Valdez BC, Jones RB, Anderlini P, Hosing C, Popat U, Qazilbash M, Kebriaei P, Alousi A, Saini N, Srour S, Rezvani K, Ramdial J, Barnett M, Gulbis A, Shigle TL, Ahmed S, Iyer S, Lee H, Nair R, Parmar S, Steiner R, Dabaja B, Pinnix C, Gunther J, Cuglievan B, Mahadeo K, Khazal S, Chuang H, Champlin R, Shpall EJ, Andersson BS. Improved outcomes of high-risk relapsed Hodgkin lymphoma patients after high-dose chemotherapy: a 15-year analysis. Haematologica 107(4):899-908, 2022. e-Pub 2022. PMID: 33951890.
65. Valdez BC, Murray D, Yuan B, Nieto Y, Popat U, Andersson BS. ABT199/venetoclax potentiates the cytotoxicity of alkylating agents and fludarabine in acute myeloid leukemia cells. Oncotarget 13(10):319-330, 2022. e-Pub 2022. PMID: 35154579.
66. Bashir Q, Milton DR, Popat UR, Kebriaei P, Hosing C, Khouri IF, Rezvani K, Nieto Y, Oran B, Srour SA, Saini NY, Olson AL, Ahmed S, Al-Atrash G, Rondon G, Konopleva MY, Champlin RE, Shpall EJ, Qazilbash MH, Pemmaraju N. Allogeneic hematopoietic cell transplantation for patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN). Bone Marrow Transplant 57(1):51-56, 2022. e-Pub 2022. PMID: 34629467.
67. Merryman RW, Redd R, Jeter E, Wong JL, McHugh K, Reynolds C, Nazzaro M, Varden A, Brown JR, Crombie JL, Davids MS, Fisher DC, Jacobsen E, Jacobson CA, Kim AI, LaCasce AS, Ng SY, Odejide OO, Parry EM, Dahi PB, Nieto Y, Joyce RM, Chen YB, Herrera AF, Armand P, Ritz J. Immune reconstitution following high-dose chemotherapy and autologous stem cell transplantation with and without pembrolizumab maintenance therapy in patients with lymphoma. Transplant Cell Ther 28(1):32.e1-32.e10, 2022. e-Pub 2022. PMID: 34670169.
68. Mehta RS, Saliba RM, Alsfeld LC, Jorgensen JL, Wang SA, Anderlini P, Al-Atrash G, Bashir Q, Ciurea SO, Hosing CM, Im JS, Kebriaei P, Khouri I, Marin D, Nieto Y, Olson A, Oran B, Popat UR, Qazilbash MH, Ramdial J, Rondon G, Saini N, Srour SA, Rezvani K, Shpall EJ, Champlin RE, Alousi AM. Bone Marrow versus Peripheral Blood Grafts for Haploidentical Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide. Transplant Cell Ther 27(12):1003.e1-1003.e13, 2021. e-Pub 2021. PMID: 34537419.
69. Mehta RS, Bassett R, Chen J, Valdez BC, Kawedia J, Alousi AM, Anderlini P, Al-Atrash G, Bashir Q, Ciurea SO, Hosing CM, Im JS, Kebriaei P, Khouri I, Marin D, Nieto Y, Olson A, Oran B, Qazilbash MH, Ramdial J, Saini N, Srour SA, Rezvani K, Shpall EJ, Andersson BS, Champlin RE, Popat UR. Myeloablative Fractionated Busulfan with Fludarabine in Older Patients: Long Term Disease-Specific Outcomes of a Prospective Phase II Clinical Trial. Transplant Cell Ther 27(11):913.e1-913.e12, 2021. e-Pub 2021. PMID: 34329753.
70. Taranto E, Redd R, Jeter E, McHugh K, Crombie JL, Fisher DC, Jacobsen E, Jacobson CA, Kim AI, LaCasce AS, Odejide OO, Dahi PB, Nieto Y, Joyce RM, Chen YB, Bonjoc KC, Chaudhry A, Herrera AF, Armand P, Merryman RW. Prognostic value of minimal residual disease among patients with classical Hodgkin lymphoma undergoing autologous stem cell transplantation. Leuk Lymphoma 62(10):2400-2407, 2021. e-Pub 2021. PMID: 35938581.
71. Al Feghali KA, Fang P, Gule-Monroe M, Milgrom S, Khoury JD, Gunther JR, Sheu T, Nair R, Ahmed S, Steiner R, Strati P, Shpall EJ, Nieto YL, Hosing C, Nastoupil LJ, Westin JR, Neelapu SS, Fowler N, Flowers C, Pinnix CC, Dabaja BS. Prognostic value of disease distribution in secondary central nervous system diffuse large B cell lymphoma treated with radiation therapy. Leuk Lymphoma 62(10):2400-2407, 2021. e-Pub 2021. PMID: 33942701.
72. Merryman RW, Castagna L, Giordano L, Ho VT, Corradini P, Guidetti A, Casadei B, Bond DA, Jaglowski S, Spinner MA, Arai S, Lowsky R, Shah GL, Perales MA, De Colella JMS, Blaise D, Herrera AF, Shouse G, Spilleboudt C, Ansell SM, Nieto Y, Badar T, Hamadani M, Feldman TA, Dahncke L, Singh AK, McGuirk JP, Nishihori T, Chavez J, Serritella AV, Kline J, Mohty M, Dulery R, Stamatoulas A, Houot R, Manson G, Moles-Moreau MP, Orvain C, Bouabdallah K, Modi D, Ramchandren R, Lekakis L, Beitinjaneh A, Frigault MJ, Chen YB, Lynch RC, Smith SD, Rao U, Byrne M, Romancik JT, Cohen JB, Nathan S, Phillips T, Joyce RM, Rahimian M, Bashey A, Ballard HJ, Svoboda J, Torri V, Sollini M, De Philippis C, Magagnoli M, Santoro A, Armand P, Zinzani PL, Carlo-Stella C. Allogeneic transplantation after PD-1 blockade for classic Hodgkin lymphoma. Leukemia 35(9):2672-2683, 2021. e-Pub 2021. PMID: 33658659.
73. Olson A, Lin R, Marin D, Rafei H, Bdaiwi MH, Thall PF, Basar R, Abudayyeh A, Banerjee P, Aung FM, Kaur I, Abueg G, Rao S, Chemaly R, Mulanovich V, Al-Atrash G, Alousi AM, Andersson BS, Anderlini P, Bashir Q, Castro KM, Daher M, Galvan IM, Hosing C, Im JS, Jones RB, Kebriaei P, Khouri I, Mehta R, Molldrem J, Nieto Y, Oran B, Popat U, Qazilbash M, Rondon G, Saini N, Spencer B, Srour S, Washington D, Barnett M, Champlin RE, Shpall EJ, Rezvani K. Third-Party BK Virus-Specific Cytotoxic T Lymphocyte Therapy for Hemorrhagic Cystitis Following Allotransplantation. J Clin Oncol 39(24):2710-2719, 2021. e-Pub 2021. PMID: 33929874.
74. Greenbaum U, Strati P, Saliba RM, Torres J, Rondon G, Nieto Y, Hosing C, Srour SA, Westin J, Fayad LE, Lee HJ, Iyer SP, Nair R, Nastoupil LJ, Parmar S, Rodriguez MA, Samaniego F, Steiner RE, Wang M, Pinnix CC, Flowers CR, Tummala S, Ramdial JL, Yalniz FF, Hawkins M, Rezvani K, Champlin RE, Shpall EJ, Neelapu SS, Kebriaei P, Ahmed S. CRP and ferritin in addition to the EASIX score predict CAR-T-related toxicity. Blood Adv 5(14):2799-2806, 2021. e-Pub 2021. PMID: 34264268.
75. Scordo M, Wang TP, Ahn KW, Chen Y, Ahmed S, Awan FT, Beitinjaneh A, Chen A, Chow VA, Dholaria B, Epperla N, Farooq U, Ghosh N, Grover N, Hamad N, Hildebrandt GC, Holmberg L, Hong S, Inwards DJ, Jimenez-Jimenez A, Karmali R, Kenkre VP, Khimani F, Klyuchnikov E, Krem MM, Munshi PN, Nieto Y, Prestidge T, Ramakrishnan Geethakumari P, Rezvani AR, Riedell PA, Seo S, Shah NN, Solh M, Yared JA, Kharfan-Dabaja MA, Herrera A, Hamadani M, Sauter CS. Outcomes Associated With Thiotepa-Based Conditioning in Patients With Primary Central Nervous System Lymphoma After Autologous Hematopoietic Cell Transplant. JAMA Oncol 7(7):993-1003, 2021. e-Pub 2021. PMID: 33956047.
76. Kerbauy LN, Marin ND, Kaplan M, Banerjee PP, Berrien-Elliott MM, Becker-Hapak MK, Basar R, Foster M, Garcia Melo L, Neal CC, McClain E, Daher M, Nunez Cortes AK, Desai S, Inng Lim FW, Mendt MC, Schappe T, Li L, Shaim H, Shanley M, Ensley EL, Uprety N, Wong P, Liu E, Ang SO, Cai R, Nandivada V, Mohanty V, Miao Q, Shen Y, Baran N, Fowlkes NW, Chen K, Muniz-Feliciano L, Champlin RE, Nieto YL, Koch J, Treder M, Fischer W, Okamoto OK, Shpall EJ, Fehniger TA, Rezvani K. Combining AFM13, a bispecific CD30/CD16 antibody, with cytokine-activated cord blood-derived NK cells facilitates CAR-like responses against CD30+ malignancies. Clin Cancer Res 27(13):3744-3756, 2021. e-Pub 2021. PMID: 33986022.
77. Dhakal B, Patel S, Girnius S, Bachegowda L, Fraser R, Davila O, Kanate AS, Assal A, Hanbali A, Bashey A, Pawarode A, Freytes CO, Lee C, Vesole D, Cornell RF, Hildebrandt GC, Murthy HS, Lazarus HM, Cerny J, Yared JA, Schriber J, Berdeja J, Stockerl-Goldstein K, Meehan K, Holmberg L, Solh M, Diaz MA, Kharfan-Dabaja MA, Farhadfar N, Bashir Q, Munker R, Olsson RF, Gale RP, Bayer RL, Seo S, Chhabra S, Hashmi S, Badawy SM, Nishihori T, Gonsalves W, Nieto Y, Efebera Y, Kumar S, Shah N, Qazilbash M, Hari P, D'Souza A. Correction to: Hematopoietic cell transplantation utilization and outcomes for primary plasma cell leukemia in the current era. Leukemia 35(7):2141, 2021. e-Pub 2021. PMID: 34091601.
78. Ahmed S, Bashir Q, Bassett R, Poon MC, Valdez B, Konoplev S, Alousi AM, Andersson BS, Ciurea S, Hosing C, Jones R, Kebriaei P, Khouri I, Kim S, Nieto Y, Olson A, Oran B, Parmar S, Qazilbash MH, Rezvani K, Shah N, Shpall EJ, Champlin R, Popat U. Eltrombopag for Post-Transplantation Thrombocytopenia: Results of Phase II Randomized, Double-Blind, Placebo-Controlled Trial. Transplant Cell Ther 27(5):430.e1-430.e7, 2021. e-Pub 2021. PMID: 33965187.
79. Joseph J, Ma J, Hennawy F, Abdulrazzaq MN, Saini N, Patel RD, Hosing CM, Alousi AM, Anderlini P, Popat UR, Qazilbash MH, Shpall EJ, Srour S, Kebriaei P, Bashir Q, Nastoupil LJ, Westin JR, Rondon G, Champlin RE, Andersson BS, Nieto Y, Muzzafar T, Ahmed S. Impact of Cell of Origin Classification on Survival Outcomes after Autologous Transplantation in Relapsed/Refractory Diffuse Large B Cell Lymphoma. Transplant Cell Ther 27(5):404.e1-404.e5, 2021. e-Pub 2021. PMID: 33965178.
80. Mehta RS, Saliba RM, Jan A, Shigle TL, Wang E, Nieto Y, Ciurea SO, Oran B, Im J, Olson A, Marin D, Qazilbash M, Khouri I, Rondon G, Anderlini P, Rezvani K, Popat U, Kebriaei P, Shpall E, Champlin R, Alousi A. Vedolizumab for Steroid Refractory Lower Gastrointestinal Tract Graft-Versus-Host Disease. Transplant Cell Ther 27(3):272.e1-272.e5, 2021. e-Pub 2021. PMID: 33781539.
81. Srour SA, Saliba RM, Bashir Q, Popat UR, Ahmed S, Mehta RS, Delgado R, Rondon G, Parmar S, Kebriaei P, Hosing C, Manasanch EE, Lee HC, Patel KK, Orlowski RZ, Shpall E, Champlin RE, Qazilbash MH, Nieto Y. Influence of Overlapping Genetic Abnormalities on Treatment Outcomes of Multiple Myeloma. Transplant Cell Ther 27(3):243.e1-243.e6, 2021. e-Pub 2021. PMID: 33781521.
82. Merryman RW, Redd RA, Nishihori T, Chavez J, Nieto Y, Darrah JM, Rao U, Byrne MT, Bond DA, Maddocks KJ, Spinner MA, Advani RH, Ballard HJ, Svoboda J, Singh AK, McGuirk JP, Modi D, Ramchandren R, Romancik J, Cohen JB, Frigault MJ, Chen YB, Serritella AV, Kline J, Ansell S, Nathan S, Rahimian M, Joyce RM, Shah M, David KA, Park S, Beaven AW, Habib A, Bachanova V, Nakhoda S, Khan N, Lynch RC, Smith SD, Ho VT, LaCasce A, Armand P, Herrera AF. Autologous stem cell transplantation after anti-PD-1 therapy for multiply relapsed or refractory Hodgkin lymphoma. Blood Adv 5(6):1648-1659, 2021. e-Pub 2021. PMID: 33710337.
83. Strati P, Cheng PTM, Steiner RE, Alcedo Andrade PE, Feng L, Sano D, Rao VA, Singh P, Miranda R, Gunther JR, Pinnix CC, Dabaja BS, Cuglievan B, Xing K, Villa D, Skinnider B, Sehn LH, Connors JM, Nieto Y, Ahmed S, Lee HJ, Savage KJ. Outcome of relapsed and refractory nodular lymphocyte-predominant Hodgkin lymphoma: a North American analysis. Br J Haematol 192(3):560-567, 2021. e-Pub 2021. PMID: 33517581.
84. Olson AL, Saliba RM, Oran B, Chen J, Alousi A, Ahmed S, Bashir Q, Ciurea SO, Hosing C, Seon Im J, Kebriaei P, Khouri IF, Mehta R, Nieto Y, Parmar S, Rezvani K, Shah N, Shpall E, Srour SA, Qazilbash M, Andersson BS, Champlin R, Popat UR. Cytogenetics and Blast Count Determine Transplant Outcomes in Patients with Active Acute Myeloid Leukemia. Acta Haematol 144(1):1-8, 2021. e-Pub 2021. PMID: 32604096.
85. Gaballa MR, Ma J, Tanner MR, Al-Juhaishi T, Bashir Q, Srour SA, Saini NY, Ramdial JL, Nieto Y, Murphy R, Rezvani K, Tang G, Lee HC, Patel KK, Kaufman GP, Manasanch EE, Ullah MR, Kebriaei P, Thomas SK, Weber DM, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH. Real-world long-term outcomes in multiple myeloma with VRD induction, Mel200-conditioned auto-HCT, and lenalidomide maintenance. Leuk Lymphoma 63(3):710-721, 2021. e-Pub 2021. PMID: 34686083.
86. Dhakal B, Patel S, Girnius S, Bachegowda L, Fraser R, Davila O, Kanate AS, Assal A, Hanbali A, Bashey A, Pawarode A, Freytes CO, Lee C, Vesole D, Cornell RF, Hildebrandt GC, Murthy HS, Lazarus HM, Cerny J, Yared JA, Schriber J, Berdeja J, Stockerl-Goldstein K, Meehan K, Holmberg L, Solh M, Diaz MA, Kharfan-Dabaja MA, Farhadfar N, Bashir Q, Munker R, Olsson RF, Gale RP, Bayer RL, Seo S, Chhabra S, Hashmi S, Badawy SM, Nishihori T, Gonsalves W, Nieto Y, Efebera Y, Kumar S, Shah N, Qazilbash M, Hari P, D'Souza A. Hematopoietic cell transplantation utilization and outcomes for primary plasma cell leukemia in the current era. Leukemia 34(12):3338-3347, 2020. e-Pub 2020. PMID: 32313109.
87. Saini N, Bashir Q, Milton DR, Tang G, Delgado R, Rondon G, Popat UR, Hosing CM, Nieto Y, Kebriaei P, Alousi AM, Mehta R, Srour S, Khouri IF, Weber DM, Thomas SK, Lee HC, Patel KK, Orlowski RZ, Champlin RE, Qazilbash MH. Busulfan and melphalan conditioning is superior to melphalan alone in autologous stem cell transplantation for high-risk MM. Blood Adv 4(19):4834-4837, 2020. e-Pub 2020. PMID: 33027527.
88. Popat U, Mehta RS, Bassett R, Kongtim P, Chen J, Alousi AM, Anderlini P, Ciurea S, Hosing C, Jones R, Kebriaei P, Khouri I, Lindsay R, Nieto Y, Olson A, Oran B, Qazilbash MH, Rondon G, Shpall EJ, Verstovsek S, Andersson BS, Champlin RE. Optimizing the Conditioning Regimen for Hematopoietic Cell Transplant in Myelofibrosis: Long-Term Results of a Prospective Phase II Clinical Trial. Biol Blood Marrow Transplant 26(8):1439-1445, 2020. e-Pub 2020. PMID: 32438043.
89. Cordas Dos Santos DM, Saliba RM, Patel R, Bashir Q, Saini N, Hosing C, Kebriaei P, Khouri IF, Nieto Y, Popat U, Ahmed H, Lee HC, Manasanch EE, Patel KK, Thomas SK, Weber DM, Orlowski RZ, Champlin RE, Qazilbash MH. Age Is a Prognostic Factor for the Overall Survival of Patients with Multiple Myeloma Undergoing Upfront Autologous Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant 26(6):1077-1083, 2020. e-Pub 2020. PMID: 31786242.
90. Kunacheewa C, Lee HC, Patel K, Thomas S, Amini B, Srour S, Bashir Q, Nieto Y, Qazilbash MH, Weber DM, Feng L, Orlowski RZ, Lin P, Manasanch EE. Minimal Residual Disease Negativity Does Not Overcome Poor Prognosis in High-Risk Multiple Myeloma: A Single-Center Retrospective Study. Clin Lymphoma Myeloma Leuk 20(5):e221-e238, 2020. e-Pub 2020. PMID: 32037287.
91. Saad A, de Lima M, Anand S, Bhatt VR, Bookout R, Chen G, Couriel D, Di Stasi A, El-Jawahri A, Giralt S, Gutman J, Ho V, Horwitz M, Hsu J, Juckett M, Kharfan-Dabaja MA, Loren A, Meade J, Mielcarek M, Moreira J, Nakamura R, Nieto Y, Roddy J, Satyanarayana G, Schroeder M, Tan CR, Tzachanis D, Burn J, Pluchino L. Hematopoietic Cell Transplantation, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 18(5):599-634, 2020. e-Pub 2020. PMID: 32519831.
92. Varma A, Abraham SC, Mehta RS, Saini NY, Honhar M, Rashid M, Chen J, Srour SA, Bashir Q, Rondon G, Oran B, Hosing CM, Nieto Y, Kebriaei P, Alousi AM, Ahmed S, Marin D, Khouri IF, Ciurea SO, Qazilbash MH, Rezvani K, Anderlini P, Andersson BS, Shpall EJ, Champlin RE, Popat UR. Idiopathic refractory ascites after allogeneic stem cell transplantation: a previously unrecognized entity. Blood Adv 4(7):1296-1306, 2020. e-Pub 2020. PMID: 32236526.
93. Varma A, Sui D, Milton DR, Tang G, Saini N, Hasan O, Mukherjee A, Joseph JJ, Bashir Q, Rondon G, Srour S, Popat UR, Hosing CM, Nieto Y, Kebriaei P, Alousi AM, Ahmed S, Mehta R, Khouri IF, Ahmed H, Iyer S, Weber DM, Thomas SK, Manasanch E, Lee HC, Patel K, Ciurea SO, Shpall EJ, Orlowski RZ, Champlin RE, Qazilbash MH. Outcome of Multiple Myeloma With Chromosome 1q Gain and 1p Deletion After Autologous Hematopoietic Stem Cell Transplantation: propensity-score matched analysis: Outcome of 1q+/1p- MM pts after auto-HCT. Biol Blood Marrow Transplant 26(4):665-671, 2020. e-Pub 2020. PMID: 31881283.
94. Malek AE, Nieto Y, Szvalb AD, Siddiqui S, Shafi MA, Hwang JP, Raad II, Torres HA. Hepatitis B Virus-associated Liver Failure in a Patient With B-cell Non-Hodgkin Lymphoma After Anti-cancer Therapy Including Ibrutinib. Clin Lymphoma Myeloma Leuk 20(3):e124-e127, 2020. e-Pub 2020. PMID: 31932250.
95. Srour SA, Singh H, McCarty J, de Groot E, Huls H, Rondon G, Qazilbash M, Ciurea S, Bardelli G, Buck J, Alousi A, Nieto Y, Rezvani K, Marin D, Popat U, Hosing C, Shpall EJ, Wierda WG, Kantarjian H, Champlin RE, Cooper LJ, Kebriaei P. Long-term outcomes of Sleeping Beauty-generated CD19-specific CAR T-cell therapy for relapsed-refractory B-cell lymphomas. Blood 135(11):862-865, 2020. e-Pub 2020. PMID: 31961918.
96. Liu E, Marin D, Banerjee P, Macapinlac HA, Thompson P, Basar R, Nassif Kerbauy L, Overman B, Thall P, Kaplan M, Nandivada V, Kaur I, Nunez Cortes A, Cao K, Daher M, Hosing C, Cohen EN, Kebriaei P, Mehta R, Neelapu S, Nieto Y, Wang M, Wierda W, Keating M, Champlin R, Shpall EJ, Rezvani K. Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors. N Engl J Med 382(6):545-553, 2020. e-Pub 2020. PMID: 32023374.
97. Badar T, Hari P, Dávila O, Fraser R, Wirk B, Dhakal B, Freytes CO, Rodriguez Valdes C, Lee C, Vesole DH, Malek E, Hildebrandt GC, Landau H, Murthy HS, Lazarus HM, Berdeja JG, Meehan KR, Solh M, Diaz MA, Kharfan-Dabaja MA, Callander NS, Farhadfar N, Bashir Q, Kamble RT, Vij R, Munker R, Kyle RA, Chhabra S, Hashmi S, Ganguly S, Jagannath S, Nishihori T, Nieto Y, Kumar S, Shah N, D'Souza A. African Americans with translocation t(11;14) have superior survival after autologous hematopoietic cell transplantation for multiple myeloma in comparison with Whites in the United States. Cancer 127(1):82-92, 2020. e-Pub 2020. PMID: 32966625.
98. Valdez BC, Li Y, Murray D, Liu Y, Nieto Y, Bashir Q, Qazilbash MH, Andersson BS. Panobinostat and venetoclax enhance the cytotoxicity of gemcitabine, busulfan, and melphalan in multiple myeloma cells. Exp Hematol 81:32-41, 2020. e-Pub 2020. PMID: 31954171.
99. Frigault MJ, Armand P, Redd RA, Jeter E, Merryman RW, Coleman KC, Herrera AF, Dahi P, Nieto Y, LaCasce AS, Fisher DC, Ng SY, Odejide OO, Freedman AS, Kim AI, Crombie JL, Jacobson CA, Jacobsen ED, Wong JL, Bsat J, Patel SS, Ritz J, Rodig SJ, Shipp MA, Chen YB, Joyce RM. PD-1 blockade for diffuse large B-cell lymphoma after autologous stem cell transplantation. Blood Adv 4(1):122-126, 2020. e-Pub 2020. PMID: 31917843.
100. Bashir Q, Chamoun K, Milton DR, Khan M, Ahmed S, Mehta R, Popat UR, Kebriaei P, Nieto Y, Oran B, Ciurea SO, Hosing C, Khouri I, Patel K, Manasanch EE, Lee HC, Orlowski RZ, Champlin RE, Qazilbash MH. Outcomes of autologous hematopoietic cell transplantation in myeloma patients aged =75 years. Leuk Lymphoma 60(14):3536-3543, 2019. e-Pub 2019. PMID: 31282244.
101. Mehta RS, Bassett R, Olson A, Chen J, Ahmed S, Alousi AM, Anderlini P, Al-Atrash G, Bashir Q, Ciurea SO, Hosing CM, Im JS, Kebriaei P, Khouri I, Marin D, Molldrem JJ, Nieto Y, Oran B, Rezvani K, Qazilbash MH, Srour SA, Shpall EJ, Andersson BS, Champlin RE, Popat UR. Myeloablative conditioning using timed-sequential busulfan plus fludarabine in older patients with acute myeloid leukemia: long term results of a prospective phase II clinical trial. Haematologica 104(12):E555-E557, 2019. e-Pub 2019. PMID: 30948491.
102. Saini N, Ma J, Milton DR, Patel R, Varma A, Bashir Q, Delgado R, Mukherjee A, Rondon G, Popat UR, Hosing CM, Nieto Y, Kebriaei P, Alousi AM, Ahmed S, Tang G, Mehta R, Srour S, Khouri IF, Iyer S, Weber DM, Thomas SK, Lee HC, Manasanch EE, Patel KK, Orlowski RZ, Champlin RE, Qazilbash MH. Impact of Autologous Transplantation in Patients with Multiple Myeloma with t(11;14): A Propensity-Score Matched Analysis. Clin Cancer Res 25(22):6781-6787, 2019. e-Pub 2019. PMID: 31481508.
103. Ahmed S, Kanakry JA, Ahn KW, Litovich C, Abdel-Azim H, Aljurf M, Bacher VU, Bejanyan N, Cohen JB, Farooq U, Fuchs EJ, Bolaños-Meade J, Ghosh N, Herrera AF, Hossain NM, Inwards D, Kanate AS, Martino R, Munshi PN, Murthy H, Mussetti A, Nieto Y, Perales MA, Romee R, Savani BN, Seo S, Wirk B, Yared JA, Sureda A, Fenske TS, Hamadani M. Lower Graft-versus-Host Disease and Relapse Risk in Post-Transplant Cyclophosphamide-Based Haploidentical versus Matched Sibling Donor Reduced-Intensity Conditioning Transplant for Hodgkin Lymphoma. Biol Blood Marrow Transplant 25(9):1859-1868, 2019. e-Pub 2019. PMID: 31132455.
104. Gowda L, Shah M, Badar I, Bashir Q, Shah N, Patel K, Kanagal-Shamanna R, Mehta R, Weber DM, Lee HC, Manasanch EE, Shah A, Thomas SK, Parmar S, Nieto Y, Orlowski RZ, Champlin R, Qazilbash MH. Primary plasma cell leukemia: autologous stem cell transplant in an era of novel induction drugs. Bone Marrow Transplant 54(7):1089-1093, 2019. e-Pub 2018. PMID: 30446740.
105. Saini NY, Saliba RM, Rondon G, Maadani F, Popat U, Hosing CM, Betul O, Bashir Q, Olson A, Nieto Y, Alousi A, Kebriaei P, Srour S, Mehta R, Anderlini P, Shpall EJ, Qazilbash MH, Khouri IF, Fayad L, Lee H, Fowler N, Parmar S, Westin J, Hagemeister F, Champlin RE, Ciurea SO. Impact of Donor Type and Melphalan Dose on Allogeneic Transplantation Outcomes for Patients with Lymphoma. Biol Blood Marrow Transplant 25(7):1340-1346, 2019. e-Pub 2019. PMID: 30763728.
106. Armand P, Chen YB, Redd RA, Joyce RM, Bsat J, Jeter E, Merryman RW, Coleman KC, Dahi PB, Nieto Y, LaCasce AS, Fisher DC, Ng SY, Odejide OO, Freedman AS, Kim AI, Crombie JL, Jacobson CA, Jacobsen ED, Wong JL, Patel SS, Ritz J, Rodig SJ, Shipp MA, Herrera AF. PD-1 Blockade with Pembrolizumab for Classical Hodgkin Lymphoma after Autologous Stem Cell Transplantation. Blood 134(1):22-29, 2019. e-Pub 2019. PMID: 30952672.
107. Kilari D, D'Souza A, Fraser R, Qayed M, Davila O, Agrawal V, Diaz MA, Chhabra S, Cerny J, Copelan E, Farhadfar N, Freytes CO, Gale RP, Ganguly S, Hildebrandt GC, Holmberg L, Kamble RT, Kapoor P, Lazarus H, Lee C, Murthy HS, Naik S, Nishihori T, Saad A, Savani BN, Seo S, Warwick A, Wirk B, Yared JA, Nieto Y, Hari P. Autologous Hematopoietic Cell Transplantation for Male Germ Cell Tumors: Improved Outcomes Over 3 Decades. Biol Blood Marrow Transplant 25(6):1099-1106, 2019. e-Pub 2019. PMID: 30794931.
108. Bashir Q, Thall PF, Milton DR, Fox PS, Kawedia JD, Kebriaei P, Shah N, Patel K, Andersson BS, Nieto YL, Valdez BC, Parmar S, Rondon G, Delgado R, Hosing C, Popat UR, Oran B, Ciurea SO, Lin P, Weber DM, Thomas SK, Lee HC, Manasanch EE, Orlowski RZ, Williams LA, Champlin RE, Qazilbash MH. Conditioning with busulfan plus melphalan versus melphalan alone before autologous haemopoietic cell transplantation for multiple myeloma: an open-label, randomized, phase 3 trial. Lancet Haematol 6(5):e266-e275, 2019. e-Pub 2019. PMID: 30910541.
109. Gopalakrishnan S, D'Souza A, Scott E, Fraser R, Davila O, Shah N, Gale RP, Kamble R, Diaz MA, Lazarus HM, Savani BN, Hildebrandt GC, Solh M, Freytes CO, Lee C, Kyle RA, Usmani SZ, Ganguly S, Assal A, Berdeja J, Kanate AS, Dhakal B, Meehan K, Kindwall-Keller T, Saad A, Locke F, Seo S, Nishihori T, Gergis U, Gasparetto C, Mark T, Nieto Y, Kumar S, Hari P. Revised-International Staging System (R-ISS) is Predictive and Prognostic for Early Relapse (<24 months) after Autologous Transplantation for Newly Diagnosed Multiple Myeloma (MM). Biol Blood Marrow Transplant 25(4):683-688, 2019. e-Pub 2019. PMID: 30579965.
110. Veltri L, Rezvani K, Oran B, Mehta R, Rondon G, Kebriaei P, Popat U, Nieto Y, Hosing C, Qazilbash M, Khouri I, Shpall E, Champlin R, Marin D. Allotransplants for patients 65 years or older with high-risk acute myeloid leukemia. Biol Blood Marrow Transplant 25(3):505-514, 2019. e-Pub 2019. PMID: 30308325.
111. Hu B, Thall P, Milton DR, Sasaki K, Bashir Q, Shah N, Patel K, Popat U, Hosing C, Nieto Y, Lin P, Delgado R, Jorgensen J, Manasanch E, Weber D, Thomas S, Orlowski RZ, Champlin R, Qazilbash MH. High-risk myeloma and minimal residual disease postautologous-HSCT predict worse outcomes. Leuk Lymphoma 60(2):1-11, 2019. e-Pub 2019. PMID: 30032678.
112. Yoder AK, Gunther JR, Milgrom SA, Mirkovic D, Nastoupil L, Neelapu S, Fanale M, Fowler N, Westin J, Lee HJ, Rodriguez MA, Iyer SP, Fayad L, Nieto YL, Hosing C, Ahmed S, Medeiros LJ, Khoury JD, Garg N, Amini B, Dabaja BS, Pinnix CC. Hitting a Moving Target: Successful Management of Diffuse Large B-cell Lymphoma Involving the Mesentery With Volumetric Image-guided Intensity Modulated Radiation Therapy. Clin Lymphoma Myeloma Leuk 19(1):e51-e61, 2019. e-Pub 2019. PMID: 30360985.
113. Kellner JN, Delemarre EM, Yvon E, Nierkens S, Boelens JJ, McNiece I, Olson A, Nieto Y, Ciurea S, Popat U, Ahmed S, Champlin R, Ramos J, Nishimoto M, Ma H, Ke Z, Thall P, Khoury JD, Negrin R, Andersson B, Parmar S. Third party, umbilical cord blood derived regulatory T-cells for prevention of graft versus host disease in allogeneic hematopoietic stem cell transplantation: feasibility, safety and immune reconstitution. Oncotarget 9(86):35611-35622, 2018. e-Pub 2018. PMID: 30479692.
114. Popat UR, Mehta RS, Bassett R, Chen J, Valdez BC, Kawedia J, Ahmed S, Alousi AM, Anderlini P, Al-Atrash G, Bashir Q, Ciurea SO, Hosing CM, Im JS, Jones R, Kebriaei P, Khouri I, Marin D, Nieto Y, Olson A, Oran B, Parmar S, Rezvani K, Qazilbash MH, Shah N, Srour SA, Shpall EJ, Champlin RE, Andersson BS. Fludarabine with a higher versus lower dose of myeloablative timed-sequential busulfan in older patients and patients with comorbidities: an open-label, non-stratified, randomised phase 2 trial. Lancet Haematol 5(11):e532-e542, 2018. e-Pub 2018. PMID: 30389035.
115. Sheu T, Milgrom SA, Andraos TY, Gunther JR, Chi L, Nastoupil L, Fowler N, Oki Y, Fanale MA, Fayad LE, Hagemeister F, Neelapu SS, Medeiros LJ, Hosing C, Nieto Y, Ahmed S, Alousi AM, Dabaja B, Pinnix CC. Response-adapted radiation therapy for newly diagnosed primary diffuse large B-cell lymphoma of the CNS treated with methotrexate-based systemic therapy. Adv Radiat Oncol 3(4):639-646, 2018. e-Pub 2018. PMID: 30370365.
116. Pinnix CC, Cella L, Andraos TY, Ayoub Z, Milgrom SA, Gunther J, Thosani S, Wogan C, Conson M, D'Avino V, Oki Y, Fanale M, Lee HJ, Neelapu S, Fayad L, Hagemeister F, Rodriguez MA, Nastoupil LJ, Nieto Y, Qiao W, Pacelli R, Dabaja B. Predictors of Hypothyroidism in Hodgkin Lymphoma Survivors After Intensity Modulated Versus 3-Dimensional Radiation Therapy. Int J Radiat Oncol Biol Phys 101(3):530-540, 2018. e-Pub 2018. PMID: 29681481.
117. Milgrom SA, Pinnix CC, Chi TL, Vu TH, Gunther JR, Sheu T, Fowler N, Westin JR, Nastoupil LJ, Oki Y, Fayad LE, Neelapu S, Rodriguez MA, Hagemeister FB, Fanale MA, Lee HJ, Hosing C, Ahmed S, Nieto Y, Shpall EJ, Dabaja BS. Radiation Therapy as an Effective Salvage Strategy for Secondary CNS Lymphoma. Int J Radiat Oncol Biol Phys 100(5):1146-1154, 2018. e-Pub 2018. PMID: 29452771.
118. Kumar SK, Dispenzieri A, Fraser R, Mingwei F, Akpek G, Cornell R, Kharfan-Dabaja M, Freytes C, Hashmi S, Hildebrandt G, Holmberg L, Kyle R, Lazarus H, Lee C, Mikhael J, Nishihori T, Tay J, Usmani S, Vesole D, Vij R, Wirk B, Krishnan A, Gasparetto C, Mark T, Nieto Y, Hari P, D'Souza A. Early relapse after autologous hematopoietic cell transplantation remains a poor prognostic factor in multiple myeloma but outcomes have improved over time. Leukemia 32(4):986-995, 2018. e-Pub 2018. PMID: 29263438.
119. Hu B, Younes A, Westin JR, Turturro F, Claret L, Feng L, Fowler N, Neelapu S, Romaguera J, Hagemeister FB, Rodriguez MA, Samaniego F, Fayad LE, Copeland AR, Nastoupil LJ, Nieto Y, Fanale MA, Oki Y. Phase-I and randomized phase-II trial of panobinostat in combination with ICE (ifosfamide, carboplatin, etoposide) in relapsed or refractory classical Hodgkin lymphoma. Leuk Lymphoma 59(4):863-870, 2018. e-Pub 2018. PMID: 28792260.
120. Ragon BK, Mehta RS, Gulbis AM, Saliba RM, Chen J, Rondon G, Popat UR, Nieto Y, Oran B, Olson AL, Patel K, Hosing CM, Qazilbash MH, Shah N, Kebriaei P, Shpall EJ, Champlin RE, Alousi AM. Pentostatin therapy for steroid-refractory acute graft versus host disease: identifying those who may benefit. Bone Marrow Transplant 53(3):315-325, 2018. e-Pub 2018. PMID: 29269797.
121. Oran B, Saliba RM, Carmazzi Y, de Lima M, Rondon G, Ahmed S, Alousi A, Andersson BS, Anderlini P, Alvarez M, Bashir Q, Ciurea S, Fernandez-Vina M, Hosing C, Kebriaei P, Korbling M, Cano P, Khouri I, Marin D, Nieto Y, Olson A, Popat U, Rezvani K, Qazilbash M, Shpall EJ, Champlin RE, Cao K. Effect of nonpermissive HLA-DPB1 mismatches after unrelated allogeneic transplantation with in vivo T-cell depletion. Blood 131(11):1248-1257, 2018. e-Pub 2018. PMID: 29386198.
122. Htut M, D'Souza A, Krishnan A, Bruno B, Zhang MJ, Fei M, Diaz MA, Copelan E, Ganguly S, Hamadani M, Kharfan-Dabaja M, Lazarus H, Lee C, Meehan K, Nishihori T, Saad A, Seo S, Ramanathan M, Usmani SZ, Gasparetto C, Mark TM, Nieto Y, Hari P. Autologous/Allogeneic Hematopoietic Cell Transplantation (HCT) Versus Tandem Autologous Transplantation for Multiple Myeloma - Comparison of Long Term Post Relapse Survival. Biol Blood Marrow Transplant 24(3):478-485, 2018. e-Pub 2018. PMID: 29079457.
123. Brammer JE, Chihara D, Poon LM, Caimi P, de Lima M, Ledesma C, Rondon G, Ciurea SO, Nieto Y, Fanale M, Dabaja B, Maziarz RT, Champlin RE, Hosing C, Oki Y. Management of Advanced and Relapsed/Refractory Extranodal Natural Killer T-Cell Lymphoma: An Analysis of Stem Cell Transplantation and Chemotherapy Outcomes. Clin Lymphoma Myeloma Leuk 18(1):e41-e50, 2018. e-Pub 2018. PMID: 29277360.
124. Valdez BC, Li Y, Murray D, Liu Y, Nieto Y, Champlin RE, Andersson BS. Combination of a hypomethylating agent and inhibitors of PARP and HDAC traps PARP1 and DNMT1 to chromatin, acetylates DNA repair proteins, down-regulates NuRD and induces apoptosis in human leukemia and lymphoma cells. Oncotarget 9(3):3908-3921, 2018. e-Pub 2018. PMID: 29423093.
125. Mahindra A, Hari P, Fraser R, Fei M, Huang J, Berdeja J, Callander N, Costa L, Diaz MA, Freytes C, Gale RP, Girnius S, Holmberg L, Kharfan-Dabaja M, Kumar S, Kyle R, Lazarus H, Lee C, Maiolino A, Moreb J, Nishihori T, Pawarode A, Saad A, Savani BN, Schriber J, William B, Wirk BM, Krishnan A, Nieto Y, D'Souza A. Autologous hematopoietic cell transplantation for multiple myeloma patients with renal insufficiency: a center for international blood and marrow transplant research analysis. Bone Marrow Transplant 52(12):1616-1622, 2017. e-Pub 2017. PMID: 28920949.
126. Shah N, Cornelison AM, Saliba R, Ahmed S, Nieto YL, Bashir Q, Parmar S, Hosing C, Popat U, Shpall EJ, Champlin RE, Qazilbash M. Inpatient vs outpatient autologous hematopoietic stem cell transplantation for multiple myeloma. Eur J Haematol 99(6):532-535, 2017. e-Pub 2017. PMID: 28895206.
127. Im JS, Abraham SC, Saliba RM, Rondon G, Ross WA, Rashid A, Shpall EJ, Popat U, Qazilbash MH, Hosing C, Oran B, Shah N, Tewari P, Nieto Y, Kebriaei P, Champlin RE, Alousi AM. Histologic Grade 1 is Associated With Increased Nonrelapsed Mortality in Lower Gastrointestinal Graft Versus Host Disease. Am J Surg Pathol 41(11):1483-1490, 2017. e-Pub 2017. PMID: 28834808.
128. Valdez BC, Li Y, Murray D, Liu Y, Nieto Y, Champlin RE, Andersson BS. The PARP inhibitor olaparib enhances the cytotoxicity of combined gemcitabine, busulfan and melphalan in lymphoma cells. Leuk Lymphoma 58(11):2705-2716, 2017. e-Pub 2017. PMID: 28394191.
129. Veltri LW, Milton DR, Delgado R, Shah N, Patel K, Nieto Y, Kebriaei P, Popat UR, Parmar S, Oran B, Ciurea S, Hosing C, Lee HC, Manasanch E, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH, Bashir Q. Outcome of autologous hematopoietic stem cell transplantation in refractory multiple myeloma. Cancer 123(18):3568-3575, 2017. e-Pub 2017. PMID: 28513828.
130. Schriber JR, Hari PN, Ahn KW, Fei M, Costa LJ, Kharfan-Dabaja MA, Angel-Diaz M, Gale RP, Ganguly S, Girnius SK, Hashmi S, Pawarode A, Vesole DH, Wiernik PH, Wirk BM, Marks DI, Nishihori T, Olsson RF, Usmani SZ, Mark TM, Nieto YL, D'Souza A. Hispanics have the lowest stem cell transplant utilization rate for autologous hematopoietic cell transplantation for multiple myeloma in the United States: A CIBMTR report. Cancer 123(16):3141-3149, 2017. e-Pub 2017. PMID: 28472539.
131. Silva JG, Maher OM, Park M, Liu D, Hernandez F, Tewari P, Nieto Y. Prognostic Analysis of Absolute Lymphocyte and Monocyte Counts after Autologous Stem Cell Transplant in Children, Adolescents, and Young Adults with Refractory or Relapsed Hodgkin's Lymphoma. Biol Blood Marrow Transplant 23(8):1276-1281, 2017. e-Pub 2017. PMID: 28435146.
132. Srour SA, Li S, Popat UR, Qazilbash MH, Lozano-Cerrada S, Maadani F, Alousi A, Kebriaei P, Anderlini P, Nieto Y, Jones R, Shpall E, Champlin RE, Hosing C. A randomized phase II study of standard-dose versus high-dose rituximab with BEAM in autologous stem cell transplantation for relapsed aggressive B-cell non-hodgkin lymphomas: long term results. Br J Haematol 178(4):561-570, 2017. e-Pub 2017. PMID: 28485023.
133. Nieto Y, Thall PF, Ma J, Valdez BC, Ahmed S, Anderlini P, Popat U, Jones RB, Shpall EJ, Hosing C, Qazilbash M, Kebriaei P, Alousi A, Timmons M, Gulbis A, Myers A, Oki Y, Fanale M, Dabaja B, Pinnix C, Milgrom S, Champlin R, Andersson BS. Phase II Trial of High-Dose Gemcitabine/Busulfan/Melphalan with Autologous Stem Cell Transplantation for Primary Refractory or Poor-Risk Relapsed Hodgkin Lymphoma. Biol Blood Marrow Transplant 24(8):1602-1609, 2017. e-Pub 2017. PMID: 29501779.
134. Pingali SR, Saliba RM, Anderlini P, Chitra H, Khouri I, Alousi AM, Nieto Y, Qazilbash MH, Champlin R, Popat UR. Age over Fifty-Five Years at Diagnosis Increases Risk of Second Malignancies after Autologous Transplantation for Patients with Hodgkin Lymphoma. Biol Blood Marrow Transplant 23(7):1059-1063, 2017. e-Pub 2017. PMID: 28389254.
135. Nieto Y, Valdez BC, Pingali SR, Bassett R, Delgado R, Nguyen J, Shah N, Popat U, Jones RB, Andersson BS, Gulbis A, Ahmed S, Bashir Q, Parmar S, Patel K, Myers A, Rondon G, Orlowski RZ, Champlin R, Qazilbash M. High-dose gemcitabine, busulfan, and melphalan for autologous stem-cell transplant in patients with relapsed or refractory myeloma: a phase 2 trial and matched-pair comparison with melphalan. Lancet Haematol 4(6):e283-e292, 2017. e-Pub 2017. PMID: 28522110.
136. Shah N, Li L, McCarty J, Kaur I, Yvon E, Shaim H, Muftuoglu M, Liu E, Orlowski RZ, Cooper L, Lee D, Parmar S, Cao K, Sobieiski C, Saliba R, Hosing C, Ahmed S, Nieto Y, Bashir Q, Patel K, Bollard C, Qazilbash M, Champlin R, Rezvani K, Shpall EJ. Phase I study of cord blood-derived natural killer cells combined with autologous stem cell transplantation in multiple myeloma. Br J Haematol 177(3):457-466, 2017. e-Pub 2017. PMID: 28295190.
137. Thompson PA, Stingo F, Keating MJ, Wierda WG, O'Brien SM, Estrov Z, Ledesma C, Rezvani K, Qazilbash M, Shah N, Parmar S, Popat U, Anderlini P, Nieto Y, Ciurea SO, Kebriaei P, Champlin R, Shpall EJ, Hosing CM. Long-term follow-up of patients receiving allogeneic stem cell transplant for chronic lymphocytic leukaemia: mixed T-cell chimerism is associated with high relapse risk and inferior survival. Br J Haematol 177(4):567-577, 2017. e-Pub 2017. PMID: 28295181.
138. Milgrom SA, Jauhari S, Plastaras JP, Nieto Y, Dabaja BS, Pinnix CC, Smith GL, Allen PK, Lukens JN, Maity A, Oki Y, Fanale MA, Nasta SD. A multi-institutional analysis of peritransplantation radiotherapy in patients with relapsed/refractory Hodgkin lymphoma undergoing autologous stem cell transplantation. Cancer 123(8):1363-1371, 2017. e-Pub 2017. PMID: 27984652.
139. Andersson BS, Thall PF, Valdez BC, Milton DR, Al-Atrash G, Chen J, Gulbis A, Chu D, Martinez C, Parmar S, Popat U, Nieto Y, Kebriaei P, Alousi A, de Lima M, Rondon G, Meng QH, Myers A, Kawedia J, Worth LL, Fernandez-Vina M, Madden T, Shpall EJ, Jones RB, Champlin RE. Fludarabine with pharmacokinetically guided IV busulfan is superior to fixed-dose delivery in pretransplant conditioning of AML/MDS patients. Bone Marrow Transplant 52(4):580-587, 2017. e-Pub 2017. PMID: 27991894.
140. Ge I, Saliba RM, Maadani F, Popat UR, Qazilbash MH, Ravi Pingali S, Shah N, Ahmed S, Bashir Q, Nieto Y, Champlin RE, Hosing C. Patient age and number of apheresis days may predict development of secondary myelodysplastic syndrome and acute myelogenous leukemia after high-dose chemotherapy and autologous stem cell transplantation for lymphoma. Transfusion 57(4):1052-1057, 2017. e-Pub 2017. PMID: 28185276.
141. Badar T, Srour S, Bashir Q, Shah N, Al-Atrash G, Hosing C, Popat U, Nieto Y, Orlowski RZ, Champlin R, Qazilbash MH. Predictors of inferior clinical outcome in patients with standard risk multiple myeloma. Eur J Haematol 98(3):263-268, 2017. e-Pub 2017. PMID: 27862330.
142. Chihara D, Fanale MA, Miranda RN, Noorani M, Westin JR, Nastoupil LJ, Hagemeister FB, Fayad LE, Romaguera JE, Samaniego F, Turturro F, Lee HJ, Neelapu SS, Rodriguez MA, Wang M, Fowler NH, Davis RE, Medeiros LJ, Hosing C, Nieto YL, Oki Y. The survival outcome of patients with relapsed/refractory peripheral T-cell lymphoma-not otherwise specified and angioimmunoblastic T-cell lymphoma. Br J Haematol 176(5):750-758, 2017. e-Pub 2017. PMID: 27983760.
143. Cornell RF, D'Souza A, Kassim AA, Costa LJ, Innis-Shelton RD, Zhang MJ, Huang J, Abidi M, Aiello J, Akpek G, Bashey A, Bashir Q, Cerny J, Comenzo R, Diaz MA, Freytes C, Gale RP, Ganguly S, Hamadani M, Hashmi S, Holmberg L, Hossain N, Kamble RT, Kharfan-Dabaja M, Kindwall-Keller T, Kyle R, Kumar S, Lazarus H, Lee C, Maiolino A, Marks DI, Meehan K, Mikhael J, Nath R, Nishihori T, Olsson RF, Ramanathan M, Saad A, Seo S, Usmani S, Vesole D, Vij R, Vogl D, Wirk BM, Yared J, Krishnan A, Mark T, Nieto Y, Hari P. Maintenance Versus Induction Therapy Choice on Outcomes after Autologous Transplantation for Multiple Myeloma. Biol Blood Marrow Transplant 23(2):269-277, 2017. e-Pub 2017. PMID: 27864161.
144. Kebriaei P, Bassett R, Lyons G, Valdez B, Ledesma C, Rondon G, Oran B, Ciurea S, Alousi A, Popat U, Patel K, Ahmed S, Olson A, Bashir Q, Shah N, Jones R, Marin D, Rezvani K, Nieto Y, Khouri I, Qazilbash M, Hosing C, Shpall E, Champlin RE, Andersson BS. Clofarabine Plus Busulfan is an Effective Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Lymphoblastic Leukemia: Long-Term Study Results. Biol Blood Marrow Transplant 23(2):285-292, 2017. e-Pub 2017. PMID: 27816651.
145. Brammer JE, Khouri I, Marin D, Ledesma C, Rondon G, Ciurea SO, Nieto Y, Champlin RE, Hosing C, Kebriaei P. Stem cell transplantation outcomes in lymphoblastic lymphoma. Leuk Lymphoma 58(2):366-371, 2017. e-Pub 2017. PMID: 27348707.
146. Cornell RF, Bachanova V, D'Souza A, Woo-Ahn K, Martens M, Huang J, Al-Homsi AS, Chhabra S, Copelan E, Diaz MA, Freytes CO, Gale RP, Ganguly S, Hamadani M, Hildebrandt G, Kamble RT, Kharfan-Dabaja M, Kindwall-Keller T, Lazarus HM, Marks DI, Nishihori T, Olsson RF, Saad A, Usmani S, Vesole DH, Yared J, Mark T, Nieto Y, Hari P. Allogeneic Transplantation for Relapsed Waldenström Macroglobulinemia and Lymphoplasmacytic Lymphoma. Biol Blood Marrow Transplant 23(1):60-66, 2017. e-Pub 2017. PMID: 27789362.
147. Cheng YC, Shi Y, Zhang MJ, Brazauskas R, Hemmer MT, Bishop MR, Nieto Y, Stadtmauer E, Ayash L, Gale RP, Lazarus H, Holmberg L, Lill M, Olsson RF, Wirk BM, Arora M, Hari P, Ueno N. Long-Term Outcome of Inflammatory Breast Cancer Compared to Non-Inflammatory Breast Cancer in the Setting of High-Dose Chemotherapy with Autologous Hematopoietic Cell Transplantation. J Cancer 8(6):1009-1017, 2017. e-Pub 2017. PMID: 28529613.
148. Mian I, Milton DR, Shah N, Nieto Y, Popat UR, Kebriaei P, Parmar S, Oran B, Shah JJ, Manasanch EE, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH, Bashir Q. Prolonged survival with a longer duration of maintenance lenalidomide after autologous hematopoietic stem cell transplantation for multiple myeloma. Cancer 122(24):3831-3837, 2016. e-Pub 2016. PMID: 27680710.
149. Gaballa S, Ge I, El Fakih R, Brammer JE, Kongtim P, Tomuleasa C, Wang SA, Lee D, Petropoulos D, Cao K, Rondon G, Chen J, Hammerstrom A, Lombardi L, Alatrash G, Korbling M, Oran B, Kebriaei P, Ahmed S, Shah N, Rezvani K, Marin D, Bashir Q, Alousi A, Nieto Y, Qazilbash M, Hosing C, Popat U, Shpall EJ, Khouri I, Champlin RE, Ciurea SO. Results of a 2-arm, phase 2 clinical trial using post-transplantation cyclophosphamide for the prevention of graft-versus-host disease in haploidentical donor and mismatched unrelated donor hematopoietic stem cell transplantation. Cancer 122(21):3316-3326, 2016. e-Pub 2016. PMID: 27404668.
150. Teo EC, Valdez BC, Ji J, Li Y, Liu Y, Brammer JE, Hosing C, Nieto Y, Champlin RE, Andersson BS. Synergistic cytotoxicity of busulfan, melphalan, gemcitabine, panobinostat, and bortezomib in lymphoma cells. Leuk Lymphoma 57(11):2644-2652, 2016. e-Pub 2016. PMID: 26980288.
151. Scott EC, Hari P, Sharma M, Le-Rademacher J, Huang J, Vogl D, Abidi M, Beitinjaneh A, Fung H, Ganguly S, Hildebrandt G, Holmberg L, Kalaycio M, Kumar S, Kyle R, Lazarus H, Lee C, Maziarz RT, Meehan K, Mikhael J, Nishihori T, Ramanathan M, Usmani S, Tay J, Vesole D, Wirk B, Yared J, Savani BN, Gasparetto C, Krishnan A, Mark T, Nieto Y, D'Souza A. Post-Transplant Outcomes in High-Risk Compared with Non-High-Risk Multiple Myeloma: A CIBMTR Analysis. Biol Blood Marrow Transplant 22(10):1893-1899, 2016. e-Pub 2016. PMID: 27496215.
152. Nieto Y, Valdez BC, Thall PF, Jones RB, Wei W, Myers A, Hosing C, Ahmed S, Popat U, Shpall EJ, Qazilbash M, Gulbis A, Anderlini P, Shah N, Bashir Q, Alousi A, Oki Y, Fanale M, Dabaja B, Pinnix C, Champlin R, Andersson BS. Double epigenetic modulation of high-dose chemotherapy with azacitidine and vorinostat for patients with refractory or poor-risk relapsed lymphoma. Cancer 122(17):2680-2688, 2016. e-Pub 2016. PMID: 27203405.
153. Valdez BC, Li Y, Murray D, Brammer JE, Liu Y, Hosing C, Nieto Y, Champlin RE, Andersson BS. Differential effects of histone deacetylase inhibitors on cellular drug transporters and their implications for using epigenetic modifiers in combination chemotherapy. Oncotarget 7(39):63829-63838, 2016. e-Pub 2016. PMID: 27564097.
154. Kebriaei P, Singh H, Huls MH, Figliola MJ, Bassett R, Olivares S, Jena B, Dawson MJ, Kumaresan PR, Su S, Maiti S, Dai J, Moriarity B, Forget MA, Senyukov V, Orozco A, Liu T, McCarty J, Jackson RN, Moyes JS, Rondon G, Qazilbash M, Ciurea S, Alousi A, Nieto Y, Rezvani K, Marin D, Popat U, Hosing C, Shpall EJ, Kantarjian H, Keating M, Wierda W, Do KA, Largaespada DA, Lee DA, Hackett PB, Champlin RE, Cooper LJ. Phase I trials using Sleeping Beauty to generate CD19-specific CAR T cells. J Clin Invest 126(9):3363-3376, 2016. e-Pub 2016. PMID: 27482888.
155. Valdez BC, Brammer JE, Li Y, Murray D, Teo EC, Liu Y, Hosing C, Nieto Y, Champlin RE, Andersson BS. Romidepsin enhances the cytotoxicity of fludarabine, clofarabine and busulfan combination in malignant T-cells. Leuk Res 47:100-108, 2016. e-Pub 2016. PMID: 27294334.
156. Milgrom SA, Nieto Y, Pinnix CC, Smith GL, Wogan CF, Rondon G, Medeiros LJ, Kebriaei P, Dabaja BS. Graft-versus-host disease after radiation therapy in patients who have undergone allogeneic stem cell transplantation: two case reports. J Med Case Rep 10(1):209, 2016. e-Pub 2016. PMID: 27465468.
157. Sekine T, Marin D, Cao K, Li L, Mehta P, Shaim H, Sobieski C, Jones R, Oran B, Hosing C, Rondon G, Alsuliman A, Paust S, Andersson B, Popat U, Kebriaei P, Muftuoglu M, Basar R, Kondo K, Nieto Y, Shah N, Olson A, Alousi A, Liu E, Sarvaria A, Parmar S, Armstrong-James D, Imahashi N, Molldrem J, Champlin R, Shpall EJ, Rezvani K. Specific combinations of donor and recipient KIR-HLA genotypes predict for large differences in outcome after cord blood transplantation. Blood 128(2):297-312, 2016. e-Pub 2016. PMID: 27247137.
158. Anderlini P, Saliba RM, Ledesma C, Plair T, Alousi AM, Hosing CM, Khouri IF, Nieto Y, Popat UR, Shpall EJ, Fanale MA, Hagemeister FB, Oki Y, Neelapu S, Romaguera JE, Younes A, Champlin RE. Gemcitabine, Fludarabine, and Melphalan for Reduced-Intensity Conditioning and Allogeneic Stem Cell Transplantation for Relapsed and Refractory Hodgkin Lymphoma. Biol Blood Marrow Transplant 22(7):1333-1337, 2016. e-Pub 2016. PMID: 27064056.
159. Cheah CY, Chihara D, Horowitz S, Sevin A, Oki Y, Zhou S, Fowler NH, Romaguera JE, Turturro F, Hagemeister FB, Fayad LE, Wang M, Neelapu SS, Nastoupil LJ, Westin JR, Rodriguez MA, Samaniego F, Anderlini P, Nieto Y, Fanale MA. Patients with classical Hodgkin lymphoma experiencing disease progression after treatment with brentuximab vedotin have poor outcomes. Ann Oncol 27(7):1317-1323, 2016. e-Pub 2016. PMID: 27091808.
160. Tu SM, Bilen MA, Hess KR, Broaddus RR, Kopetz S, Wei C, Pagliaro LC, Karam JA, Ward JF, Wood CG, Rao P, Tu ZH, General R, Chen AH, Nieto YL, Yeung SJ, Lin SH, Logothetis CJ, Pisters LL. Intratumoral heterogeneity: Role of differentiation in a potentially lethal phenotype of testicular cancer. Cancer 122(12):1836-1843, 2016. e-Pub 2016. PMID: 27018785.
161. Ji J, Valdez BC, Li Y, Liu Y, Teo EC, Nieto Y, Champlin RE, Andersson BS. Cladribine, gemcitabine, busulfan, and SAHA combination as a potential pretransplant conditioning regimen for lymphomas: A preclinical study. Exp Hematol 44(6):458-465, 2016. e-Pub 2016. PMID: 26976752.
162. Aung FM, Lichtiger B, Rondon G, Yin CC, Alousi A, Ahmed S, Andersson BS, Bashir Q, Ciurea SO, Hosing C, Jones R, Kebriaei P, Khouri I, Nieto Y, Oran B, Parmar S, Qazilbash M, Shah N, Shpall EJ, Champlin RE, Popat U. Pure Red Cell Aplasia in Major ABO Mismatched Allogeneic Hematopoietic Stem Cell Transplantation is Associated with Severe Pancytopenia. Biol Blood Marrow Transplant 22(5):961-965, 2016. e-Pub 2016. PMID: 26921820.
163. Shinozuka K, Tang H, Jones RB, Li D, Nieto Y. Impact of Polymorphic Variations of Gemcitabine Metabolism, DNA Damage Repair, and Drug-Resistance Genes on the Effect of High-Dose Chemotherapy for Relapsed or Refractory Lymphoid Malignancies. Biol Blood Marrow Transplant 22(5):843-849, 2016. e-Pub 2016. PMID: 26743341.
164. Yabe M, Medeiros LJ, Tang G, Wang SA, Ahmed S, Nieto Y, Hu S, Bhagat G, Oki Y, Patel KP, Routbort M, Luthra R, Fanale MA, Bueso-Ramos CE, Jorgensen JL, Vega F, Chen W, Hoehn D, Konoplev S, Milton DR, Wistuba I, Li S, You MJ, Young KH, Miranda RN. Prognostic Factors of Hepatosplenic T-cell Lymphoma: Clinicopathologic Study of 28 Cases. Am J Surg Pathol 40(5):676-88, 2016. e-Pub 2016. PMID: 26872013.
165. Pinnix CC, Shah JJ, Chuang H, Costelloe CM, Medeiros LJ, Wogan CF, Reed V, Smith GL, Milgrom S, Patel K, Huo J, Turturro F, Romaguera J, Fayad L, Oki Y, Fanale MA, Westin J, Nastoupil L, Hagemeister FB, Rodriguez A, Qazilbash M, Shah N, Bashir Q, Ahmed S, Nieto Y, Hosing C, Rohren E, Dabaja B. Doxorubicin-Based Chemotherapy and Radiation Therapy Produces Favorable Outcomes in Limited-Stage Plasmablastic Lymphoma: A Single-Institution Review. Clin Lymphoma Myeloma Leuk 16(3):122-128, 2016. e-Pub 2016. PMID: 26795083.
166. Hosing C, Bassett R, Dabaja B, Talpur R, Alousi A, Ciurea S, Popat U, Qazilbash M, Shpall EJ, Oki Y, Nieto Y, Pinnix C, Fanale M, Maadani F, Donato M, Champlin R, Duvic M. Allogeneic Stem Cell Transplantation in Patients With Cutaneous Lymphoma: Updated Results From a Single Institution. Ann Oncol 26(12):2490-2495, 2015. e-Pub 2015. PMID: 26416896.
167. Nieto Y, Valdez BC, Thall PF, Ahmed S, Jones RB, Hosing C, Popat U, Shpall EJ, Qazilbash M, Gulbis A, Anderlini P, Alousi A, Shah N, Bashir Q, Liu Y, Oki Y, Hagemeister F, Fanale M, Dabaja B, Pinnix C, Champlin R, Andersson BS. Vorinostat Combined with High-Dose Gemcitabine, Busulfan and Melphalan with Autologous Stem-Cell Transplantation in Patients with Refractory Lymphomas. Biol Blood Marrow Transplant 21(11):1914-1920, 2015. e-Pub 2015. PMID: 26071868.
168. Kazmi SM, Nusrat M, Gunaydin H, Cornelison AM, Shah N, Kebriaei P, Nieto Y, Parmar S, Popat UR, Oran B, Shah JJ, Orlowski RZ, Champlin RE, Qazilbash MH, Bashir Q. Outcomes Among High-Risk and Standard-Risk Multiple Myeloma Patients Treated With High-Dose Chemotherapy and Autologous Hematopoietic Stem-Cell Transplantation. Clin Lymphoma Myeloma Leuk 15(11):687-93, 2015. e-Pub 2015. PMID: 26361647.
169. Valdez, B, Brammer, JE, Li, Y, Murray, D, Liu, Y, Hosing, C, Nieto, Y, Champlin, RE, Andersson, BS. Romidepsin targets multiple survival signaling pathways in malignant T cells. Blood cancer journal 5(10), 2015. e-Pub 2015. PMID: 25957314.
170. Oran B, Cao K, Saliba RM, Rezvani K, de Lima M, Ahmed S, Hosing CM, Popat UR, Carmazzi Y, Kebriaei P, Nieto Y, Rondon G, Willis D, Shah N, Parmar S, Olson A, Moore B, Marin D, Mehta R, Fernández-Viña M, Champlin RE, Shpall EJ. Better Allele-Level Matching Improves Transplant Related Mortality After Double Cord Blood Transplantation. Haematologica 100(10):1361-1370, 2015. e-Pub 2015. PMID: 26250579.
171. Nieto Y, Tu SM, Bassett R, Jones RB, Gulbis AM, Tannir N, Kingham A, Ledesma C, Margolin K, Holmberg L, Champlin R, Pagliaro L. Bevacizumab/high-dose chemotherapy with autologous stem-cell transplant for poor-risk relapsed or refractory germ-cell tumors. Ann Oncol 26(10):2125-32, 2015. e-Pub 2015. PMID: 26199392.
172. Youssef B, Shank J, Reddy JP, Pinnix CC, Farha G, Akhtari M, Allen PK, Fanale MA, Garcia JA, Horace PH, Milgrom S, Smith GL, Nieto Y, Arzu I, Wang H, Fowler N, Rodriguez MA, Dabaja B. Incidence and predictors of Lhermitte's sign among patients receiving mediastinal radiation for lymphoma. Radiat Oncol 10(1):206, 2015. e-Pub 2015. PMID: 26407853.
173. El Fakih R, Fox P, Popat U, Nieto Y, Shah N, Parmar S, Oran B, Ciurea S, Kebriaei P, Hosing C, Ahmed S, Shah J, Orlowski R, Champlin R, Qazilbash M, Bashir Q. Autologous Hematopoietic Stem Cell Transplantation in Dialysis-Dependent Myeloma Patients. Clin Lymphoma Myeloma Leuk 15(8):472-6, 2015. e-Pub 2015. PMID: 25963284.
174. Afable M, Caimi PF, Hosing C, de Lima M, Khouri I, William BM, Nieto Y, Cooper BW, Anderlini P, Gerson SL, Lazarus HM, Champlin R, Popat U. Hematopoietic Progenitor Cell Harvesting Is Feasible after Treatment with Brentuximab Vedotin in CD30(+) Lymphoma Patients Who Received Multiple Prior Lines of Treatment. Biol Blood Marrow Transplant 21(8):1529-31, 2015. e-Pub 2015. PMID: 25937397.
175. Konopleva M, Benton CB, Thall PF, Zeng Z, Shpall E, Ciurea SO, Kebriaei P, Alousi AM, Popat UR, Anderlini P, Nieto Y, Parmar S, Qiao W, Chen J, Rondon G, McMullin BA, Wang, R, Schober W, Woodworth GG, Gulbis, Cool AM, RM, Andreeff M, Champlin RE. Leukemia cell mobilization with G-CSF plus plerixafor during busulfan-fludarabine conditioning in allogeneic stem cell transplantation. Bone Marrow Transplantation 50(7):939-946, 2015. e-Pub 2015. PMID: 25867648.
176. Konopleva M, Benton CB, Thall PF, Zeng Z, Shpall E, Ciurea S, Kebriaei P, Alousi A, Popat U, Anderlini P, Nieto Y, Parmar S, Qiao W, Chen J, Rondon G, McMullin B, Wang RY, Lu H, Schober W, Woodworth G, Gulbis A, Cool R, Andreeff M, Champlin R. Leukemia cell mobilization with G-CSF plus plerixafor during busulfan-fludarabine conditioning for allogeneic stem cell transplantation. Bone Marrow Transplant 50(7):939-46, 2015. e-Pub 2015. PMID: 25867648.
177. Popat U, Mehta RS, Rezvani K, Fox P, Kondo K, Marin D, McNiece I, Oran B, Hosing C, Olson A, Parmar S, Shah N, Andreeff M, Kebriaei P, Kaur I, Yvon E, de Lima M, Cooper LJ, Tewari P, Champlin RE, Nieto Y, Andersson BS, Alousi A, Jones RB, Qazilbash MH, Bashir Q, Ciurea S, Ahmed S, Anderlini P, Bosque D, Bollard C, Molldrem JJ, Chen J, Rondon G, Thomas M, Miller L, Wolpe S, Simmons P, Robinson S, Zweidler-McKay PA, Shpall EJ. Enforced fucosylation of cord blood hematopoietic cells accelerates neutrophil and platelet engraftment after transplantation. Blood 125(19):2885-92, 2015. e-Pub 2015. PMID: 25778529.
178. Pinnix CC, Dabaja B, Ahmed MA, Chuang HH, Costelloe C, Wogan CF, Reed V, Romaguera JE, Neelapu S, Oki Y, Rodriguez MA, Fayad L, Hagemeister FB, Nastoupil L, Turturro F, Fowler N, Fanale MA, Nieto Y, Khouri IF, Ahmed S, Medeiros LJ, Davis RE, Westin J. Single-institution experience in the treatment of primary mediastinal B cell lymphoma treated with immunochemotherapy in the setting of response assessment by (18)fluorodeoxyglucose positron emission tomography. Int J Radiat Oncol Biol Phys 92(1):113-21, 2015. e-Pub 2015. PMID: 25863759.
179. Pinnix CC, Smith GL, Milgrom S, Osborne EM, Reddy JP, Akhtari M, Reed V, Arzu I, Allen PK, Wogan CF, Fanale MA, Oki Y, Turturro F, Romaguera J, Fayad L, Fowler N, Westin J, Nastoupil L, Hagemeister FB, Rodriguez MA, Ahmed S, Nieto Y, Dabaja B. Predictors of radiation pneumonitis in patients receiving intensity modulated radiation therapy for hodgkin and non-hodgkin lymphoma. Int J Radiat Oncol Biol Phys 92(1):175-82, 2015. e-Pub 2015. PMID: 25863764.
180. Alousi AM, Brammer JE, Saliba RM, Andersson B, Popat U, Hosing C, Jones R, Shpall EJ, Khouri I, Qazilbash M, Nieto Y, Shah N, Ahmed S, Oran B, Al Atrash G, Ciurea S, Kebriaei P, Chen J, Rondon G, Champlin RE. Phase II Trial Of Gvhd Prophylaxis with Post-Transplantation Cyclophosphamide Following Reduced-Intensity Busulfan/Fludarabine (Bu/Flu) Conditioning for Hematological Malignancies. Biol Blood Marrow Transplant 21(5):906-12, 2015. e-Pub 2015. PMID: 25667989.
181. Valdez BC, Brammer JE, Li Y, Murray D, Liu Y, Hosing C, Nieto Y, Champlin RE, Andersson BS. Romidepsin targets multiple survival signaling pathways in malignant T cells. Blood Cancer J 5:e357, 2015. e-Pub 2015. PMID: 26473529.
182. Lee HC, Mulanovich V, Nieto Y. Progressive multifocal leukoencephalopathy after allogeneic bone marrow transplantation for acute myeloid leukemia. J Natl Compr Canc Netw 12(12):1660-4, 2014. e-Pub 2014. PMID: 25505206.
183. Oki Y, Noorani M, Lin P, Davis RE, Neelapu SS, Ma L, Ahmed M, Rodriguez MA, Hagemeister FB, Fowler N, Wang M, Fanale MA, Nastoupil L, Samaniego F, Lee HJ, Dabaja BS, Pinnix CC, Medeiros LJ, Nieto Y, Khouri I, Kwak LW, Turturro F, Romaguera JE, Fayad LE, Westin JR. Double hit lymphoma: the MD Anderson Cancer Center clinical experience. Br J Haematol 166(6):891-901, 2014. e-Pub 2014. PMID: 24943107.
184. Valdez BC, Zander AR, Song G, Murray D, Nieto Y, Li Y, Champlin RE, Andersson BS. Synergistic cytotoxicity of gemcitabine, clofarabine and edelfosine in lymphoma cell lines. Blood Cancer J 4(1):e171, 2014. e-Pub 2014. PMID: 24413065.
185. Bashir Q, Khan H, Thall PF, Liu P, Shah N, Kebriaei P, Parmar S, Oran B, Ciurea S, Nieto Y, Jones R, Hosing CM, Popat UR, Dinh YT, Rondon G, Orlowski RZ, Shah JJ, De Lima M, Shpall E, Champlin R, Giralt S, Qazilbash MH. A Randomized Phase II Trial of Fludarabine/Melphalan 100 versus Fludarabine/Melphalan 140 Followed by Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Multiple Myeloma. Biol Blood Marrow Transplant 19(10):1453-1458, 2013. e-Pub 2013. PMID: 23872222.
186. Smith VR, Popat U, Ciurea S, Nieto Y, Anderlini P, Rondon G, Alousi A, Qazilbash M, Kebriaei P, Khouri I, de Lima M, Champlin R, Hosing C. Just-in-time rescue plerixafor in combination with chemotherapy and granulocyte-colony stimulating factor for peripheral blood progenitor cell mobilization. Am J Hematol 88(9):754-7, 2013. e-Pub 2013. PMID: 23749720.
187. Valdez BC, Wang G, Murray D, Nieto Y, Li Y, Shah J, Turturro F, Wang M, Weber DM, Champlin RE, Qazilbash MH, Andersson BS. Mechanistic studies on the synergistic cytotoxicity of the nucleoside analogs gemcitabine and clofarabine in multiple myeloma: Relevance of p53 and its clinical implications. Exp Hematol 41(8):719-30, 2013. e-Pub 2013. PMID: 23648290.
188. Poon LM, Hamdi A, Saliba R, Rondon G, Ledesma C, Kendrick M, Qazilbash M, Hosing C, Jones RB, Popat UR, Nieto Y, Alousi A, Ciurea S, Shpall EJ, Champlin RE, Kebriaei P. Outcomes of adults with acute lymphoblastic leukemia (ALL) relapsing after allogeneic hematopoietic stem cell transplantation (HSCT). Biol Blood Marrow Transplant 19(7):1059-64, 2013. e-Pub 2013. PMID: 23644077.
189. Nieto Y. Transplantation for Refractory Germ Cell Tumors: Does it Really Make a Difference?. Curr Oncol Rep 15(3):232-238, 2013. e-Pub 2013. PMID: 23494829.
190. Poon LM, Bassett R, Rondon G, Hamdi A, Qazilbash M, Hosing C, Jones RB, Shpall EJ, Popat UR, Nieto Y, Worth LL, Cooper L, De Lima M, Champlin RE, Kebriaei P. Outcomes of second allogeneic hematopoietic stem cell transplantation for patients with acute lymphoblastic leukemia. Bone Marrow Transplant 48(5):666-670, 2013. e-Pub 2013. PMID: 23085830.
191. Aung FM, Lichtiger B, Bassett R, Liu P, Alousi A, Bashir Q, Ciurea SO, de Lima MJ, Hosing C, Kebriaei P, Nieto Y, Oran B, Parmar S, Qazilbash M, Shah N, Khouri I, Champlin RE, Popat U. Incidence and natural history of pure red cell aplasia in major ABO-mismatched haematopoietic cell transplantation. Br J Haematol 160(6):798-805, 2013. e-Pub 2013. PMID: 23330820.
192. Nieto Y, Popat U, Anderlini P, Valdez B, Andersson B, Liu P, Hosing C, Shpall EJ, Alousi A, Kebriaei P, Qazilbash M, Parmar S, Bashir Q, Shah N, Khouri I, Rondon G, Champlin R, Jones RB. Autologous Stem-Cell Transplantation for Refractory or Poor-Risk Relapsed Hodgkin's Lymphoma: Effect of the Specific High-Dose Chemotherapy Regimen on Outcome. Biol Blood Marrow Transplant 19(3):410-417, 2013. e-Pub 2013. PMID: 23128322.
193. Kebriaei P, Madden T, Wang X, Thall PF, Ledesma C, de Lima M, Shpall EJ, Hosing C, Qazilbash M, Popat U, Alousi A, Nieto Y, Champlin RE, Jones RB, Andersson BS. Intravenous BU plus Mel: an effective, chemotherapy-only transplant conditioning regimen in patients with ALL. Bone Marrow Transplant 48(1):26-31, 2013. e-Pub 2013. PMID: 22732703.
194. de Lima M, McNiece I, Robinson SN, Munsell M, Eapen M, Horowitz M, Alousi A, Saliba R, McMannis JD, Kaur I, Kebriaei P, Parmar S, Popat U, Hosing C, Champlin R, Bollard C, Molldrem JJ, Jones RB, Nieto Y, Andersson BS, Shah N, Oran B, Cooper LJ, Worth L, Qazilbash MH, Korbling M, Rondon G, Ciurea S, Bosque D, Maewal I, Simmons PJ, Shpall EJ. Cord-blood engraftment with ex vivo mesenchymal-cell coculture. N Engl J Med 367(24):2305-15, 2012. e-Pub 2012. PMID: 23234514.
195. Kebriaei P, Basset R, Ledesma C, Ciurea S, Parmar S, Shpall EJ, Hosing C, Khouri I, Qazilbash M, Popat U, Alousi A, Nieto Y, Jones RB, de Lima M, Champlin RE, Andersson BS. Clofarabine Combined with Busulfan Provides Excellent Disease Control in Adult Patients with Acute Lymphoblastic Leukemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant 18(12):1819-1826, 2012. e-Pub 2012. PMID: 22750645.
196. Ciurea SO, Mulanovich V, Saliba RM, Bayraktar UD, Jiang Y, Bassett R, Wang SA, Konopleva M, Fernandez-Vina M, Montes N, Bosque D, Chen J, Rondon G, Alatrash G, Alousi A, Bashir Q, Korbling M, Qazilbash M, Parmar S, Shpall E, Nieto Y, Hosing C, Kebriaei P, Khouri I, Popat U, de Lima M, Champlin RE. Improved Early Outcomes Using a T-cell Replete Graft Compared with T-cell Depleted Haploidentical Hematopoietic Stem-Cell Transplantation. Biol Blood Marrow Transplant 18(12):1835-1844, 2012. e-Pub 2012. PMID: 22796535.
197. Nieto Y, Thall P, Valdez B, Andersson B, Popat U, Anderlini P, Shpall EJ, Bassett R, Alousi A, Hosing C, Kebriaei P, Qazilbash M, Frazier E, Gulbis A, Chancoco C, Bashir Q, Ciurea S, Khouri I, Parmar S, Shah N, Worth L, Rondon G, Champlin R, Jones RB. High-Dose Infusional Gemcitabine Combined with Busulfan and Melphalan with Autologous Stem-Cell Transplant in Patients with Refractory Lymphoid Malignancies. Biol Blood Marrow Transplant 18(11):1677-1686, 2012. e-Pub 2012. PMID: 22643322.
198. Valdez BC, Nieto Y, Murray D, Li Y, Wang G, Champlin RE, Andersson BS. Epigenetic modifiers enhance the synergistic cytotoxicity of combined nucleoside analog-DNA alkylating agents in lymphoma cell lines. Exp Hematol 40(10):800-810, 2012. e-Pub 2012. PMID: 22687754.
199. Martin PJ, Rizzo JD, Wingard JR, Ballen K, Curtin PT, Cutler C, Litzow MR, Nieto Y, Savani BN, Schriber JR, Shaughnessy PJ, Wall DA, Carpenter PA. First- and Second-Line Systemic Treatment of Acute Graft-versus-Host Disease: Recommendations of the American Society of Blood and Marrow Transplantation. Biol Blood Marrow Transplant 18(8):1150-63, 2012. e-Pub 2012. PMID: 22510384.
200. Anderlini P, Saliba R, Acholonu S, Okoroji GJ, Ledesma C, Andersson BS, Jones R, Popat UR, Hosing CM, Nieto Y, Qazilbash MH, Ueno NT, Giralt SA, de Lima MJ, Champlin RE. Donor leukocyte infusions (DLIs) in recurrent hodgkin lymphoma (HL) following allogeneic stem cell transplantation: ten-year experience at the M.D. anderson cancer center. Leuk Lymphoma 53(6):1239-1241, 2012. e-Pub 2012. PMID: 22132837.
201. Valdez BC, Murray D, Nieto Y, Li Y, Wang G, Champlin RE, Andersson BS. Synergistic cytotoxicity of the DNA alkylating agent busulfan, nucleoside analogs and SAHA in lymphoma cell lines. Leuk Lymphoma 53(5):973-981, 2012. e-Pub 2012. PMID: 22023523.
202. Ciurea SO, Saliba RM, Hamerschlak N, Karduss Aurueta AJ, Bassett R, Fernandez-Vina M, Petropoulos D, Worth LL, Chan KW, Couriel DR, Rondon G, Sharma M, Qazilbash M, Jones RB, Kebriaei P, McMannis J, Hosing CM, Nieto Y, Champlin RE, Shpall EJ, de Lima M. Fludarabine, Melphalan, Thiotepa and ATG Conditioning for Unrelated Cord Blood Transplantation. Leuk Lymphoma 53(5):901-906, 2012. e-Pub 2012. PMID: 21988645.
203. Anderlini P, Saliba RM, Ledesma C, Chancoco C, Alousi AM, Shpall EJ, Popat UR, Hosing CM, Khouri IF, Nieto Y, Ciurea S, Younes A, Fanale MA, Acholonu S, Valverde R, Champlin RE. Gemcitabine, fludarabine and melphalan (G-FM) as a reduced-intensity conditioning regimen for allogeneic stem cell transplantation in relapsed and refractory hodgkin lymphoma: preliminary results. Leuk Lymphoma 53(3):499-502, 2012. e-Pub 2012. PMID: 21859247.
204. Popat U, de Lima MJ, Saliba RM, Anderlini P, Andersson BS, Alousi AM, Hosing C, Nieto Y, Parmar S, Khouri IF, Kebriaei P, Qazilbash M, Champlin RE, Giralt SA. Long-term outcome of reduced-intensity allogeneic hematopoietic SCT in patients with AML in CR. Bone Marrow Transplant 47(2):212-6, 2012. e-Pub 2012. PMID: 21423123.
205. Nieto Y, Shpall EJ. High-Dose Chemotherapy with Autologous Stem Cell Transplant for Breast Cancer: What Have We Learned 25 Years Later?. Biol Blood Marrow Transplant 18(1):3-5, 2012. e-Pub 2012. PMID: 22146617.
206. Mego M, Gao H, Lee BN, Cohen EN, Tin S, Giordano A, Wu Q, Liu P, Nieto Y, Champlin RE, Hortobagyi GN, Cristofanilli M, Ueno NT, Reuben JM. Prognostic Value of EMT-Circulating Tumor Cells in Metastatic Breast Cancer Patients Undergoing High-Dose Chemotherapy with Autologous Hematopoietic Stem Cell Transplantation. J Cancer 3:369-380, 2012. e-Pub 2012. PMID: 23074378.
207. Alatrash G, de Lima M, Hamerschlak N, Pelosini M, Wang X, Xiao L, Kerbauy F, Chiattone A, Rondon G, Qazilbash MH, Giralt SA, de Padua Silva L, Hosing C, Kebriaei P, Zhang W, Nieto Y, Saliba RM, Champlin RE, Andersson BS. Myeloablative Reduced-Toxicity i.v. Busulfan-Fludarabine and Allogeneic Hematopoietic Stem Cell Transplant for Patients with Acute Myeloid Leukemia or Myelodysplastic Syndrome in the Sixth through Eighth Decades of Life. Biol Blood Marrow Transplant 17(10):1490-6, 2011. e-Pub 2011. PMID: 21338705.
208. Yang H, Robinson SN, Nieto Y, Jones RJ, Gocke CD, Lu J, Giralt SA, Jones RB, Decker WK, Xing D, Steiner D, Champlin RE, McMannis JD, Ng J, Thomas MW, Shah N, Andersson BS, Parmar S, Shpall EJ. Ex vivo graft purging and expansion of autologous blood progenitor cell products from patients with Multiple Myeloma. Cancer Res 71(14):5040-9, 2011. e-Pub 2011. PMID: 21646477.
209. Kebriaei P, Madden T, Kazerooni R, Wang X, Thall PF, Ledesma C, Nieto Y, Shpall EJ, Hosing C, Qazilbash M, Popat U, Khouri I, Champlin RE, Jones RB, Andersson BS. Intravenous Busulfan Plus Melphalan Is a Highly Effective, Well-Tolerated Preparative Regimen for Autologous Stem Cell Transplantation in Patients with Advanced Lymphoid Malignancies. Biol Blood Marrow Transplant 17(3):412-20, 2011. e-Pub 2011. PMID: 20674757.
210. Ramos CA, Saliba RM, de Pádua Silva L, Khorshid O, Shpall EJ, Giralt S, Patah PA, Hosing CM, Popat UR, Rondon G, Nieto Y, Champlin RE, de Lima M. Resolved hepatitis B virus infection is not associated with worse outcomes after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 16(5):686-94, 2010. e-Pub 2010. PMID: 20056165.
211. Burger JA, Velev NS, Jabbour EJ, Wierda WG, Ravandi F, Cortes JE, Kantarjian H, Nieto YL, Shpall EJ, Jorgensen JL. Failure is not fatal: long-term remission in refractory acute myeloid leukemia (AML) after graft failure of cord blood stem cells. Leukemia 24(3):666-8, 2010. e-Pub 2010. PMID: 20054352.
212. Nieto Y, Aramendía JM, Espinós J, De la Cruz S, Fernández-Hidalgo O, Santisteban M, Arbea L, Aristu J, Martínez-Monge R, Moreno M, Pina L, Sola J, Zornoza G, Regueira FM. Sequential administration of dose-dense epirubicin/cyclophosphamide followed by docetaxel/capecitabine for patients with HER2-negative and locally advanced or node-positive breast cancer. Cancer Chemother Pharmacol 65(3):457-465, 2010. e-Pub 2010. PMID: 19526361.
213. Popat U, Saliba R, Thandi R, Hosing C, Qazilbash M, Anderlini P, Shpall E, McMannis J, Körbling M, Alousi A, Andersson B, Nieto Y, Kebriaei P, Khouri I, de Lima M, Weber D, Thomas S, Wang M, Jones R, Champlin R, Giralt S. Impairment of filgrastim-induced stem cell mobilization after prior lenalidomide in patients with multiple myeloma. Biol Blood Marrow Transplant 15(6):718-23, 2009. e-Pub 2009. PMID: 19450756.
214. Jones RB, Nieto Y, Wall D, Wingard JR, Rizzo JD, McCarthy PL, Oliansky D, Hahn T, Evidence-Based Reviews ASCO. Methodology for updating published evidence-based reviews evaluating the role of blood and marrow transplantation in the treatment of selected diseases: a policy statement by the american society for blood and marrow transplantation. Biol Blood Marrow Transplant 15(6):761-2, 2009. e-Pub 2009. PMID: 19450763.
215. Ramos CA, Saliba RM, de Pádua L, Khorshid O, Shpall EJ, Giralt S, Patah PA, Hosing CM, Popat UR, Rondon G, Khouri IF, Nieto YL, Champlin RE, de Lima M. Impact of hepatitis C virus seropositivity on survival after allogeneic hematopoietic stem cell transplantation for hematologic malignancies. Haematologica 94(2):249-57, 2009. e-Pub 2009. PMID: 19144658.
216. Qazilbash MH, Saliba RM, Nieto Y, Parikh G, Pelosini M, Khan FB, Jones RB, Hosing C, Mendoza F, Weber DM, Wang M, Popat U, Alousi A, Anderlini P, Champlin RE, Giralt S. Arsenic trioxide with ascorbic acid and high-dose melphalan: results of a phase II randomized trial. Biol Blood Marrow Transplant 14(12):1401-7, 2008. e-Pub 2008. PMID: 19041063.
217. Oliansky DM, Appelbaum F, Cassileth PA, Keating A, Kerr J, Nieto Y, Stewart S, Stone RM, Tallman MS, Jr MP, Hahn T. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of acute myelogenous leukemia in adults: an evidence-based review. Biology of Blood and Marrow Transplantation 14(2):137-80, 2008. e-Pub 2008. PMID: 18215777.
218. González-Cao M, Viteri S, Díaz-Lagares A, González A, Redondo P, Nieto Y, Espinós J, Chopitea A, Ponz M, Martín-Algarra S. Preliminary results of the combination of bevacizumab and weekly Paclitaxel in advanced melanoma. Oncology 74(1-2):12-16, 2008. e-Pub 2008. PMID: 18536525.
219. Nieto, Y, Aldaz, A, Rifón, J, Pérez-Calvo, J, Zafra, A, Zufia, L, Viúdez, A, Viteri, S, Aramendía, JM, Aristu, J, Centeno, C, Moreno, M, Sayar, O, Hernández, M. Phase I and Pharmacokinetic Study of Gemcitabine Administered at Fixed-Dose Rate, Combined with Docetaxel/Melphalan/Carboplatin, with Autologous Hematopoietic Progenitor-Cell Support, in Patients with Advanced Refractory Tumors. Biology of Blood and Marrow Transplantation 13(11):1324-1337, 2007. e-Pub 2007. PMID: 17950919.
220. Nieto Y, Aldaz A, Rifón J, Pérez-Calvo J, Zafra A, Zufia L, Viúdez A, Viteri S, Aramendía JM, Aristu J, Centeno C, Moreno M, Sayar O, Hernández M. Phase I and Pharmacokinetic Study of Gemcitabine Administered at Fixed-Dose Rate, Combined with Docetaxel/Melphalan/Carboplatin, with Autologous Hematopoietic Progenitor-Cell Support, in Patients with Advanced Refractory Tumors. Biology of Blood and Marrow Transplantation 13(11):1324-1337, 2007. e-Pub 2007.
221. Nieto Y, Nawaz F, Jones RB, Shpall EJ, Nawaz S. Prognostic Significance of Overexpression and Phosphorylation of Epidermal Growth Factor Receptor (EGFR) and the Presence of Truncated EGFRvIII in Locoregionally Advanced Breast Cancer. J Clin Oncol 25(28):4405-4413, 2007. e-Pub 2007. PMID: 17906204.
222. Nieto Y, Woods J, Nawaz F, Baron A, Jones RB, Shpall EJ, Nawaz S. Prognostic analysis of tumour angiogenesis, determined by microvessel density and expression of vascular endothelial growth factor, in high-risk primary breast cancer patients treated with high-dose chemotherapy. British Journal of Cancer 97(3):391-7, 2007. e-Pub 2007. PMID: 17609662.
223. Santisteban M, Nieto Y, De la Cruz S, Aristu J, Zubieta JL, Fernández Hidalgo O. Primary central nervous system lymphoma treated with rituximab plus temozolomide in a second line schedule. Clinical and Translational Oncology 9(7):465-7, 2007. e-Pub 2007. PMID: 17652061.
224. González Cao M, Viteri S, Garrán C, Nieto Y, Aristu J, Ponz M, Martín Algarra S. Response of resistant melanoma to a combination of weekly paclitaxel and bevacizumab. Clinical Translational Oncology 9(2):119-20, 2007. e-Pub 2007. PMID: 17329225.
225. Woodward W, Vinh-Hung V, Ueno N, Chung Cheng Y, Royce M, Tai P, Vlastos G, Wallace AM, Hortobagyi GN, Nieto Y. Prognostic Value of Nodal Ratios in Node-Positive Breast Cancer. Journal of Clinical Oncology 24(18):2910-2916, 2006. e-Pub 2006.
226. Espinós, J, Rifón, J, Pérez-Calvo, J, Nieto, Y. Idiopathic hyperammonemia following high-dose chemotherapy. Bone marrow transplantation 37(9):899, 2006. e-Pub 2006. PMID: 16547487.
227. Espinos J, Rifon J, Perez-Calvo J, Nieto Y. Idiopathic hyperammonemia following high-dose chemotherapy. Bone Marrow Transplantation 37:899 - 899, 2006. e-Pub 2006.
228. Nieto, Y, Patton, N, Hawkins, T, Spearing, R, Bearman, SI, Jones, R, Shpall, E, Rabinovitch, R, Zeng, C, Barón, AE, McSweeney, PA. Tacrolimus and mycophenolate mofetil after nonmyeloablative matched-sibling donor allogeneic stem-cell transplantations conditioned with fludarabine and low-dose total body irradiation. Biology of Blood and Marrow Transplantation 12(2):217-225, 2006. e-Pub 2006. PMID: 16443519.
229. Nieto Y, Patton N, Hawkins T, Spearing R, Bearman SI, Jones RB, Shpall EJ, Rabinovitch R, Zeng C, Barón A, McSweeney PA. Tacrolimus and Mycophenolate Mofetil after Nonmyeloablative Matched-Sibling Donor Allogeneic Stem-Cell Transplantations Conditioned with Fludarabine and Low-Dose Total Body Irradiation. Biology of Blood and Marrow Transplantation 12:217-225, 2006. e-Pub 2006.
230. Nieto Y, Santisteban M, Aramendía JM, Fernández-Hidalgo O, García-Manero M, López G. Docetaxel administered during pregnancy for inflammatory breast carcinoma. Clinical Breast Cancer 6(6):533-534, 2006. e-Pub 2006. PMID: 16595038.
231. Gutman, J, Shpall, E, Nieto, Y, McSweeney, PA, McNiece, I. Long-term follow-up of patients with breast cancer transplanted with autologous ex vivo expanded peripheral blood progenitor cells. Cell Preservation Technology 4(1):4-8, 2006. e-Pub 2006.
232. Jones R, Nieto Y, Rizzo JD, Wall D, Wingard JR, McCarthy P, Hahn T, for Blood SCFEROTAS, Transplantation M. The evolution of the evidence-based review: evaluating the science enhances the art of medicine--statement of the Steering Committee for Evidence-Based Reviews of the American Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant 11(11):819-22, 2005. e-Pub 2005. PMID: 16275587.
233. Gutman, J, Bearman, SI, Nieto, Y, Sweetenham, JW, Jones, R, Shpall, E, Zeng, C, Barón, AE, McSweeney, PA. Autologous transplantation followed closely by reduced-intensity allogeneic transplantation as consolidative immunotherapy in advanced lymphoma patients. Bone marrow transplantation 36(5):443-451, 2005. e-Pub 2005. PMID: 15995712.
234. Rosinski, S, McNiece, I, Shpall, E, Clough, N, Russell, P, Blunk, B, Nieto, Y. Prognostic analysis of pre-transplant peripheral T-cell levels in patients receiving an autologous hematopoietic progenitor-cell transplant. Bone marrow transplantation 36(5):425-430, 2005. e-Pub 2005. PMID: 15980880.
235. Rosinski SL, McNiece IK, Shpall EJ, Clough N, Russell P, Blunk B, Nieto Y. Prognostic analysis of pre-transplant peripheral T-cell levels in patients receiving an autologous hematopoietic progenitor-cell transplant. Bone Marrow Transplantation 36:425 - 430, 2005. e-Pub 2005.
236. Gutman JA, Bearman SI, Nieto Y, Sweetenham JW, Jones RB, Shpall EJ, Zeng C, Baron A, McSweeney PA. Autologous transplantation followed closely by reduced-intensity allogeneic transplantation as consolidative immunotherapy in advanced lymphoma patients: a feasibility study. Bone Marrow Transplantation 36:443–451, 2005. e-Pub 2005.
237. Nieto Y, Shpall EJ, Bearman SI, Jones RB. Evaluation of the effect of age on treatment-related mortality and relapse in patients with high-risk primary breast cancer receiving high-dose chemotherapy. American Journal of Clinical Oncology 28(3):248-54, 2005. e-Pub 2005. PMID: 15923796.
238. Nieto, Y, Shpall, E, Bearman, SI, McSweeney, PA, Cagnoni, P, Matthes, S, Gustafson, D, Long, M, Barón, AE, Jones, R. Phase I and pharmacokinetic study of docetaxel combined with melphalan and carboplatin, with autologous hematopoietic progenitor cell support, in patients with advanced refractory malignancies. Biology of Blood and Marrow Transplantation 11(4):297-306, 2005. e-Pub 2005. PMID: 15812395.
239. Nieto Y, Shpall EJ, Bearman SI, McSweeney PA, Cagnoni PJ, Matthes S, Gustafson D, Long M, Barón AE, Jones RB. Phase I and pharmacokinetic study of docetaxel combined with melphalan and carboplatin, with autologous hematopoietic progenitor cell support, in patients with advanced refractory malignancies. Biology of Blood and Marrow Transplantation 11(4):297-306, 2005. e-Pub 2005.
240. Nieto Y, Vredenburgh JJ, Shpall EJ, Bearman SI, McSweeney PA, Chao N, Rizzieri D, Gasparetto C, Matthes S, Barón AE, Jones RB. Phase II feasibility and pharmacokinetic study of concurrent administration of trastuzumab and high-dose chemotherapy in advanced HER2+ breast cancer. Clinical Cancer Research 10(21):7136-43, 2004. e-Pub 2004. PMID: 15534084.
241. Robertson KB, Barron MA, Nieto Y. West Nile virus infection in bone marrow transplant patients. Bone Marrow Transplantation 34:823-824, 2004. e-Pub 2004.
242. Nieto Y, Shpall EJ, McNiece IK, Nawaz S, Beaudet J, Rosinski S, Pellom J, Slat-Vasquez V, McSweeney PA, Bearman SI, Murphy J, Jones RB. Prognostic analysis of early lymphocyte recovery in patients with advanced breast cancer receiving high-dose chemotherapy with an autologous hematopoietic progenitor cell transplant. Clinical Cancer Research 10(15):5076-86, 2004. e-Pub 2004. PMID: 15297410.
243. Parikh CR, Sandmaier BM, Storb RF, Blume KG, Sahebi F, Maloney DG, Maris MB, Nieto Y, Edelstein CL, Schrier RW, McSweeney P. Acute renal failure after nonmyeloablative hematopoietic cell transplantation. Journal of the American Society of Nephrology 15(7):1868-1876, 2004. e-Pub 2004. PMID: 15213275.
244. Nieto Y, Franklin WA, Jones RB, Berman SI, Pellom J, Barón AE, Shpall EJ. Prognostic significance of occult tumor cells in the apheresis products of patients with advanced breast cancer receiving high-dose chemotherapy and autologous hematopoietic progenitor cell support. Biology of Blood and Marrow Transplantation 10(6):415-425, 2004. e-Pub 2004. PMID: 15148495.
245. Nieto, Y, Nawaz, S, Shpall, E, Bearman, SI, Murphy, J, Jones, R. Long-Term Analysis and Prospective Validation of A Prognostic Model for Patients with High-Risk Primary Breast Cancer Receiving High-Dose Chemotherapy. Clinical Cancer Research 10(8):2609-2617, 2004. e-Pub 2004. PMID: 15102662.
246. Jones RB, Stockerl-Goldstein KE, Klein J, Murphy J, Blume KG, Dansey R, Martinez C, Matthes S, Nieto Y. A randomized trial of amifostine and carmustine-containing chemotherapy to assess lung-protective effects. Biology of Blood Marrow Transplantation 10(4):276-282, 2004. e-Pub 2004. PMID: 15077226.
247. Nieto Y, Nawaz S, Shpall EJ, Bearman SI, Murphy J, Jones RB. Long-Term Analysis and Prospective Validation of a Prognostic Model for Patients with High-Risk Primary Breast Cancer Receiving High-Dose Chemotherapy. Clinical Cancer Research 10:2609-2617, 2004. e-Pub 2004.
248. Khorshid O, de Meis E, Martin T, Jones RB, Shpall EJ, Nieto Y, Khouri I, Shahjahan M, Gajewski J, Giralt S, Champlin R, de Lima M. Unrelated umbilical cord blood stem cell transplant after failure of haploidentical or matched unrelated donor hematopoietic stem cell transplant. Leukemia 17(12):2538-40, 2003. e-Pub 2003. PMID: 14523458.
249. Medeiros, BC, Kolhouse, JF, Cagnoni, P, Ryder, J, Nieto, Y, Rabinovitch, R, Shpall, E, Bearman, SI, Jones, R, McSweeney, PA. Nonmyeloablative allogeneic hematopoietic stem cell transplantation for congenital sideroblastic anemia. Bone marrow transplantation 31(11):1053-1055, 2003. e-Pub 2003. PMID: 12774059.
250. Medeiros BC, Kolhouse JF, Cagnoni PC, Ryder J, Nieto Y, Rabinovitch R, Shpall EJ, Bearman SI, Jones RB, McSweeney PA. Nonmyeloablative allogeneic hematopoietic stem cell transplantation for congenital sideroblastic anemia. Bone Marrow Transplantation 31:1053-1055, 2003. e-Pub 2003.
251. Shpall EJ, Quinones R, Giller R, Zeng C, Baron AE, Jones RB, Bearman SI, Nieto Y, Freed B, Madinger N, Hogan CJ, Vasquez VS, Russell P, Blunk B, Schissel D, Hild E, Malcolm J, Ward W, McNiece IK. Transplantation of ex vivo expanded cord blood. Biology of Blood and Marrow Transplantation 8(7):368-376, 2002. e-Pub 2002.
252. Nieto Y, Nawaz S, Jones RB, Shpall EJ, Cagnoni PJ, McSweeney PA, Barón A, Razook C, Matthes S, Bearman SI. Prognostic Model for Relapse After High-Dose Chemotherapy With Autologous Stem-Cell Transplantation for Stage IV Oligometastatic Breast Cancer. J Clin Oncol 20(3):707-718, 2002. e-Pub 2002. PMID: 11821452.
253. Nieto, Y, Bearman, SI, Shpall, E, Jones, R, Cagnoni, P, Rabinovitch, R, McSweeney, PA. Intensive chemotherapy for progressive chronic lymphocytic leukemia administered early after a nonmyeloablative allograft. Bone marrow transplantation 28(11):1083-1086, 2001. e-Pub 2001. PMID: 11781620.
254. Nieto Y, Bearman SI, Shpall EJ, Jones RB, Cagnoni PJ, Rabinovitch RA, McSweeney PA. Intensive chemotherapy for progressive chronic lymphocytic leukemia administered early after a nonmyeloablative allograft. Bone Marrow Transplantation 28:1083-1086, 2001. e-Pub 2001.
255. Nieto, Y. Pharmacodynamics of high-dose chemotherapy. Current Drug Metabolism 2(1):53-66, 2001. e-Pub 2001. PMID: 11465151.
256. McNiece I, Jones R, Bearman SI, Cagnoni P, Nieto Y, Franklin W, Ryder J, Steele A, Stoltz J, Russell P, McDermitt J, Hogan C, Murphy J, Shpall EJ. Ex vivo expanded peripheral blood progenitor cells provide rapid neutrophil recovery after high-dose chemotherapy in patients with breast cancer. Blood 96(9):3001-3007, 2000. e-Pub 2000. PMID: 11049977.
257. Nieto Y, Champlin RE, Wingard JR, Vredenburgh JJ, Elias AD, Richardson P, Glaspy J, Jones RB, Stiff PJ, Bearman SI, Cagnoni PJ, McSweeney PA, LeMaistre CF, Pecora AL, Shpall EJ. Status of high-dose chemotherapy for breast cancer: A review. Biology of Blood and Marrow Transplantation Vol. 6, Issue 5:476-495, 2000. e-Pub 2000.
258. Nieto, Y, Russ, P, Everson, GT, Bearman, SI, Cagnoni, P, Jones, R, Shpall, E. Acute pancreatitis during immunosuppression with tacrolimus following an allogeneic umbilical cord blood transplantation. Bone marrow transplantation 26(1):109-111, 2000. e-Pub 2000. PMID: 10918414.
259. Nieto Y, Russ P, Everson G, Bearman SI, Cagnoni PJ, Jones RB, Shpall EJ. Acute pancreatitis during immunosuppression with tacrolimus following an allogeneic umbilical cord blood transplantation. Bone Marrow Transplantation 26:109-111, 2000. e-Pub 2000.
260. Nieto, Y, Cagnoni, P, Nawaz, S, Shpall, E, Yerushalmi, R, Cook, B, Russell, P, McDermit, J, Murphy, J, Bearman, SI, Jones, R. Evaluation of the predictive value of Her-2/neu overexpression and p53 mutations in high-risk primary breast cancer patients treated with high-dose chemotherapy and autologous stem-cell transplantation. Journal of Clinical Oncology 18(10):2070-2080, 2000. e-Pub 2000. PMID: 10811672.
261. Nieto Y, Cagnoni PJ, Nawaz S, Shpall EJ, Yerushalmi R, Cook B, Russell P, McDermit J, Murphy J, Bearman SI, Jones RB. Evaluation of the Predictive Value of Her-2/neu Overexpression and p53 Mutations in High-Risk Primary Breast Cancer Patients Treated With High-Dose Chemotherapy and Autologous Stem-Cell Transplantation. Journal of Clinical Oncology 18(10):2070-2080, 2000. e-Pub 2000.
262. Nieto Y, Cagnoni PJ, Bearman SI, Shpall EJ, Matthes S, Jones RB. Cardiac toxicity following high-dose cyclophosphamide, cisplatin, and BCNU (STAMP-I) for breast cancer. Biology of Blood and Marrow Transplantation 6(2):198-203, 2000. e-Pub 2000.
263. Nieto, Y, Cagnoni, P, Bearman, SI, Shpall, E, Matthes, S, Jones, R. Cardiac Toxicity Following High-Dose Cyclophosphamide, Cisplatin, and BCNU (STAMP-1) for Breast Cancer. Biology of Blood and Marrow Transplantation 6(2 A):198-203, 2000. e-Pub 2000. PMID: 10816028.
264. Nieto, Y, Champlin, RE, Wingard, JR, Vredenburgh, J, Elias, A, Richardson, PG, Glaspy, JA, Jones, R, Stiff, PJ, Bearman, SI, Cagnoni, P, McSweeney, PA, LeMaistre, CF, Pecora, AL, Shpall, E. Status of High-Dose Chemotherapy for Breast Cancer. Biology of Blood and Marrow Transplantation 6(5):476-495, 2000. e-Pub 2000. PMID: 11063377.
265. Nieto, Y, Cagnoni, P, Shpall, E, Xu, X, Murphy, J, Vredenburgh, J, Chao, NJ, Bearman, SI, Jones, R. A predictive model for relapse in high-risk primary breast cancer patients treated with high-dose chemotherapy and autologous stem-cell transplant. Clinical Cancer Research 5(11):3425-3431, 1999. e-Pub 1999. PMID: 10589754.
266. Nieto Y, Cagnoni PJ, Shpall EJ, Xu X, Murphy J, Vredenburgh J, Chao NJ, Bearman SI, Jones RB. A Predictive Model for Relapse in High-Risk Primary Breast Cancer Patients Treated with High-Dose Chemotherapy and Autologous Stem-Cell Transplant. Clinical Cancer Research 5(11):3425-3431, 1999. e-Pub 1999.
267. Nieto, Y, Shpall, E. Autologous stem-cell transplantation for solid tumors in adults. Hematology/Oncology Clinics of North America 13(5):939-968, 1999. e-Pub 1999. PMID: 10553256.
268. Bearman, SI, Vredenburgh, J, Cagnoni, P, Shpall, E, Nieto, Y, Ross, M, Peters, WP, Jones, R. High-dose therapy with autologous hematopoietic cell support as salvage treatment for patients with breast cancer who have relapsed after previous high-dose chemotherapy. Bone marrow transplantation 24(5):491-495, 1999. e-Pub 1999. PMID: 10482932.
269. Bearman SI, Vredenburgh JJ, Cagnoni PJ, Shpall EJ, Nieto Y, Ross M, Peters WP, Jones RB. High-dose therapy with autologous hematopoietic cell support as salvage treatment for patients with breast cancer who have relapsed after previous high-dose chemotherapy. Bone Marrow Transplantation 24:491-495, 1999. e-Pub 1999.
270. Nieto Y, Cagnoni PJ, Shpall EJ, Matthes S, Barón A, Jones RB, Bearman SI. Phase II trial of high-dose chemotherapy with autologous stem cell transplant for stage IV breast cancer with minimal metastatic disease. Clinical Cancer Research 5(7):1731-1737, 1999. e-Pub 1999. PMID: 10430076.
271. Nieto, Y, Ross, M, Gianani, R, Shpall, E, Cagnoni, P, Bearman, SI, Jones, R. Post-mortem incidental finding of cytomegalovirus oophoritis after an allogeneic stem cell transplant. Bone marrow transplantation 23(12):1323-1324, 1999. e-Pub 1999. PMID: 10414924.
272. Nieto Y, Ross M, Gianani R, Shpall EJ, Cagnoni PJ, Bearman SI, Jones RB. Post-mortem incidental finding of cytomegalovirus oophoritis after an allogeneic stem cell transplant. Bone Marrow Transplantation 23:1323-1324, 1999. e-Pub 1999.
273. Nieto Y, Xu X, Cagnoni PJ, Matthes S, Shpall EJ, Bearman SI, Murphy J, Jones RB. Nonpredictable pharmacokinetic behavior of high-dose cyclophosphamide in combination with cisplatin and 1,3-bis(2-chloroethyl)-1-nitrosourea. Clinical Cancer Research 5(4):747-751, 1999. e-Pub 1999. PMID: 10213208.
274. McNiece I, Jones R, Cagnoni P, Bearman S, Nieto Y, Shpall EJ. Ex-vivo expansion of hematopoietic progenitor cells: preliminary results in breast cancer. Hematology and Cell Therapy 41(2):82-86, 1999. e-Pub 1999. PMID: 10344558.
275. Nieto, Y, Cagnoni, P, Bearman, SI, Shpall, E, Matthes, S, DeBoom, T, Barón, AE, Jones, R. Acute encephalopathy. Clinical Cancer Research 5(3):501-506, 1999. e-Pub 1999. PMID: 10100699.
276. Shpall EJ, Jones RB, Bearman SI, Cagnoni PJ, Nieto Y, McNiece IK. Peripheral blood stem cell transplantation in breast cancer. Baillieres Best Practice and Research Clinical Haematology 12(1-2):219-232, 1999. e-Pub 1999. PMID: 11000995.
277. Nieto Y, Cagnoni PJ, Bearman SI, Shpall EJ, Matthes S, DeBoom T, Baron A, Jones RB. Acute Encephalopathy: A New Toxicity Associated with High-Dose Paclitaxel1. Clinical Cancer Research 5:501-506, 1999. e-Pub 1999.
278. Nieto Y, Alonso JL, Ayala F, Ortega L, Casado A, Martín M, Díaz-Rubio E. End-stage acute hepatic failure as clinical presentation of liver metastases from breast cancer. Tumori 84(5):616-617, 1998. e-Pub 1998. PMID: 9862530.
279. Nieto Y, Martín M, Alonso JL, Casado A, Ayala F, López-Martín JA, Rodríguez-Lescure A, Díaz-Rubio E. Weekly continuous infusion of 5-fluorouracil with oral leucovorin in metastatic breast cancer patients with primary resistance to doxorubicin. Breast Cancer Research and Treatment 50(2):167-174, 1998. e-Pub 1998. PMID: 9822221.
280. Cagnoni, P, Nieto, Y, Shpall, E, Bearman, SI, Barón, AE, Ross, M, Matthes, S, Dunbar, SE, Jones, R. High-dose chemotherapy with autologous hematopoietic progenitor-cell support as part of combined modality therapy in patients with inflammatory breast cancer. Journal of Clinical Oncology 16(5):1661-1668, 1998. e-Pub 1998. PMID: 9586876.
281. Cagnoni PJ, Nieto Y, Shpall EJ, Bearman SI, Baron AE, Ross M, Matthes S, Dunbar SE, Jones RB. High-dose chemotherapy with autologous hematopoietic progenitor-cell support as part of combined modality therapy in patients with inflammatory breast cancer. Journal of Clinical Oncology 16(5):1661-1668, 1998. e-Pub 1998.
282. Ballesteros MD, Rubio MA, Redondo MJ, Cabrerizo L, Romeo S, Alonso JL, Nieto Y, Ayala F, Martín M. Parenteral nutrition of patients under intensive chemotherapy: comparative study of two lipid emulsions [Spanish]. Nutrición hospitalaria 13(4):177-180, 1998. e-Pub 1998. PMID: 9780749.
283. Martín M, Casado A, Llorente L, López Martín JA, Rodríguez Lescure A, Nieto Y, Ayala F, Pérez Calvo J, Alonso JL, Pérez López C, Villegas A, Díaz-Rubio E. High-dose chemotherapy with four drugs and peripheral blood progenitor cell autologous transplantation in disseminated breast cancer [Spanish]. Medicina Clinica 109(20):775-81, 1997. e-Pub 1997. PMID: 9493155.
284. Martin M, Casado A, López-Martin JA, Rodriguez-Lescure A, Nieto Y, Ayala F, Diaz-Rubio E. Preliminary results. UFT/methotrexate/leucovorin for breast Ca patients in progression after HDCT/PBPC support. Oncology (Williston Park, N.Y.) 9(Suppl 10):83-85, 1997. e-Pub 1997. PMID: 9348575.
285. Suarez R, Martin F, Lopez E, Nunez C, Nieto Y, Sanchez-Yus. Zoster-Like Skin Metastasis in a Case of Breast Carcinoma: An Unusal Presentation [Spanish]. Actas Dermo-Sifiliticas 85(4):251-254, 1994. e-Pub 1994.

Invited Articles

1. Vinh-Hung V, Nguyen NP, Cserni G, Truong P, Woodward W, Verkooijen HM, Promish D, Ueno NT, Tai P, Nieto Y, Joseph S, Janni W, Vicini F, Royce M, Storme G, Wallace AM, Vlastos G, Bouchardy C, Hortobagyi GN. Prognostic value of nodal ratios in node-positive breast cancer: a compiled update. Future Oncol 5(10):1585-603, 2009. e-Pub 2009. PMID: 20001797.
2. Nieto Y, Shpall EJ. High-Dose Chemotherapy for Breast Cancer: Is Another Look Warranted?. Current Opinion in Oncology 21:150-157, 2009. e-Pub 2009.
3. Nieto Y, Jones RB, Shpall EJ. Stem-cell transplantation for the treatment of advanced solid tumors. Springer Seminars in Immunopathology 26(1-2):31-56, 2004. e-Pub 2004. PMID: 15368078.
4. Nieto Y, Jones RB, Shpall EJ. High-Dose Chemotherapy for Breast Cancer: Is Another Look Warranted?. Current Opinion in Oncology 16(2):114-119, 2004. e-Pub 2004.
5. Nieto Y, Vaughan WP. Pharmacokinetics of High-Dose Chemotherapy. Bone Marrow Transplantation 33:259-269, 2004. e-Pub 2004.
6. Nieto Y. The verdict is not in yet. Analysis of the randomized trials of high-dose chemotherapy for breast cancer. Haematologica 88(2):201-211, 2003. e-Pub 2003. PMID: 12604410.
7. Nieto Y. Pharmacodynamics of High-Dose Chemotherapy. Current Drug Metabolism 2(1):53-66, 2001. e-Pub 2001.
8. Nieto Y, Shpall EJ. High-Dose Chemotherapy for Breast Cancer. Cancer Treatment Research 103:77-114, 2000. e-Pub 2000.
9. Beaudet J, McNiece I, Jones RB, Bearman SI, Cagnoni PJ, Nieto Y, McSweeney P, Shpall EJ. The Use of Hematopoietic Growth Factors to Support Patients Recovering from Dose Intensive Therapies. Seminars in Breast Disease 3(3):144-152, 2000. e-Pub 2000.
10. McNiece IK, Jones RB, Cagnoni PJ, Bearman SI, Nieto Y, Shpall EJ. Ex-Vivo Expansion of Hematopoietic Progenitor Cells. Hematol Cell Ther 41:82-86, 1999. e-Pub 1999.
11. Nieto Y, Shpall EJ. Autologous Stem-Cell Transplantation for Solid Tumors in Adults. Hematology/Oncology Clinics of North America 13(5):939-968, 1999. e-Pub 1999.
12. Nieto Y, Cagnoni PJ, Shpall EJ. High-Dose Chemotherapy in Gynecologic Malignancies. Cancer Treatment Research 95:277-285, 1998. e-Pub 1998.
13. Shpall EJ, Cagnoni PJ, Bearman SI, Ross M, Nieto Y, Jones RB. Peripheral Blood Stem Cell Harvesting and CD34-Positive Cell Selection. Cancer Treatment and Research 77:143-157, 1997. e-Pub 1997.
14. Nieto Y, Alonso JL. High-Dose Chemotherapy for Small-Cell Lung Cancer [Spanish]. Revisiones en Cáncer (Reviews on Cancer), 1996. e-Pub 1996.
15. Nieto YL. Treatment of Prostate Cancer [Spanish]. Sandorama 2(1), 1995. e-Pub 1995.
16. Casado A, Lopez-Martin A, Nieto Y. Treatment of Ovarian Cancer [Spanish]. Sandorama 1(1), 1995. e-Pub 1995.
17. Ayala F, Nieto Y. Salvage Therapy for High-Grade Non-Hodgkin’s Lymphomas [Spanish]. Revisiones en Cáncer (Reviews on Cancer) 8(5):144-152, 1994. e-Pub 1994.

Review Articles

1. Sheikh IN, Elgehiny A, Ragoonanan D, Mahadeo KM, Nieto Y, Khazal S. Management of Aggressive Non-Hodgkin Lymphomas in the Pediatric, Adolescent, and Young Adult Population: An Adult vs. Pediatric Perspective. Cancers (Basel) 14(12), 2022. e-Pub 2022. PMID: 35740580.
2. Myers AL, Kawedia JD, Champlin RE, Kramer MA, Nieto Y, Ghose R, Andersson BS. Clarifying busulfan metabolism and drug interactions to support new therapeutic drug monitoring strategies: a comprehensive review. Expert Opin Drug Metab Toxicol 13(9):901-923, 2017. e-Pub 2017. PMID: 28766962.
3. Wang E, Gulbis A, Hart JW, Nieto Y. The Emerging Role of Gemcitabine in Conditioning Regimens for Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant 20(9):1382-9, 2014. e-Pub 2014. PMID: 24816580.
4. Nieto Y, Shpall EJ. High-dose chemotherapy for high-risk primary and metastatic breast cancer: is another look warranted?. Curr Opin Oncol 21(2):150-7, 2009. e-Pub 2009. PMID: 19532017.
5. Woodward, W, Vinh-Hung, V, Ueno, NT, Yee, CC, Royce, M, Tai, P, Vlastos, G, Wallace, A, Hortobagyi, GN, Nieto, Y. Prognostic value of nodal ratios in node-positive breast cancer. Journal of Clinical Oncology 24(18):2910-2916, 2006. e-Pub 2006. PMID: 16782931.
6. Nieto, Y. DNA-binding agents. Cancer chemotherapy and biological response modifiers 22:163-203, 2005. e-Pub 2005. PMID: 16110612.
7. Nieto, Y, Jones, R, Shpall, E. High-dose chemotherapy for breast cancer. Current opinion in oncology 16(2):114-119, 2004. e-Pub 2004. PMID: 15075901.
8. Nieto, Y, Vaughan, W. Pharmacokinetics of high-dose chemotherapy. Bone marrow transplantation 33(3):259-269, 2004. e-Pub 2004. PMID: 14647243.
9. Nieto, Y. DNA-binding agents. Cancer chemotherapy and biological response modifiers 21:171-209, 2003. e-Pub 2003. PMID: 15338745.
10. Nieto, Y, Jones, R. DNA-binding agents. Cancer chemotherapy and biological response modifiers 19:189-213, 2001. e-Pub 2001. PMID: 11686014.
11. Nieto, Y, Shpall, E. High-dose chemotherapy for breast cancer. Cancer treatment and research 103:77-114, 2000. e-Pub 2000. PMID: 10948443.
12. Beaudet, J, McNiece, I, Jones, R, Bearman, SI, Cagnoni, P, Nieto, Y, McSweeney, PA, Shpall, E. The use of hematopoietic growth factors to support patients with breast cancer recovering from dose intensive theraphies. Seminars in Breast Disease 3(3):144-152, 2000. e-Pub 2000.
13. Nieto, Y, Cagnoni, P, Shpall, E. High-dose chemotherapy in gynecologic malignancies. Cancer treatment and research 95:277-285, 1998. e-Pub 1998. PMID: 9619289.
14. Shpall, E, Cagnoni, P, Bearman, SI, Ross, M, Nieto, Y, Jones, R. Peripheral blood stem cell harvesting and CD34-positive cell selection. Cancer Treat Res 77:143-157, 1997. e-Pub 1997. PMID: 9071502.

Professional Educational Materials

1. Nieto YL, Díaz-Rubio E. Colon Cancer. Interactive Clinical Case in CD-ROM, 1996.

Other Articles

1. Nieto Y, Banerjee P, Kaur I, Basar R, Li Y, Daher M, Rafei H, Kerbauy LN, Kaplan M, Marin D, Griffin L, Barnett M, Bassett R, Uprety N, Shrestha R, Silva FR, Islam S, Ganesh C, Borneo Z, Ramdial J, Ramirez A, Hosing C, Alousi A, Popat U, Qazilbash M, Ahmed S, Iyer S, Sainz TP, Vega F, Fowlkes NW, Alexis K, Emig M, Harstrick A, Overesch A, Shpall EJ, Rezvani K Author Correction: Allogeneic NK cells with a bispecific innate cell engager in refractory relapsed lymphoma: a phase 1 trial. Nat Med 31(8):2816, 2025. PMID: 40571757.
2. Dhakal B, Patel S, Girnius S, Bachegowda L, Fraser R, Davila O, Kanate AS, Assal A, Hanbali A, Bashey A, Pawarode A, Freytes CO, Lee C, Vesole D, Cornell RF, Hildebrandt GC, Murthy HS, Lazarus HM, Cerny J, Yared JA, Schriber J, Berdeja J, Stockerl-Goldstein K, Meehan K, Holmberg L, Solh M, Diaz MA, Kharfan-Dabaja MA, Farhadfar N, Bashir Q, Munker R, Olsson RF, Gale RP, Bayer RL, Seo S, Chhabra S, Hashmi S, Badawy SM, Nishihori T, Gonsalves W, Nieto Y, Efebera Y, Kumar S, Shah N, Qazilbash M, Hari P, D'Souza A Correction to: Hematopoietic cell transplantation utilization and outcomes for primary plasma cell leukemia in the current era. Leukemia 35(6):1828, 2021. PMID: 33782538.
3. Nieto Y, Tu SM, Bassett R, Jones RB, Gulbis AM, Tannir N, Kingham A, Ledesma C, Margolin K, Holmberg L, Champlin R, Pagliaro L Bevacizumab/high-dose chemotherapy with autologous stem-cell transplant for poor-risk relapsed or refractory germ-cell tumors. Ann Oncol 26(12):2507-2508, 2015. PMID: 26487577.
4. Hamdi A, Mulanovich VE, Matin SF, Landon G, Sircar K, Tu SM, Nieto Y Isolated Renal Mucormycosis in a Transplantation Recipient. J Clin Oncol 33(10):e50-1, 2015. PMID: 24821884.
5. Mehta RS, Di Stasi A, Andersson BS, Nieto Y, Jones R, de Lima M, Hosing C, Popat U, Kebriaei P, Oran B, Alousi A, Rezvani K, Qazilbash M, Bashir Q, Bollard C, Cooper L, Worth L, Tewari P, McNiece I, Willhelm K, Champlin R, Shpall EJ The Development of a Myeloablative, Reduced-Toxicity, Conditioning Regimen for Cord Blood Transplantation. Clin Lymphoma Myeloma Leuk 14(1):e1-5, 2014. PMID: 24169268.
6. McNiece, I, Jones, R, Bearman, SI, Cagnoni, P, Nieto, Y, Shpall, E Ex Vivo Expansion of Hematopoietic Cells. The Keio Journal of Medicine 48(Suppl 1):A32-A36, 1999.

Editorials

1. Jones RB, Nieto YL, Rizzo JD, Wall D, Wingard JR, McCarthy PJ, Hahn T. The Evolution of Evidence-Based Review: Evaluating the Science Enhances the Art of Medicine-Statement of the Steering Committee for Evidence-Based Reviews of the American Society for Blood and Marrow Transplantation. Blood and Marrow Transplantation 11:819-822, 2005.

Abstracts

1. Sarubbi C, Miatech J, Forsberg M, Demla A, Rahman Z, Pawelek J, MItchell D, Donald S, Garcia C, Suello K, Codrington K, Hunter L, Garcia R, Martinez C, Rondon G, Alatrash G, Aljawai Y, Alousi A, Bashir Q, Champlin R, Chen G, Hosing C, Im J, Kebriaei P, Khouri I, Lin P, Marin D, Mehta R, Nieto Y, Olson A, Oran B, Qazilbash M, Ramdial J, Popat U, Smallbone P, Srour S, Tewari P, Flowers C, Shpall E, Fingrut W. Optimizing essential, complex hematologic care for patients living with disabilities. Blood/ASH Annual Abstract. e-Pub 2025.
2. Aljawai Y, Milton D, Mehta R, Marin D, Nieto Y, Chen G, Oran B, Smallbone P, Hosing C, Pasvolsky O, Alousi A, Kebriaei P, Popat U, Champlin R, Shpall E. Older donor age is not associated with inferior survival in contemporary haploidentical transplantation. Blood/ASH Annual Abstract. e-Pub 2025.
3. Popat U, Bassett R, Alousi A, Alatrash G, Aljawai Y, Bashir Q, Chen G, Fingrut W, Hosing C, Im J, Kebriaei P, Marin D, Nieto Y, Olson A, Oran B, Qazilbash M, Ramdial J, Saini N, Smallbone P, Srour S, Champlin R, Shpall E. Myeloablative fractionated busulfan, fludarabine, cladribine, thiotepa, and venetoclax (Cladillac) conditioning for high-risk AML: A phase 2 trial. Blood/ASH Annual Abstract. e-Pub 2025.
4. Forsberg M, Kaur I, Pirtle R, Daher M, Basar R, Washington D, Asfaw T, Castro K, Ramirez A, Shaftoe S, Oran B, Lin P, Nieto Y, Mulanovich V, Ariza-Heredia E, Aljawai Y, Chen G, Alousi A, Kebriaei P, Fingrut W, Im J, Khouri I, Olson A, Mehta R, Popat U, Ramdial J, Srour S, Saini N, Smallbone P, Bashir Q, Champlin R, Shpall E, Rezvani K, Marin D. Administration of off-the-shelf, expanded, most closely HLA matched, third party viral specific T cells for the therapy of adenovirus related disease in adult immunocompromised patients. Blood/ASH Annual Abstract. e-Pub 2025.
5. Wakefield C, Milton D, Tanner M, Bashir Q, Srour S, Saini N, Lin P, Ramdial J, Nieto Y, Tang G, Haider A, Aljawai Y, Kebriaei P, Patel K, Thomas S, Orlowski R, Champlin R, Shpall E, Qazilbash M, Pasvolsky O. Simplified frailty score for patients with multiple myeloma undergoing autologous stem cell transplant. Blood/ASH Annual Abstract. e-Pub 2025.
6. Sainz T, Mohanty V, Pan Y, Gui X, Sahu V, Casasent A, Basi A, Kettlun C, Pacheco C, Wilson A, Donoso JA, Mundhada A, Henderson J, Nieto Y, Burks J, Green MR, Chen K, Vega F. Integrative profiling of t-follicular helper cells heterogeneity and tumor microenvironment signatures in angioimmunoblastic T cell lymphoma. Blood/ASH Annual Abstract. e-Pub 2025.
7. Nair R, Lopez S, Aickareth A, Weaver D, Liu Q, Xiong W, Malpica L, Fayad L, Ramos J, Nieto Y, Huen A, Iyer S. Single center updated analysis of patients with Relapsed/Refractory peripheral T-cell lymphoma treated with linperlisib. Blood/ASH Annual Abstract. e-Pub 2025.
8. Hosing C, Saliba RM, Alousi A, Alatrash G, Aljawai Y, Bashir Q, Chen G, Fingrut W, Im J, Kebriaei P, Marin D, Nieto Y, Olson A, Oran B, Qazilbash M, Ramdial J, Smallbone P, Popat U, Champlin R, Maadani F, Guillermo-Pacheco M, Rezvani K, Shpall E, Kadia T, Srour S. Allogeneic stem cell transplant for T-prolymphocytic leukemia: A single center analysis. Blood/ASH Annual Abstract. e-Pub 2025.
9. Saliba RM, Miatech J, Ramdial J, Rondon G, Alatrash G, Alousi A, Bashir Q, Chen G, Fingrut W, Hosing C, Kebriaei P, Khouri I, Marin D, Nieto Y, Olson A, Oran B, Popat U, Qazilbash M, Smallbone P, Srour S, Tanner M, Rezvani K, Champlin R, Shpall E, Mehta R. MMF is associated with higher non-relapse mortality and inferior survival in AML/MDS patients receiving peripheral blood matched allogeneic stem cell transplantation with post-transplant cyclophosphamide based gvhd prophylaxis. Blood/ASH Annual Abstract. e-Pub 2025.
10. Gunther J, Huen A, Dai J, Iyer S, Torres-Cabala C, Fayad L, Malpica L, Lin T, Fang P, Wu S, Pinnix C, Xu J, Nair R, Srour S, Khouri R, Ramdial J, Nieto Y, Hosing C, Dabaja B. Condensed total skin electron beam therapy prior to allogeneic stem cell transplantation in patients with cutaneous T-cell lymphoma/sezary syndrome. Blood/ASH Annual Abstract. e-Pub 2025.
11. Srour SA, Saliba RM, Ramdial JL, Smallbone P, Im JS, Olson AL, Kusy CC, Oran B, Chen GL, Qazilbash MH, Kebriaei P, Hosing CM, Khouri IF, Alousi AM, Bashir Q, Marin D, Nieto Y, Shpall EJ, Champlin RE, Popat UR. Fractionated Busulfan, Fludarabine and Thiotepa Myeloablative Conditioning to Improve Transplant Outcomes for Myelofibrosis. ASTCT Tandem Meetings 31(2):Supplement, 2025. e-Pub 2025.
12. Kawedia JD, Hilaire MR, Liu X, Drisgill A, Gulbis AM, Nieto Y, Popat UR, Andersson BS, Salamone SJ, Shpall EJ. Evaluation of Busulfan Exposure Calculations Using Novel Busulfan Immunoassay with Standard Mass Spectrometry Based Analytical Method. ASTCT Tandem Meetings 31(2):Supplement, 2025. e-Pub 2025.
13. Cervoni-Curet FN, Milton DR, Garcia R, Hunter L, Ledesma C, Martinez CS, Rondon G, Carmazzi Y, Cao K, Al-Atrash G, Aljawai YM, Alousi AM, Bashir Q, Chen GL, Hosing CM, Im JS, Kebriaei P, Khouri IF, Marin D, Mehta RS, Nieto Y, Olson AL, Oran B, Popat UR, MD, Qazilbash MH, Ramdial JL, Smallbone P, Saini NY, Srour SA, Champlin RE, Flowers C, Shpall EJ, Fingrut WB. Disparities in Allograft Access in the Era of Post-Transplant Cyclophosphamide (PTCy)-Based Graft-Versus-Host Disease Prophylaxis. ASTCT Tandem Meetings 31(2):Supplement, 2025. e-Pub 2025.
14. Pasvolsky O, Milton DR, Tanner MR, Bashir Q, Srour SA, Saini NY, Lin P, Saeed A, Haider AA, Ramdial JL, Nieto Y, Tang G, Aljawai YM, Kebriaei P, Lee HC, Patel KK, Becnel MR, Thomas SK, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH. Outcomes of Patients with IgD Multiple Myeloma Undergoing Autologous Hematopoietic Stem Cell Transplant. ASTCT Tandem Meetings 31(2):Supplement, 2025. e-Pub 2025.
15. Popat UR, Bassett RL, Alousi AM, Alatrash G, Aljawai YM, Bashir Q, Chen GL, Fingrut WB, Gulbis AM, Hosing CM, Im JS, Kebriaei P, Marin D, Mehta RS, Nieto Y, Olson AL, Oran B, Qazilbash MH, Ramdial JL, Saini NY, Smallbone P, Srour SA, Valdez BC, Champlin RE, Andersson BS, Shpall EJ. Myeloablative Fractionated Busulfan, Fludarabine, Cladribine, Thiotepa and Venetoclax (Cladillac) Conditioning Regimen for Allogeneic Stem Cell Transplantation in Very High-Risk AML/MDS: A Phase 2 Trial. ASTCT Tandem Meetings 31(2):Supplement, 2025. e-Pub 2025.
16. Pasvolsky O, Milton DR, Tanner MR, Bashir Q, Srour SA, Saini NY, Lin P, Siddiqui UR, Khan HN, Haider AA, Ramdial JL, Nieto Y, Tang G, Lakhani K, Aljawai YM, Kebriaei P, Lee HC, Patel KK, Thomas SK, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH. Daratumumab-Based Second Line Therapy Improves Outcomes after VRD Induction, Upfront Autologous Transplant and Lenalidomide Maintenance. ASTCT Tandem Meetings 31(2):Supplement, 2025. e-Pub 2025.
17. Kim K, Huen AO, Dai J, Lohray R, Dabaja B, Gunther JR, Wu SY, Torres-Cabala CA, Nair R, Malpica L, Nieto Y, Ramdial JL, Hosing CM, Srour SA, Iyer SP. Outcomes of Allogeneic Stem-Cell Transplant in Large-Cell Transformation of Mycosis Fungoides. ASTCT Tandem Meetings 31(2):Supplement, 2025. e-Pub 2025.
18. Popat UR, Alousi AM, Bassett RL, Alatrash G, Aljawai YM, Bashir Q, Chen GL, Fingrut WB, Hosing CM, Im JS, Kebriaei P, Khouri IF, Marin D, Mehta RS, Nieto Y, Olson AL, Oran B, Qazilbash MH, Ramdial JL, Saini NY, Shigle TL, Smallbone P, Srour SA, Champlin RE, Shpall EJ. Jak Inhibitor Itacitinib with Ptcy and Tacrolimus to Prevent Gvhd in a Myeloablative Fractionated Busulfan Regimen: A Phase 2 Trial. ASTCT Tandem Meetings 31(2):Supplement, 2025. e-Pub 2025.
19. Hosing CM, Saliba RM, Alousi AM, Alatrash G, Aljawai YM, Bashir Q, Chen GL, Fingrut WB, Im JS, Kebriaei P, Marin D, Nieto Y, Olson AL, Oran B, Qazilbash MH, Ramdial JL, Saini NY, Smallbone P, Srour SA, Bazinet A, Garcia-Manero G, Champlin RE, Andersson BS, Shpall EJ, Popat UR. Allogeneic Stem Cell Transplant with Myeloablative Fractionated Busulfan, Fludarabine and Thiotepa Conditioning Regimen in Older Patients with High Risk MDS. ASTCT Tandem Meetings 31(2):Supplement, 2025. e-Pub 2025.
20. Ramdial J, Chien K, Lin R, Duong J, Mehta R, Oran B, Popat U, Kebriaei P, Rezvani K, Alatrash G, Chen G, Nieto Y, Maiti A, Short N, Issa G, Borthakur G, Kantarjian H, Champlin R, Shpall E, Dinardo C. A phase II open-label study of olutasidenib post-transplant maintenance therapy for patients with IDH1-mutated myeloid malignancies. 2025 ASCO Annual Meeting. e-Pub 2025.
21. Cervoni Curet FN, Bassett RL, Pasvolsky O, Deen AF, Tanner MR, Bashir Q, Srour SA, Saini NY, Ramdial J, Nieto Y, Lee HC, Patel KK, Kebriaei P, Fingrut WB, Smallbone P, Becnel MR, Gaballa MR, Thomas SK, Ye J, Orlowski RZ, Champlin RE, Shpall EJ, Qazilbash MH. Impact of Ethnicity on Long Term Outcomes of High-Dose Chemotherapy and Upfront Autologous Hematopoietic Stem Cell Transplantation in Patients with Multiple Myeloma. Blood/ASH Annual Abstract, 2024. e-Pub 2024.
22. Popat U, Bassett RL, Alousi AM, Alatrash G, Aljawai YM, Bashir Q, Chen G, Fingrut WB, Hosing C, Im JS, Kebriaei P, Marin D, Nieto Y, Olson AL, Oran B, Qazilbash MH, Ramdial J, Saini NY, Smallbone P, Srour SA, Valdez BC, Champlin RE, Andersson BS, Shpall EJ. Myeloablative Fractionated Busulfan, Fludarabine, Cladribine, Thiotepa and Venetoclax (Cladillac) Conditioning Regimen for Very High-Risk AML/MDS: A Phase 2 Trial. Blood/ASH Annual Abstract, 2024. e-Pub 2024.
23. Pasvolsky O, Milton DR, Tanner MR, Bashir Q, Srour SA, Saini NY, Lin P, Patel A, Khan HN, Ramdial J, Nieto Y, Tang G, MD, Haider A, Aljawai YM, Ahmed S, Kebriaei P, Lee HC, Ye C, Patel KK, Thomas SK, Orlowski RZ, Champlin RE, Shpall EJ, Qazilbash MH. Outcomes of Patients with Multiple Myeloma with Deletion 1p Following Autologous Stem Cell Transplant. Blood/ASH Annual Abstract, 2024. e-Pub 2024.
24. Srour SA, Saliba RM, Ramdial J, Smallbone P, Im JS, Olson AL, Kusy CC, Oran B, Chen G, Qazilbash MH, Kebriaei P, Hosing C, Khouri IF, Alousi AM, Bashir Q, Marin D, Nieto Y, Shpall EJ, Champlin RE, Popat U. Fractionated Busulfan, Fludarabine and Thiotepa Myeloablative Conditioning to Improve Transplant Outcomes for Myelofibrosis. Blood/ASH Annual Abstract, 2024. e-Pub 2024.
25. Patel R, Gurumurthi A, Feng L, Westin J, Nastoupil LJ, Nair R, Iyer SP, Torres JM, Nieto Y, Kebriaei P, Hawkins M, Chihara D, Malpica L, Adkins S, Shpall EJ, Ramdial JL, Strati P, Hosing CM, Neelapu SS, Ahmed S. Factors associated with manufacturing failure of commercial CD19 CAR-T cell products for large b cell lymphoma (LBCL). ASCO Annual Meeting 42(Suppl 16), 2024. e-Pub 2024.
26. Patel RD, Feng L, Westin JR, Nair R, Fayad L, Steiner R, Oran B, Chihara D, Shpall EJ, Strati P, Neelapu SS, Gurumurthi A, Nastoupi LJ, Iyer SP, Samaniego F, Nieto YL, Hawkins M, Adkins S, Ramdial J, Hosing C, Ahmed S. Clinical Factors Associated with Failure to Manufacture Commercial CAR-T Cell Products Among LBCL Patients. ASTCT Annual Abstract 30(2, Supplement):S214, 2024. e-Pub 2024.
27. Pasvolsky O, Wang Z, Khan HN, Bashir Q, Saini NY, Ramdial J, Aljawai Y, Lee HC, Kebriaei P, Weber DM, Shpall EJ, Qazilbash MH, Milton DR, Tanner MR, Srour SA, Lin P, Nieto YL, Ansari A, Patel KK, Thomas SK, Orlowski RZ, Champlin RE. Long-Term Responders after Upfront Autologous Hematopoietic Stem Cell Transplant for Multiple Myeloma. ASTCT Annual Abstract 30(2, Supplement):S379-S380, 2024. e-Pub 2024.
28. Kawedia JD, Liu X, Sui D, Gulbis AM, Ramdial J, Srour SA, Popat UR, Nieto Y, Kebriaei P, Saini NY, Lin P, Aljawai Y, Pasvolsky O, Lee HC, Orlowski RZ, Thomas SK, Patel KK, Knape C, Delgado R, Champlin RE, Shpall EJ, Qazilbash MH, Thall P. Lower PG-Free Mel (Evomela) Clearance and Higher Exposure Are Associated with Better Treatment Response in Newly Diagnosed Multiple Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplantation. ASTCT Annual Abstract, 2024. e-Pub 2024.
29. Ramdial J, Lin R, Valdez BC, Srour SA, Qazilbash MH, Shpall EJ, Jimenez E, Shigle TL, Nieto Y, Thall P, Hosing C, Popat UR, Alousi AM, Barnett M, Gulbis AM. A Comparison of Gemcitabine/Clofarabine/Busulfan (Gem/Clo/Bu) Myeloablative Conditioning with Fludarabine/Melphalan (Flu/Mel) Reduced Intensity Conditioning for Allogeneic Stem-Cell Transplant (alloSCT) for Aggressive Lymphomas. ASTCT Annual Abstract 30(2, Supplement):S168, 2024. e-Pub 2024.
30. Ramdial J, Valdez BC, Lin R, Thall P, Wei A, Hosing C, Srour SA, Popat UR, Qazilbash MH, Alousi AM, Barnett M, Gulbis AM, Shigle TL, Shpall EJ, Andersson BS, Nieto Y. Gemcitabine (Gem) /Clofarabine (Clo) /Busulfan (Bu) (GemCloBu): A New Myeloablative Conditioning Regimen with Reduced Toxicity and High Activity for Allogeneic Stem-Cell Transplant (alloSCT) for Aggressive Lymphomas. ASTCT Annual Abstract 30(2, Supplement):S56, 2024. e-Pub 2024.
31. Nieto Y, Valdez BC, Thall P, Bassett R, Ramdial J, Srour SA, Saini NY, Hosing C, Alousi AM, Qazilbash MH, Popat UR, Barnett M, Gulbis AM, Shigle TL, Pacheco MV, Ledesma C, Ahmed S, Iyer SP, Nair R, Strati P, Westin JR, Champlin RE, Shpall EJ, Andersson BS. The Combination of the PARP Inhibitor Olaparib with High-Dose Chemotherapy (HDC) and Autologous Stem-Cell Transplant (ASCT) Demonstrates High Activity for Refractory Lymphomas, Including Prior Failures of CAR-T. ASTCT Annual Abstract 30(2, Supplement):S36, 2024. e-Pub 2024.
32. Merryman RW, Rhoades J, Xiong K, Antel K, An HH, Redd RA, McDonough MM, Guerrero L, Crnjac A, Sridhar S, Blewett T, Chen J, Dahi PB, Nieto Y, Chen Y, Herrera AF, Joyce RM, Armand P, Murakami MA, Adalsteinsson V. A Personalized Whole Genome-Informed Assay Targeting Single Mutant in Circulating Tumor DNA Can Identify MRD and Predict Relapse in DLBCL. Blood/ASH Annual Abstract 142(Supplement I), 2023. e-Pub 2023.
33. Pasvolsky O, Ghanem S, Milton DR, Rauf M, Tanner MR, Bashir Q, Srour SA, Saini NY, Lin P, Ramdial J, Nieto Y, Khan HN, Kebriaei P, Lee H, Patel KK, Thomas SK, Weber DM, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH. Outcomes of Patients with Multiple Myeloma and 1q Gain/Amplification Receiving Autologous Hematopoietic Stem Cell Transplant: The MD Anderson Cancer Center Experience. Blood/ASH Annual Abstract 142(Supplement I), 2023. e-Pub 2023.
34. Marcoux C, Saliba RM, Wallis W, Khazal S, Ragoonanan D, Rondon G, Tewari P, Popat UR, Oran B, Olson AL, Bashir Q, Qazilbash MH, Alousi A, Hosing C, Nieto Y, Alatrash G, Marin D, Rezvani K, Khouri IF, Srour SA, Champlin RE, Shpall EJ, Kebriaei P. Incidence and Risk Factors of Veno-Occlusive Disease Are Different in Younger Versus Older Adults Undergoing Allogeneic Hematopoietic Stem Cell Transplantation. Blood/ASH Annual Abstract 142(Supplement I), 2023. e-Pub 2023.
35. Alzahrani K, Pasvolsky O, Wang Z, Milton DR, Tanner MR, Bashir Q, Srour SA, Saini NY, Lin P, Ramdial J, Nieto Y, Lee H, Patel KK, Manasanch EE, Kebriaei P, Thomas SK, Weber DM, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH. Impact of Revised International Staging System 2 (R2-ISS) Risk Stratification on Outcomes of Patients with Multiple Myeloma Receiving Autologous Hematopoietic Stem Cell Transplantation. Blood/ASH Annual Abstract 142(Supplement I), 2023. e-Pub 2023.
36. Qazilbash MH, Khan HN, Milton DR, Pasvolsky O, Tanner MR, Popat UR, Kebriaei P, Hosing C, Khouri IF, Rezvani K, Nieto Y, Oran B, Srour SA, Saini NY, Olson AL, Ahmed S, Alatrash G, Rondon G, Konopleva MY, Champlin RE, Shpall EJ, Bashir Q, Pemmaraju N. Patient Characteristics and Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation for Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN). Blood/ASH Annual Abstract 142(Supplement I), 2023. e-Pub 2023.
37. Nieto Y, Banerjee P, Kaur I, Griffin L, Barnett M, Ganesh C, Borneo Z, Bassett RL, Kerbauy LN, Basar R, Kaplan M, Esqueda D, Ramdial J, Ahmed S, Hosing C, Srour SA, Alousi A, Qazilbash MH, Steiner RE, Alexis K, Emig M, Harstrick A, Shpall EJ, Rezvani K. Innate Cell Engager (ICE®) AFM13 Combined with Preactivated and Expanded (P+E) Cord Blood (CB)-Derived Natural Killer (NK) Cells for Patients with Refractory CD30-Positive Lymphomas: Final Results. Blood/ASH Annual Abstract 142(Supplement I), 2023. e-Pub 2023.
38. Pasvolsky O, Marcoux C, Dai J, Milton DR, Tanner MR, Syed N, Bashir Q, Srour SA, Saini NY, Lin P, Ramdial J, Nieto Y, Lee H, Patel KK, Manasanch EE, Kebriaei P, Thomas SK, Weber DM, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH. Trends in Outcomes over Three Decades after Upfront Autologous Stem Cell Transplant for Multiple Myeloma at MD Anderson Cancer Center. Blood/ASH Annual Abstract 142(Supplement I), 2023. e-Pub 2023.
39. Pasvolsky O, Pasyar S, Bassett RL, Khan HN, Tanner MR, Bashir Q, Srour SA, Saini NY, Lin P, Ramdial J, Nieto Y, Lee, H, Patel KK, Kebriaei P, Thomas SK, Weber DM, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH. Impact of Pre-Transplant Minimal Residual Disease in Patients with Multiple Myeloma with ≥ Very Good Partial Response Receiving Autologous Hematopoietic Stem Cell Transplantation. Blood/ASH Annual Abstract 142(Supplement I), 2023. e-Pub 2023.
40. Bashir Q, Thall P, Sui D, Kawedia J, Knape C, Delgado R, Schindler JL, Popat UR, Kebriaei P, Hosing C, Khouri IF, Nieto Y, Oran B, Srour SA, Saini NY, Olson AL, Ahmed S, Alatrash G, Rondon G, Lee H, Thomas SK, Manasanch EE, Patel KK, Orlowski RZ, Champlin RE, Shpall EJ, Qazilbash MH. Phase 1/2 Trial to Jointly Optimize Dose and Administration Schedule of Evomela in Newly Diagnosed Multiple Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplantation. Blood/ASH Annual Abstract 142(Supplement I), 2023. e-Pub 2023.
41. Xiang JJ, Campbell MT, Tu SM, Araujo JC, Nieto Y, Lin JK, Xiao L, Shah AY, Wang J. Doxorubicin, paclitaxel, and cisplatin (ATP) for refractory germ cell tumors. ASCO Annual Abstract Suppl 16, 2023. e-Pub 2023.
42. Popat UR, Lontos K, Bassett RL, Alousi AM, Alatrash G, Bashir Q, Hosing CM, Im JS, Kebriaei P, Marin E, Mehta RS, Nieto Y, Oran B, Olson AL, Qazilbash MH, Ramdial JL, Srour SA, Shpall EJ, Champlin RE, Andersson BS. Myeloablative fractionated busulfan-based conditioning regimen in patients with AML and MDS: Results of a randomized clinical trial comparing 2 fractionation schedules. ASCO Annual Abstract Suppl 16, 2023. e-Pub 2023.
43. Shi D, Hosing C, Khouri IF, Saengboon S, Saini NY, Ramdial J, Akin S, Bashir Q, Steiner R, Dabaja B, Pinnix C, Ahmed S, Alousi AM, Anderlini P, Kebriaei P, Qazilbash MH, Popat UR, Shpall EJ, Champlin RE, Nieto Y, Srour SA. Long-Term Outcomes after Autologous Stem Cell Transplant (ASCT) for Primary Central Nervous System Lymphoma (PCNSL). ASTCT Annual Abstract 29(2):S383, 2023. e-Pub 2023.
44. Kawedia JD, Liu X, Ramdial J, Srour SA, Mehta RS, Popat UR, Nieto Y, Saini NY, Kebriaei P, Knape C, Gulbis AM, Champlin RE, Shpall EJ, Qazilbash MH, Bashir Q. Creatinine Clearance Is Associated with Propylene Glycol-Free Melphalan (Evomela) Pharmacokinetics and Gastrointestinal Toxicities in Newly Diagnosed Multiple Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplantation. ASTCT Annual Abstract 29(2):S439, 2023. e-Pub 2023.
45. Pasvolsky O, Bassett R, Ghanem S, Cuglievan B, Priti T, Hosing C, Srour SA, Ramdial J, Mahadeo KM, Khazal SJ, Petropoulos D, Popat UR, Qazilbash MH, Kebriaei P, Champlin RE, Shpall EJ, Nieto Y. Characteristics and Outcomes of Children, Adolescents and Young Adults with Relapsed/Refractory Non-Hodgkin Lymphoma Undergoing First Autologous Hematopoietic Stem Cell Transplant. ASTCT Annual Abstract 29(2):S379, 2023. e-Pub 2023.
46. Pasvolsky O, Saliba RM, Masood A, Mohamedi AH, Tanner MR, Bashir Q, Srour SA, Saini NY, Ramdial J, Nieto Y, Lee HC, Patel KK, Kebriaei P, Thomas SK, Weber DM, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH. Impact of Gender on Outcomes of Patients with Multiple Myeloma Undergoing Autologous Hematopoietic Stem Cell Transplant. ASTCT Annual Abstract 29(2):S405, 2023. e-Pub 2023.
47. Nieto Y, Yang Z, Valdez BC, Kundu S, Bassett R, Barnett M, Bashir Q, Ramdial J, Saini NY, Srour SA, Im JS, Kebriaei P, Popat UR, Gulbis AM, Cool R, Shigle TL, Wallis WD, Yeh J, Delgado R, Qureshi S, Lee HC, Manasanch E, Orlowski RZ, Thomas SK, Shpall EJ, Andersson BS, Qazilbash MH. Safety and Efficacy of a New High-Dose Chemotherapy Regimen of Panobinostat, Gemcitabine, Busulfan and Melphalan (Pano/GBM) with Autologous Stem Cell Transplant (ASCT) for Patients with High-Risk or Refractory/Relapsed Myeloma – Matched Pair Comparisons with a Concurrent Control Cohort. ASTCT Annual Abstract 29(2):S32, 2023. e-Pub 2023.
48. SaengboonS, Khouri IF, Hosing C, Ramdial J, Saini NY, Akin S, Shi D, Steiner R, Malpica L, Ahmed S, Westin JR, Dabaja B, Wu SY, Alousi AM, Kebriaei P, Qazilbash MH, Popat UR, Champlin RE, Shpall EJ, Nieto Y, Srour SA. Timing of Autologous Stem Cell Transplantation (ASCT) in Patients with Primary Central Nervous System Lymphoma (PCNSL). ASTCT Annual Abstract 29(2):S385-S386, 2023. e-Pub 2023.
49. Chan KH, Ramdial J, Hosing C, Srour SA, Alousi AM, Kebriaei P, Popat UR, Qazilbash MH, Ahmed S, Iyer SP, Lee HJ, Nair R, Steiner R, Strati P, Dabaja B, Fang P, Gunther JR, Pinnix C, Wu SY, Cuglievan B, Mahadeo KM, Champlin RE, Shpall EJ, Nieto Y. Outcome of Patients with Classical Hodgkin Lymphoma (cHL) Relapsing after an Autologous Stem-Cell Transplant (ASCT). ASTCT Annual Abstract 29(2):S382, 2023. e-Pub 2023.
50. Popat UR, Saliba RM, Mehta RS, Alousi AM, Al-Atrash G, Bashir Q, Hosing CM, Gulbis AM, Im JS, Kebriaei P, Khouri IF, Kawedia JD, Marin D, Nieto Y, Olson A, Oran B, Ramdial J, Saini NY, Shigle TL, Srour SA, Rezvani K, Qazilbash MH, Andersson BS, Shpall EJ, Champlin RE. Myeloablative Fractionated Busulfan Fludarabine and Thiotepa Regimen for Haploidentical Donor Transplantation. ASTCT Annual Abstract 29(2):S167, 2023. e-Pub 2023.
51. Pasvolsky O, Milton DR, Masood A, Sami SS, Tanner MR, Bashir Q, Srour, SA, Saini NY, Ramdial J, Nieto Y, Lee HC, Patel KK, Kebriaei P, Thomas SK, Weber DM Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH. Single-Agent Lenalidomide Maintenance after Upfront Autologous Stem Cell Transplant for Newly Diagnosed Multiple Myeloma: The MD Anderson Cancer Center Experience. ASTCT Annual Abstract 29(2):S398-S399, 2023. e-Pub 2023.
52. Uday R Popat UR, Saliba RM, Mehta RS, Alousi AM, Al-Atrash G, Bashir Q, Chen J, Gulbis AM, Hosing CM, Im JS, Kebriaei P, Khouri IF, Kawedia JD, Marin D, Nieto Y, Olson A, Oran B, Ramdial J, Saini NY, Srour SA, Rezvani K, Qazilbash MH. Myeloablative Fractionated Busulfan Regimens in Matched Donor Transplantation. ASTCT Annual Abstract 29(2):S164-S165, 2023. e-Pub 2023.
53. Mehta RS, Saliba RM, Alousi AM, Alatrash G, Bashir Q, Hosing C, Kebriaei P, Khouri IF, Nieto Y, Oran B, Popat UR, Qazilbash MH, Ramdial JL, Rondon G, Srour SA, Rezvani K, Champlin RE, Shpall EJ, Cao K. Son Vs Daughter Haploidentical Donor for T Cell-Replete HCT with Ptcy Prophylaxis. Blood/ASH Annual Abstract, 2022. e-Pub 2022.
54. Mehta RS, Saliba RM, Alousi AM, Alatrash G, Bashir Q, Hosing C, Kebriaei P, Khouri IF, Nieto Y, Oran B, Popat UR, Qazilbash MH, Ramdial JL, Rondon G, Srour SA, Rezvani K, Champlin RE, Shpall EJ, Cao K. HLA B-Leader Mismatch Is Associated with Poor Outcomes in NIMA/NIPA Mismatched Haploidentical Sibling Donor HCT. Blood/ASH Annual Abstract, 2022. e-Pub 2022.
55. Tang K, Khwaja R, Feng L, Strati P, Steiner RE, Nair R, Flowers CR, Saini N, Ramdial JL, Srour SA, Champlin RE, Rondon G, Torres J, Kebriaei P, Nastoupil LJ, Mistry H, Shpall EJ, Nieto Y, Westin J, Neelapu SS, Ahmed S. Comorbidities Associated with Early Mortality after CD19 CAR-T Cell Therapy. Blood/ASH Annual Abstract, 2022. e-Pub 2022.
56. Nair R, Ayers A, Nastoupil LJ, Gunther JR, Fayad L, Fowler NH, Miranda RN, Hagemeister FB, Lee HJ, Rodriguez MA, Steiner R, Strati P, Nieto Y, Ramdial JL, Chihara D, Wang ML, Malpica Castillo LE, Saini N, Jain P, Pinnix CC, Dabaja BS, Green MR, Flowers CR, Medeiros LJ, Marques-Piubelli ML, Vega F, Noorani M, Ahmed S, Westin J, Neelapu SS, Feng L, Iyer SP. CD19 CAR-T Outcomes in Patients with EBV-Positive DLBCL. Blood/ASH Annual Abstract, 2022. e-Pub 2022.
57. Mehta RS, Saliba RM, Alousi AM, Alatrash G, Bashir Q, Kebriaei P, Khouri IF, Nieto Y, Oran B, Popat UR, Qazilbash MH, Ramdial JL, Rondon G, Srour SA, Rezvani K, Champlin RE, Shpall EJ, Cao K. Mother Vs Father Haploidentical Donor for T Cell-Replete HCT with Ptcy Prophylaxis. Blood/ASH Annual Abstract, 2022. e-Pub 2022.
58. Nieto Y, Valdez BC, Thall PF, Ramdial JL, Srour SA, Hosing C, Saini N, Alousi AM, Qazilbash MH, Popat UR, Gulbis A, Shigle TL, Bassett R, Guillermo-Pacheco M, Ledesma C, Strati P, Ahmed S, Steiner R, Westin J, Nair R, Iyer SP, Champlin RE, Shpall EJ, Andersson BS. High Efficacy of the PARP Inhibitor Olaparib Combined with High-Dose Chemotherapy and Autologous Stem-Cell Transplant for Refractory Lymphomas. Blood/ASH Annual Abstract, 2022. e-Pub 2022.
59. Merrill MH, Dahi PB, Redd RA, McDonough MM, Chen Y, LaCasce AS, Fisher DC, Herrera AF, Jacobson CA, Kim AI, Merryman RW, Odejide OO, Ng S, Nieto Y, Sauter CS, Shah GL, Zain J, Armand P, Jacobsen ED. A Phase 2 Study of Pembrolizumab (MK-3475) after Autologous Stem Cell Transplantation in Patients with T-Cell Non-Hodgkin Lymphoma. Blood/ASH Annual Abstract, 2022. e-Pub 2022.
60. Agbedia OO, Prakash R, Xu J, Becnel MR, Nair R, Steiner RE, Feng L, Lee HJ, Strati P, Ahmed S, Parmar S, Nieto Y, Hosing C, Westin J, Nastoupil LJ, Vo A, Samaniego F, Fowler NH, Saini N, Khouri IF, Im JS, Fayad L, Jain P, Wang ML, Miranda RN, Vega F, Medeiros J, Oki Y, Flowers CR, Neelapu SS, Iyer SP. Updated Results of an Investigator-Initiated Phase II Study of Pembrolizumab and Romidepsin for Patients with Relapsed or Refractory T-Cell Lymphoma (TCL) with Survival Analysis. Blood/ASH Annual Abstract, 2022. e-Pub 2022.
61. Pasvolsky O, Milton DR, Masood A, Shehzad SS, Tanner MR, Bashir Q, Srour SA, Saini N, Ramdial JL, Nieto Y, Lee HC, Patel K, Kebriaei P, Thomas SK, Weber DM, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH. Autologous Stem Cell Transplantation for Patients with Multiple Myeloma with Translocation (4:14): The MD Anderson Cancer Center Experience. Blood/ASH Annual Abstract, 2022. e-Pub 2022.
62. Khawaja F, Prakash R, Sassine J, Handley G, VanWieren T, Angelidakis G, Iyer SP, Ramdial JL, Ahmed S, Nieto Y, Spallone A, Ariza-Heredia EJ, Chemaly R. Cytomegalovirus (CMV) Reactivation within in the First Year after Chimeric Antigen Receptor (CAR) T Cell Therapy: Experience from the First Two Years at a Major Cancer Center. Blood/ASH Annual Abstract, 2022. e-Pub 2022.
63. Pasvolsky O, Milton DR, Rauf M, Ghanem S, Masood A, Mohamedi AH, Tanner MR, Bashir Q, Srour SA, Saini N, Lin P, Ramdial JL, Nieto Y, Tang G, Lee HC, Patel K, Kebriaei P, Thomas SK, Weber DM, Orlowski RZ, Rezvani K, Shpall EJ, Champlin RE, Lin P, Qazilbash MH. Impact of Presence and Amount of Clonal Plasma Cells in Autografts Affect Outcomes in High-Risk Multiple Myeloma Patients Undergoing Autologous Hematopoietic Stem Cell Transplant. Blood/ASH Annual Abstract, 2022. e-Pub 2022.
64. Nieto Y, Banerjee PP, Kaur I, Griffin L, Ganesh C, Kerbauy L, Basar R, Kaplan M, Islam S, Esqueda D, Bassett R, Timmons M, Ramdial JL, Srour SA, Saini N, Hosing C, Ahmed S, Iyer SP, Alexis K, Emig M, Harstrick A, Shpall EJ, Rezvani K. Innate Cell Engager AFM13 Combined with Preactivated and Expanded Cord Blood-Derived NK Cells for Patients with Double Refractory CD30+ Lymphoma. Blood/ASH Annual Abstract, 2022. e-Pub 2022.
65. Srour SA, Mehta RS, Shah N, Qazilbash MH, Im J, Bashir Q, Saini N, Nieto Y, Khouri IF, Daher M, Kebriaei P, Popat UR, Manasanch EE, Lee HC, Thomas SK, Orlowski RZ, Champlin RE, Shpall EJ, Rezvani K. Phase II study of umbilical cord blood–derived natural killer (CB-NK) cells with elotuzumab, lenalidomide, and high-dose melphalan followed by autologous stem cell transplantation (ASCT) for patients with high-risk multiple myeloma (HRMM). ASCO Annual Abstract(Supplement 16), 2022. e-Pub 2022.
66. Pasvolsky O, Milton DR, Rauf M, Tanner MR, Bashir Q, Srour SA, Saini N, Ramdial JL, Nieto Y, Lee HC, Patel KK, Kebriaei P, Thomas SK, Weber DM, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH. Lenalidomide: Based maintenance after autologous hematopoietic stem cell transplant for patients with high-risk multiple myeloma. ASCO Annual Abstract(Supplement 16), 2022. e-Pub 2022.
67. Mamlouk O, Strati P, Feng L, Sun R, Steiner RE, Nair R, Flowers C, Ramdial JL, Saini N, Srour SA, Champlin RE, Kebriaei P, Nastoupil LJ, Rodriguez MA, Shpall EJ, Nieto Y, Westin J, Neelapu SS, Mandayam S, Ahmed S. Real-world analysis of safety and efficacy of CAR T-cell therapy in patients with lymphoma with decreased renal function. ASCO Annual Abstract(Supplement 16), 2022. e-Pub 2022.
68. Nieto Y, Banerjee P, Kaur I, Bassett R, Kerbauy L, Basar R, Kaplan M, Griffin L, Esqueda D, Ganesh C, Barnett M, Alousi A, Hosing C, Ramdial J, Saini N, Srour S, Alexis K, Harstrick A, Shpall EJ, Rezvani K. Innate cell engager (ICE®) AFM13 combined with preactivated and expanded cord blood (CB)-derived NK cells for patients with refractory/relapsed CD30+ lymphoma. AACR Annual Abstract, 2022. e-Pub 2022.
69. Gaballa M, Ma J, Tanner MR, Rauf M, Bashir Q, Srour SA, Saini NY, Ramdial J, Nieto Y, Murphy R, Rezvani K, Tang G, Lin P, Lee HC, Patel KK, Ullah MR, Kaufman G, Manasanch E, Kebriaei P, Thomas S, Weber D, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH. KRD vs. VRD as Induction before Autologous Hematopoietic Progenitor Cell Transplantation for High-Risk Newly Diagnosed Multiple Myeloma. ASTCT Annual Abstract 28(3), 2022. e-Pub 2022.
70. Kawedia JD, Liu X, Ramdial J, Srour SA, Mehta RS, Popat UR, Nieto Y, Saini NY, Kebriaei P, Knape C, Gulbis AM, Champlin RE, Shpall EJ, Qazilbash MH, Bashir Q. Captisol-Enabled Melphalan (Evomela) Pharmacokinetics between Short and Long Infusion Arms in Newly Diagnosed Multiple Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplantation. ASTCT Annual Abstract 28(3), 2022. e-Pub 2022.
71. Khawaja F, Sassine J, Handley G, Iyer SP, Ramdial J, Ahmed S, Nieto Y, Spallone A, Ariza-Heredia EJ, Chemaly RF. Herpesviruses Infections in CAR T Cell Recipients. ASTCT Annual Abstract 28(3), 2022. e-Pub 2022.
72. Zurko JC, Ramdial J, Ahmed S, Szabo A, Iovino L, Shadman M, Acharya UH, Jacobson CA, Soiffer RJ, Wang TP, Komanduri KV, Iqbal M, Kharfan-Dabaja MA, Ayala E, Samara Y, Pia AD, Feldman T, Ahmed N, Jacobs R, Ghosh N, Dholaria B, Oluwole OO, Hess B, Nieto Y, Hamadani M, Herrera AF. Allogeneic Hematopoietic Cell Transplantation for Relapsed/Refractory Large B-Cell Lymphoma after CAR T-Cell Therapy Failure. ASTCT Annual Abstract 28(3), 2022. e-Pub 2022.
73. Popat UR, Mehta RS, Bassett R, Alousi AM, Al-Atrash G, Bashir Q, Hosing C, Im JS, Kebriaei P, Kawedia JD, Khouri IF, Marin D, Nieto Y, Olson A, Oran B, Ramdial J, Saini NY, Srour SA, Valdez BC, Rezvani K, Qazilbash MH, Kadia TM, Kantarjian H, Shpall EJ, Champlin RE, Andersson BS. Post-Transplant Cyclophosphamide Versus Tacrolimus and Methotrexate to Prevent Graft-Versus-Host Disease in Recipients of Matched Donor Transplantation: Comparison of Sequential Cohorts in a Prospective Trial. ASTCT Annual Abstract 28(3), 2022. e-Pub 2022.
74. Popat UR, Mehta RS, Bassett R, Alousi AM, Al-Atrash G, Bashir Q, Hosing C, Im JS, Kebriaei P, Gulbis AM, Marin D, Nieto Y, Olson A, Oran B, Ramdial J, Saini NY, Srour SA, Valdez BC, Rezvani K, Qazilbash MH, Kadia TM, Konopleva M, Shpall EJ, Andersson BS, Champlin RE. Myeloablative Fractionated Busulfan Conditioning Regimen with Venetoclax in Patients with AML/MDS: Prospective Phase II Clinical Trial. ASTCT Annual Abstract 28(3), 2022. e-Pub 2022.
75. Popat UR, Mehta RS, Thall P, Bassett R, Alousi AM, Al-Atrash G, Bashir Q, Hosing C, Im JS, Kebriaei P, Marin D, Nieto Y, Olson A, Oran B, Ramdial J, Saini NY, Srour SA, Valdez BC, Rezvani K, Qazilbash MH, Daver N, Ravandi F, Shpall EJ, Champlin RE, Andersson BS. Myeloablative Fractionated Busulfan Conditioning Regimen with Sorafenib in Patients with AML: Results of Phase I Clinical Trial. ASTCT Annual Abstract 28(3), 2022. e-Pub 2022.
76. Popat UR, Mehta RS, Bassett R, Alousi AM, Al-Atrash G, Bashir Q, Hosing C, Im JS, Kebriaei P, Kawedia JD, Khouri IF, Marin D, Nieto Y, Olson A, Oran B, Ramdial J, Saini NY, Srour SA, Rezvani K, Qazilbash MH, Shpall EJ, Andersson BS, Champlin RE. Optimizing Myeloablative Fractionated Busulfan, Fludarabine and Thiotepa Regimen: Results of Two Parallel Cohorts in a Phase 2 Prospective Clinical Trial. ASTCT Annual Abstract 28(3), 2022. e-Pub 2022.
77. Malpica-Castillo L, Feng L, Xu J, Nair R, Elias A, Jain P, Chihara D, Steiner R, Fayad L, Samaniego F, Ahmed S, Fowler NH, Nastoupil L, Srour SA, Nieto Y, Hosing C, Miranda RN, Vega F, Pinnix CC, Gunther JR, Fang P, Wu S, Dabaja BS, Medeiros J, Wang M, Neelapu SS, Flowers CR, Iyer SP. Long Term Outcome Patterns and Risk Factors for Early Mortality and Disease Progression in ALK-Positive Anaplastic Large Cell Lymphoma. Blood/ASH Annual Abstract 138(Supplement 1):2463, 2021. e-Pub 2021.
78. Nair R, Feng L, Gunther JR, Xu J, Malpica-Castillo L, Huen A, Torres Cabala C, Heberton M, Fang P, Ahmed S, Miranda RN, Fayad L, Steiner R, Lee HJ, Chihara D, Jain P, Srour SA, Nieto Y, Nastoupil L, Pinnix CC, Neelapu SS, Flowers CR, Medeiros LJ, Hosing C, Wang M, Dabaja BS, Vega F, Iyer SP. Outcomes of Patients with Extranodal Natural Killer/T-Cell Lymphoma: Single Institution Series. Blood/ASH Annual Abstract 138(Supplement 1):4536, 2021. e-Pub 2021.
79. Taranto E, Redd RA, Jeter E, McHugh KM, Brown JR, Crombie JL, Davids MS, Fisher DC, Freedman AS, Jacobsen ED, Jacobson C, Kim AI, LaCasce AS, Lampson BL, Ng SY, Odejide OO, Parry EM, Dahi PB, Nieto Y, Joyce RM, Chen Y, Herrera AF, Armand P, Merryman RW. Prognostic Value of Minimal Residual Disease (MRD) Among Patients with Classical Hodgkin Lymphoma Undergoing Autologous Stem Cell Transplantation. Blood/ASH Annual Abstract 138(Supplement 1):3491, 2021. e-Pub 2021.
80. Popat UR, Mehta RS, Bassett R, Alousi AM, Alatrash G, Bashir Q, Hosing C, Im JS, Kebriaei P, Gulbis A, Marin D, Nieto Y, Olson AL, Oran B, Ramdial JL, Saini N, Srour SA, Valdez BC, Rezvani K, Qazilbash MH, Kadia TM, Konopleva M, Shpall EJ, Andersson BS, Champlin RE. Myeloablative Fractionated Busulfan Conditioning Regimen with Venetoclax in Patients with AML/MDS: Prospective Phase II Clinical Trial. Blood/ASH Annual Abstract 138(Supplement 1):2879, 2021. e-Pub 2021.
81. Bashir Q, Thall PF, Sui D, Ramdial JL, Srour SA, Mehta RS, Popat UR, Nieto Y, Saini N, Kebriaei P, Manasanch EE, Lee HC, Kaufman GP, Thomas SK, Patel KK, Orlowski RZ, Knape CG, Kawedia JD, Champlin RE, Shpall EJ, Liu X, Qazilbash MH. A Prospective Phase I/II Trial to Jointly Optimize the Administration Schedule and Dose of Melphalan for Injection (Evomela) As a Preparative Regimen for Autologous Hematopoietic Stem Cell Transplantation in Newly Diagnosed Multiple Myeloma. Blood/ASH Annual Abstract 138(Supplement 1):3941, 2021. e-Pub 2021.
82. Popat UR, Mehta RS, Bassett R, Alousi AM, Alatrash G, Bashir Q, Hosing C, Im JS, Kebriaei P, Kawedia JD, Khouri IF, Marin D, Nieto Y, Olson AL, Oran B, Ramdial JL, Saini N, Srour SA, Valdez BC, Rezvani K, Qazilbash MH, Kadia TM, Kantarjian H, Shpall EJ, Champlin RE, Andersson BS. Post-Transplant Cyclophosphamide Versus Tacrolimus and Methotrexate to Prevent Graft-Versus-Host Disease in Recipients of Matched Donor Transplantation: Comparison of Sequential Cohorts in a Prospective Trial. Blood/ASH Annual Abstract 138(Supplement 1):1803, 2021. e-Pub 2021.
83. Kamel S, Chen L, Ravizzini G, Chen H, Schmidt J, Ahmed S, Nair R, Steiner RE, Cuglievan B, Nieto Y, Miranda RN, Fang P, Gunther JR, Pinnix CC, Wang M, Pan T, Lee HJ. Radiomic Phenotypes of High and Low Lesion SUV Components for the Prediction of Refractory Disease in Hodgkin's Lymphoma Patients Treated with ABVD Based Therapy. Blood/ASH Annual Abstract 138(Supplement 1):3996, 2021. e-Pub 2021.
84. Gouni S, Westin JR, Mistry H, Steiner RE, James J, Parmar S, Noorani M, Fowler NH, Horowitz SB, Feng L, Fayad LE, Iyer SP, Green MR, Hawkins M, Flowers CR, Ahmed S, Nastoupil L, Neelapu SS, Nieto Y, Strati P. Axicabtagene Ciloleucel in Relapsed or Refractory Large B-Cell Lymphoma Patients in Complete Metabolic Response at Time of Infusion. Blood/ASH Annual Abstract 138(Supplement 1):1740, 2021. e-Pub 2021.
85. Popat UR, Bassett R, Thall PF, Alousi AM, Alatrash G, Bashir B, Hosing C, Im JS, Kebriaei P, Marin D, Nieto Y, Olson AL, Oran B, Ramdial JL, Saini N, Srour SA, Valdez BC, Rezvani K, Qazilbash MH, Daver N, Ravandi F, Shpall EJ, Champlin RE, Andersson BS, Mehta RS. Myeloablative Fractionated Busulfan Conditioning Regimen with Sorafenib in Patients with AML: Results of Phase I Clinical Trial. Blood/ASH Annual Abstract 138(Supplement 1):556, 2021. e-Pub 2021.
86. Nair R, Deen N, Ahmed S, Miranda RN, Fowler NH, Fayad L, Steiner RE, Hagemeister FB, Rodriguez MA, Lee HJ, Strati P, Malpica-Castillo L, Chihara D, Jain P, Gunther JR, Flowers CR, Medeiros LJ, Nieto Y, Ramdial JL, Neelapu SS, Nastoupil L, Green MR, Wang M, Vega F, Feng L, Iyer SP, Westin JR. Outcome of Patients with T- Cell Histiocyte Rich B Cell Lymphoma: Single Institution Series. Blood/ASH Annual Abstract 138(Supplement 1):1448, 2021. e-Pub 2021.
87. Popat UR, Mehta RS, Bassett R, Alousi AM, Alatrash G, Bashir Q, Hosing C, Im JS, Kebriaei P, Kawedia JD, Khouri IF, Marin D, Nieto Y, Olson AL, Oran B, Ramdial JL, Saini N, Srour SA, Rezvani K, Qazilbash MH, Shpall EJ, Andersson BS, Champlin RE. Optimizing Myeloablative Fractionated Busulfan, Fludarabine and Thiotepa Regimen: Results of Two Parallel Cohorts in a Phase 2 Prospective Clinical Trial. Blood/ASH Annual Abstract 138(Supplement 1):1802, 2021. e-Pub 2021.
88. Al-Juhaishi T, Malek AE, Milton DR, Ramdial JL, Daher M, Olson AL, Srour SA, Alatrash G, Oran B, Mehta RS, Khouri IF, Bashir Q, Shah N, Ciurea SO, Rondon G, Maadani F, Hosing C, Marin D, Kebriaei P, Rezvani K, Nieto Y, Anderlini P, Alousi AM, Qazilbash MH, Popat UR, Champlin RE, Shpall EJ, Mulanovich V, Ahmed S. Incidence and Outcomes of Toxoplasma Reactivation in Patients with Hematologic Diseases after Allogeneic Hematopoietic Stem Cell Transplantation. Blood/ASH Annual Abstract 138(Supplement 1):1779, 2021. e-Pub 2021.
89. Gaballa M, Ma J, Bashir Q, Srour SA, Saini NY, Ramdial J, Nieto Y, Murphy R, Lee HC, Patel KK, Kebriaei P, Thomas S, Weber D, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH. Long-Term Outcomes of Multiple Myeloma Patients Treated with VRD Induction, Autologous Hematopoietic Cell Transplantation with Melphalan 200 Mg/m2 Conditioning, and Lenalidomide Maintenance. TCT Abstract 2021, 2021. e-Pub 2021.
90. Ahmed S, Strati P, Fayad LE, Hagemeister FB, Lee HJ, Iyer SP, Nair R, Parmar S, Rodriguez MA, Samaniego F, Steiner RE, Wang M, Pinnix CC, Flowers CR, Horowitz SB, Claussen CM, Johnson NA, Mistry H, Adkins S, Shpall EJ, Kebriaei P, Nieto Y, Hawkins M, Neelapu S, Nastoupil LJ, Westin J. Efficacy of Chimeric Antigen Receptor (CAR) T-Cell Therapy, Axicabtagene Ciloleucel (axi-cel), in Patients with Refractory Large B-Cell Lymphoma (LBCL). TCT Abstract 2021, 2021. e-Pub 2021.
91. Nieto Y, Banerjee P, Kaur I, Thall P, Hosing C, Srour SA, Griffin L, Barnett M, Champlin RE, Shpall EJ, Rezvani K. Immunotherapy with Ex Vivo-Expanded Cord Blood (CB)-Derived NK Cells Combined with High-Dose Chemotherapy (HDC) and Autologous Stem Cell Transplant (ASCT) for B-Cell Non-Hodgkin’s Lymphoma (NHL). TCT Abstract 2021, 2021. e-Pub 2021.
92. Srour SA, Bashir Q, Milton DR, Nieto Y, Mehta RS, Saini N, Delgado R, Rondon G, Ciurea SO, Popat UR, Khouri IF, Kebriaei P, Manasanch EE, Hosing C, Patel KK, Lee HC, Shpall EJ, Orlowski RZ, Champlin RE, Qazilbash MH. Long-Term Survival for Myeloma after Autologous Stem Cell Transplantation. ASH Abstract 2020, 2020. e-Pub 2020.
93. Srour SA, Nieto Y, Iyer SP, Miranda RN, Maadani F, Rondon G, Saini N, Strati P, Daher M, Nair R, Dabaja BS, Popat UR, Qazilbash MH, Shpall EJ, Flowers C, Champlin RE, Hosing C, Khouri IF. Autologous Stem Cell Transplantation for Angioimmunoblastic T-Cell Lymphoma. ASH Abstract 2020, 2020. e-Pub 2020.
94. Ramdial JL, Ma J, Milton DR, Delgado R, Bashir Q, Srour SA, Saini N, Nieto Y, Hosing C, Popat UR, Murphy R, Lee HC, Patel KK, Manasanch EE, Thomas SK, Kaufman GP, Weber DM, Orlowski RZ, Champlin RE, Qazilbash MH. PBSC Mobilization for Auto-HSCT in Myeloma: Growth Factors Vs Growth Factors + Chemotherapy. ASH Abstract 2020, 2020. e-Pub 2020.
95. Srour SA, Bashir Q, Milton DR, Nieto Y, Mehta RS, Saini N, Delgado R, Rondon G, Hosing C, Ciurea SO, Daher M, Popat UR, Khouri IF, Kebriaei P, Manasanch EE, Kaufman GP, Patel KK, Shpall EJ, Lee HC, Orlowski RZ, Champlin RE, Qazilbash MH. Survival Trends in Multiple Myeloma after Autologous Hematopoietic Stem Cell Transplantation. ASH Abstract 2020, 2020. e-Pub 2020.
96. Greenbaum U, Strati P, Saliba RM, Torres J, Rondon G, Nieto Y, Hosing C, Srour SA, Westin J, Fayad L, Lee HJ, Iyer SP, Nastoupil LJ, Parmar S, Rodriguez MA, Samaniego F, Steiner RE, Wang M, Pinnix CC, Flowers C, Tummala S, Ramdial J, Yalniz FF, Hawkins M, Rezvani K, Champlin RE, Shpall EJ, Neelapu SS, Kebriaei P, Ahmed S. The Easix (Endothelial Activation and Stress Index) Score Predicts for CAR T Related Toxicity in Patients Receiving Axicabtagene Ciloleucel (axi-cel) for Non-Hodgkin Lymphoma (NHL). ASH Abstract 2020, 2020. e-Pub 2020.
97. Manasanch EE, Han G, Zhang Z, Dang M, Singh M, Khan M, Singh S, Lee HC, Patel KK, Kaufman GP, Amini B, Bashir Q, Srour SA, Nieto Y, Qazilbash MH, Berkova Z, Lin P, Berry D, Thomas SK, Weber DM, Futreal PA, Wang L, Orlowski RZ, Neelapu SS. Extensive Changes of the Immune Microenvironment Are Associated with Progression from Precursor Stages to Multiple Myeloma. ASH Abstract 2020, 2020. e-Pub 2020.
98. Al Hadidi S, Nair R, Steiner RE, Ahmed S, Strati P, Parmar S, Iyer SP, Gunther JR, Pinnix CC, Dabaja BS, Nieto Y, Samaniego F, Cuglievan B, Jain P, Fang P, Miranda RN, Medeiros J, Feng L, Chuang H, Wang M, Lee HJ. Association of Epstein–Barr Virus with Advanced Stage and Survival Outcomes in Classic Hodgkin’s Lymphoma. ASH Abstract 2020, 2020. e-Pub 2020.
99. Mehta RS, Saliba RM, Jan A, Shigle TL, Wang E, Rondon G, Nieto Y, Ciurea S, Oran B, Im JS, Olson AL, Marin D, Qazilbash MH, Khouri IF, Anderlini P, Rezvani K, Popat UR, Kebriaei P, Shpall EJ, Champlin RE, Alousi AM. Vedolizumab for Steroid Refractory Lower Gastrointestinal Tract Graft Versus Host Disease. ASH Abstract 2020, 2020. e-Pub 2020.
100. Iyer SP, Xu J, Becnel MR, Nair R, Steiner R, Feng L, Lee HJ, Strati P, Ahmed S, Parmar S, Nieto Y, Hosing C, Westin J, Nastoupil LJ, Vo A, Samaniego F, Fowler NH, Saini N, Khouri IF, Im JS, Jain P, Fayad L, Wang M, Miranda RN, Vega F, Flowers C, Neelapu SS. A Phase II Study of Pembrolizumab in Combination with Romidepsin Demonstrates Durable Responses in Relapsed or Refractory T-Cell Lymphoma (TCL). ASH Abstract 2020, 2020. e-Pub 2020.
101. Saini N, Ma J, Bashir Q, Delgado R, Rondon G, Popat UR, Hosing C, Nieto Y, Kebriaei P, Alousi AM, Mehta RS, Srour SA, Khouri IF, Weber DM, Thomas SK, Lee HC, Patel KK, Orlowski RZ, Champlin RE, Qazilbash MH. African-Americans Multiple-Myeloma Patients Undergoing Upfront Autologous Stem Cell Transplant Have Similar Survival Outcomes Compared to Whites: A Propensity-Score Matched Analysis. ASH Abstract 2020, 2020. e-Pub 2020.
102. Herrera AF, Chen L, Nieto Y, Holmberg L, Johnston PB, Mei M, Popplewell L, Armenian SH, Cao T, Farol L, Sahebi F, Spielberger R, Chen R, Nademanee AP, Peters L, Kennedy N, Rosen ST, Kwak LW, Forman SJ, Feldman TA. Consolidation with Nivolumab and Brentuximab Vedotin after Autologous Hematopoietic Cell Transplantation in Patients with High-Risk Hodgkin Lymphoma. ASH Abstract 2020, 2020. e-Pub 2020.
103. Andersson BS, Thall P, Valdez BC, Ma J, Chen J, Ahmed S, Alousi AM, Bashir Q, Ciurea SO, Gulbis A, Hosing C, Jones RB, Kawedia J, Kebriaei P, Kornblau SM, Myers A, Oran B, Rezvani K, Shah N, Shpall EJ, Parmar S, Popat UR, Nieto Y, Champlin RE. A Randomized Study of Pretransplant Conditioning Therapy for AML/MDS with Fludarabine ± Clofarabine and Once Daily IV Busulfan with Allogeneic Hematopoietic Transplantation for AML and MDS. ASH Abstract 2020, 2020. e-Pub 2020.
104. Saini N, Ma J, Timmons M, Alousi AM, Anderlini P, Andersson BS, Hosing C, Ramdial J, Kebriaei P, Popat UR, Qazilbash MH, Shpall EJ, Srour SA, Valdez BC, Dabaja BS, Pinnix CC, Gunther JR, Maadani F, Rondon G, Champlin RE, Nieto Y. High-Dose Chemotherapy (HDC) with Autologous Stem-Cell Transplant (ASCT) with Consolidative Radiation Therapy (RT) for Relapsed or Refractory (R/R) Primary Mediastinal B-Cell Lymphoma (PMBCL): 20-Year Experience at MD Anderson Cancer Center (MDACC). ASH Abstract 2020, 2020. e-Pub 2020.
105. Gaballa MR, Al-Juhaishi T, Bashir Q, Srour SA, Saini N, Ramdial J, Nieto Y, Murphy R, Lee HC, Patel KK, Kebriaei P, Thomas SK, Weber DM, Orlowski RZ, Champlin RE, Qazilbash MH. Outcomes of Patients with Multiple Myeloma Who Received VRD Induction, Autologous Hematopoietic Cell Transplantation and Lenalidomide Maintenance. ASH Abstract 2020, 2020. e-Pub 2020.
106. Nieto Y, Gruschkus SK, Jones RB, Valdez BC, Timmons M, Hosing C, Anderlini P, Kebriaei P, Popat UR, Qazilbash MH, Alousi AM, Srour SA, Saini N, Ramdial J, Im JS, Shpall EJ, Rezvani K, Gulbis A, Shigle TL, Mahadeo KM, Khazal S, Khouri IF, Dabaja BS, Pinnix CC, Gunther JR, Lee H, Ahmed S, Steiner RE, Iyer SP, Nair R, Parmar S, Cuglievan B, Maadani F, Rondon G, Champlin RE, Borje S Andersson BS. Factors Associated with the Improvement of Outcomes of High-Risk Relapsed Hodgkin Lymphoma (HL) Patients Receiving High-Dose Chemotherapy (HDC) and Autologous Stem-Cell Transplantation (ASCT): The MD Anderson Cancer Center Experience. ASH Abstract 2020, 2020. e-Pub 2020.
107. Merryman RW, Redd RA, Taranto E, Ahmed G, Jeter E, McHugh KM, Brown JR, Crombie J, Davids MS, Fisher DC, Freedman AS, Jacobsen E, Jacobson C, Kim AI, LaCasce AS, Lampson BL, Ng S, Odejide OO, Dahi PB, Nieto Y, Joyce RM, Chen Y, Herrera AF, Armand P. Prognostic Value of Circulating Tumor DNA (ctDNA) in Autologous Stem Cell Graft and Post-Transplant Plasma Samples Among Patients with Diffuse Large B-Cell Lymphoma. ASH Abstract 2020, 2020. e-Pub 2020.
108. Srour SA, Xu J, Al-Juhaishi T, Steiner RE, Ensor J, Ahmed S, Parmar S, Strati P, Nastoupil LJ, Nieto Y, Hosing C, Lee HJ, Westin J, Fowler NH, Fayad L, Dabaja BS, Pinnix CC, Gunther JR, Fang P, Samaniego F, Jain P, Champlin RE, Khouri IF, Wang M, Miranda RN, Vega F, Neelapu SS, Flowers C, Iyer SP. Retrospective Review of Prognostic and Predictors Markers in Newly Diagnosed Angioimmunoblastic T Cell Lymphoma at UT MD Anderson Cancer Center. ASH Abstract 2020, 2020. e-Pub 2020.
109. Rafei H, Imahashi N, Basar R, Banerjee PP, Daher M, Ganesh C, Hosing C, Kaur I, Kebriaei P, Khouri IF, Mehta R, Nieto Y, Olson AL, Qazilbash MH, Spencer BP, Srour S, Shpall EJ, Champlin RE, Marin D, Rezvani K. Off-the-shelf virus specific T-cells for therapy of adenovirus disease in immunosuppressed patients. ASCO 2019, 2019. e-Pub 2019.
110. Popat UR, Mehta RS, Bassett R, Olson AL, Alousi AM, Anderlini P, Alatrash G, Bashir Q, Ciurea SO, Hosing C, Kebriaei P, Khouri IF, Marin D, Nieto Y, Oran B, Rezvani K, Qazilbash MH, Shpall EJ, Champlin RE, Andersson B. Post-transplant cyclophosphamide in matched and haploidentical transplant recipients receiving myeloablative timed sequential busulfan conditioning regimen: Results of a phase II study. ASCO 2019, 2019. e-Pub 2019.
111. Rafei H, Fernández-Viña M, Carmazzi Y, Moore B, Willis D, Basar R, Banerjee PP, Daher M, Hosing C, Kebriaei P, Khouri IF, Mehta R, Nieto Y, Qazilbash MH, Shpall EJ, Champlin RE, Marin D, Rezvani K, Cao K. Role of killer cell immunoglobulin-like receptor (KIR)-ligand interactions to prevent relapse in patients (pts) receiving matched unrelated stem cell transplant (SCT) for acute myeloid leukemia (AML). ASCO 2019, 2019. e-Pub 2019.
112. Chen Y, Armand P, Redd RA, Bsat J, Merryman RW, Coleman K, Herrera AF, Dahi PB, Nieto Y, LaCasce AS, Fisher DC, Ng SY, Odejide OO, Freedman AS, Kim AI, Crombie JL, Jacobson CA, Jacobsen ED, Wong JL, Patel SS, Ritz J, Rodig SJ, Shipp MA, Joyce RM. Blockade for Diffuse Large B-Cell Lymphoma after Autologous Stem Cell Transplantation. ASH 2018, 2018. e-Pub 2018.
113. Popat U, Mehta RS, Bassett Jr RL, Olson AL, Chen J, Ahmed S, Alousi AM, Anderlini P, Alatrash G, Bashir Q, Ciurea SO, Hosing C, Im JS, Kebriaei P, Khouri IF, Marin D, Nieto Y, Oran B, Rezvani K, Qazilbash MJ, Shpall EJ, Champlin RE, Andersson BS. Timed Sequential Busulfan and Post-Transplantation Cyclophosphamide in Matched and Haploidentical Transplantation: Results of a Phase II Study. ASH 2018, 2018. e-Pub 2018.
114. Saini NY, Patel R, Varma A, Bashir Q, Delgado R, Popat U, Hosing C, Nieto Y, Kebriaei P, Alousi AM, Ahmed S, Mukherjee A, Mehta RS, Khouri IF, Ciurea SO, Shpall EJ, Hasan O, Weber DM, Thomas SK, Lee HC, Manasanch EE, Patel KK, Orlowski RZ, Champlin RE, Qazilbash MH. Melphalan-Based Autologous Transplantation in the Octogenarian Multiple Myeloma Patient Population. ASH 2018, 2018. e-Pub 2018.
115. Saini NY, Patel R, Varma A, Bashir Q, Hasan O, Delgado R, Rondon G, Mukherjee A, Popat U, Hosing C, Nieto Y, Kebriaei P, Weber DM, Thomas SK, Lee HC, Manasanch EE, Orlowski RZ, Champlin RE, Qazilbash MH, Patel KK. Long-Term Durable Responses after Autologous Stem Cell Transplantation in POEMS Syndrome. ASH 2018, 2018. e-Pub 2018.
116. Saini NY, Saliba RM, Rondon G, Maadani F, Popat U, Oran B, Hosing C, Bashir Q, Olson AL, Nieto Y, Alousi AM, Kebriaei P, Srour SA, Mehta RS, Anderlini P, Shpall EJ, Qazilbash MH, Khouri IF, Fayad LE, Lee HJ, Fowler NH, Parmar S, Westin JR, Hagemeister FB, Champlin RE, Ciurea SO. Allogeneic Transplantation for Lymphoid Malignancies with Fludarabine and Melphalan Conditioning and Different Donor Types. ASH 2018, 2018. e-Pub 2018.
117. Lin P, Veltri LW, Rezvani K, Oran B, Ahmed S, Alatrash G, Mehta RS, Rondon G, Kebriaei P, Popat U, Nieto Y, Hosing C, Jones RB, Qazilbash MH, Khouri IF, Shpall EJ, Champlin RE, Marin D. Allotransplants for Patients 65 Years or Older with High-Risk Acute Myeloid Leukemia. ASH 2018, 2018. e-Pub 2018.
118. Oran B, Ciurea SO, Marin D, McCarty JM, Bashir Q, Ahmed S, Olson AL, Popat U, Nieto Y, Kebriaei P, Shpall EJ, Agrawal T, Champlin RE. Safety Analysis of Intra-Patient Dose- Study of Crenolanib Maintenance Therapy in Patients with FLT3 Mutant AML Following Allogeneic Hematopoietic Stem Cell Transplant. ASH 2018, 2018. e-Pub 2018.
119. Varma A, Saini NY, Sui D, Milton DR, Hasan O, Mukherjee A, Bashir Q, Rondon G, Srour SA, Popat U, Hosing C, Nieto Y, Kebriaei P, Alousi AM, Mehta RS, Khouri IF, Weber DM, Thomas SK, Manasanch EE, Lee HC, Patel KK, Ciurea SO, Shpall EJ, Orlowski RZ, Champlin RE, Qazilbash MH. Outcome of Multiple Myeloma with Chromosome 1q Gain and 1p Deletion after High-Dose Therapy and Autologous Hematopoietic Stem Cell Transplantation. ASH 2018, 2018. e-Pub 2018.
120. Patel R, Saini NY, Varma A, Hasan O, Bashir Q, Delgado R, Popat U, Hosing C, Mukherjee A, Nieto Y, Kebriaei P, Weber DM, Thomas SK, Lee HC, Manasanch EE, Orlowski RZ, Champlin RE, Qazilbash MH, Patel KK. Outcome of Autologous Stem Cell Transplantation in Waldenström's Macroglobulinemia. ASH 2018, 2018. e-Pub 2018.
121. Saini NY, Varma A, Ma J, Milton DR, Patel R, Hasan O, Bashir Q, Nieto Y, Mukherjee A, Delgado R, Rondon G, Popat U, Hosing C, Kebriaei P, Alousi AM, Ahmed S, Mehta RS, Ciurea SO, Khouri IF, Shpall EJ, Weber DM, Thomas SK, Lee HC, Manasanch EE, Patel KK, Orlowski RZ, Champlin RE, Qazilbash MH. Impact of t(11;14) on the Outcome of Autologous Transplantation in Multiple Myeloma: A Matched-Pair Analysis. ASH 2018, 2018. e-Pub 2018.
122. Armand P, Chen Y, Redd RA, Joyce RM, Bsat J, Merryman RW, Coleman K, Dahi PB, Nieto Y, LaCasce AS, Fisher DC, Ng SY, Odejide OO, Freedman AS, Kim AI, Crombie JL, Jacobson CA, Jacobsen ED, Wong JL, Lipschitz M, Patel SS, Ritz J, Rodig SJ, Shipp MA, Herrera AF. PD-1 Blockade with Pembrolizumab for Classical Hodgkin Lymphoma after Autologous Stem Cell Transplantation. ASH 2018, 2018. e-Pub 2018.
123. Dos Santos DMC, Saliba RM, Patel R, Bashir Q, Hosing C, Kebriaei P, Khouri IF, Nieto Y, Popat U, Lee HC, Manasanch EE, Patel KK, Thomas SK, Weber DM, Orlowski RZ, Champlin RE, Qazilbash MH. Older Age As a Prognostic Factor for Overall Survival for Multiple Myeloma Patients Undergoing Upfront Autologous Hematopoietic Stem Cell Transplantation. ASH 2018, 2018. e-Pub 2018.
124. Gowda L, Shah MV, Badar I, Bashir Q, Shah N, Patel K, Kanagal-Shamanna R, Mehta RS, Weber D, Lee HC, Manasanch E, Shah AR, Thomas S, Parmar S, Nieto Y, Orlowski RZ, Champlin RE, Qazilbash MH. Primary Plasma Cell Leukemia: Stem Cell Transplant in an Era of Novel Induction Drugs. ASBMT 2018 24(3):S260-S261, 2018. e-Pub 2018.
125. Qazilbash MH, Milton D, Bashir Q, Shah N, Nieto Y, Popat UR, Mehta RS, Kebriaei P, Delgado R, Rondon G, Weber D, Thomas S, Lee HC, Manasanch E, Patel K, Orlowski RZ, Champlin RE. Continuing Improvement in the Outcome of Patients with Multiple Myeloma Undergoing Auto-HCT Over Three Decades. ASBMT 2018 24(3):S50-S51, 2018. e-Pub 2018.
126. Bashir Q, Milton D, Popat UR, Oran B, Nieto Y, Kebriaei P, Ciurea SO, Ahmed S, Mehta RS, Olson A, Parmar S, Alatrash G, Hosing CM, Shah N, Patel K, Weber D, Thomas S, Manasanch E, Lee HC, Orlowski RC, Champlin RE, Qazilbash MH. Impact of Maintenance Therapy in High-Risk Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplantation. ASBMT 2018 24(3):S254, 2018. e-Pub 2018.
127. Kebriaei P, Huls H, Olivares S, Orozco AF, Su S, Maiti SN, De Groot E, Smith A, Yang Y, Rondon G, Qazilbash MH, Ciurea SO, Alousi AM, Nieto Y, Marin DC, Popat U, Hosing C, Kantarjian HM, Rezvani K, Shpall EJ, Champlin RE, Cooper LJN, Singh H. Long Term Follow up after Adoptive Transfer of CD19-Specific CAR+ T Cells Genetically Modified Via Non-Viral Sleeping Beauty System Following Hematopoietic Stem Cell Transplantation (HSCT). ASH 2017, 2017. e-Pub 2017.
128. Gowda L, Saliba RM, Shah MV, Rondon G, Badar I, Olson AL, Ciurea SO, Kebriaei P, Srour SA, Parmar S, Nieto Y, Ahmed S, Mehta RS, Alatrash G, Marin DC, Andersson BS, Oran B, Bashir Q, Qazilbash MH, Hosing C, Khouri IF, Alousi AM, Anderlini P, Shpall EJ, Rezvani K, Champlin RE, Popat U. Graft Failure Post Allogeneic Stem Cell Transplant: Conditioning Regimen Improves Engraftment and Survival. ASH 2017, 2017. e-Pub 2017.
129. Qazilbash MH, Bashir Q, Thall PF, Milton DR, Shah N, Patel KK, Andersson BS, Nieto Y, Kebriaei P, Valdez BC, Kawedia J, Parmar S, Delgado R, Ahmed S, Hosing C, Popat U, Shpall EJ, Weber DM, Thomas SK, Manasanch EE, Lee HC, Orlowski RZ, Champlin RE. A Randomized Phase III Trial of Busulfan + Melphalan Vs Melphalan Alone for Multiple Myeloma. ASH 2017, 2017. e-Pub 2017.
130. Nieto Y, Thall PF, Valdez BC, Ma J, Timmons M, Trapp M, Ahmed S, Shpall EJ, Jones RB, Hosing C, Anderlini P, Popat U, Qazilbash MH, Alousi A, Gulbis AM, Ledesma C, Champlin RE, Andersson BS. Gemcitabine/Clofarabine/Busulfan: A New Myeloablative Reduced-Toxicity Conditioning Regimen with High Activity for Allogeneic Stem-Cell Transplant (alloSCT) in Aggressive Lymphomas. ASH 2017, 2017. e-Pub 2017.
131. Scott E, Hari P, Kumar S, Fraser R, Davila O, Nieto Y, Mark TM, Kumar SK, Gasparetto CJ, D'Souza A. A Comparison between 3 Staging Systems in Multiple Myeloma Using the Center for International Blood and Marrow Transplant Research (CIBMTR) Database. ASH 2017, 2017. e-Pub 2017.
132. Kumar S, D'Souza A, Scott EC, Fraser R, Davila O, Gasparetto CJ, Kumar SK, Mark TM, Nieto Y, Hari P. Revised-International Staging System (R-ISS) Is Independently Predictive and Prognostic for Early Relapse (<24 months) after Upfront Autologous Hematopoietic Cell Transplantation (AHCT) for Newly Diagnosed Multiple Myeloma (MM. ASH 2017, 2017. e-Pub 2017.
133. Kellner J, Ciurea SO, Olson AL, Nieto Y, Andersson BS, Khoury JD, Champlin RE, Nierkens S, Boelens JJ, Blazar B, Parmar S. Cord Blood Regulatory T Cells for Prevention of Graft Versus Host Disease. ASH 2017, 2017. e-Pub 2017.
134. Claussen CM, Chuang T, Chaudhry M, Lee HC, Patel KK, Bashir Q, Parmar S, Ahmed S, Mehta RS, Thomas SK, Richards TA, Nieto Y, Shpall EJ, Qazilbash MH, Amini B, Davis RE, Neelapu SS, Weber DM, Orlowski RZ, Feng L, Manasanch EE. Gene Expression Profiling Is a Strong Predictor of Clinical Outcomes in Newly Diagnosed Multiple Myeloma. ASH 2017, 2017. e-Pub 2017.
135. Srour SA, Saliba RM, Delgado R, Qazilbash MH, Bashir Q, Shah N, Popat UR, Ahmed S, Patel K, Jones R, Rondon G, Champlin RE, Nieto Y. Influence of Overlapping Genetic Abnormalities on Treatment Outcomes of Multiple Myeloma. ASH 2016, 2016. e-Pub 2016.
136. Cornelison AM, Saliba RM, Ahmed S, Nieto Y, Bashir Q, Shah N, Parmar S, Patel K, Hosing C, Popat UR, Shpall EJ, Champlin RE, Qazilbash MH. Durable Remission and Survival in Relapsed/Refractory Multiple Myeloma after Allogeneic Hematopoietic Stem Cell Transplantation. ASH 2016, 2016. e-Pub 2016.
137. Hill L, Saliba RM, Chen J, Rondon G, Qazilbash MH, Popat UR, Shah N, Neumann JL, Hymes SR, Hosing C, Kebriaei P, Nieto Y, Oran B, Olson A, Ciurea SO, Rezvani K, Marin D, Champlin RE, Shpall EJ, Alousi AM. Predictors for Steroid Tapering in Patients with Acute Graft-Versus-Host Disease and Their Impact on Graft-Versus-Host Disease Response and Non-Relapse Mortality: Older Age and Co-Morbidities Are Associated with Quicker Tapering and Worse Outcomes. ASH 2016, 2016. e-Pub 2016.
138. Srour SA, Khouri IF, Lozano-Cerrada S, Nieto Y, Alousi AM, Popat UR, Qazilbash MH, Anderlini P, Kebriaei P, Shpall EJ, Champlin RE, Hosing C. Rituximab Combined with BEAM and Autologous Stem Cell Transplantation for Older Patients with Relapsed Aggressive B-Cell Lymphomas. ASH 2016, 2016. e-Pub 2016.
139. Ragon BK, Gulbis AM, Saliba RM, Chen J, Rondon G, Popat UR, Nieto Y, Oran B, Olson AL, Patel K, Hosing CM, Qazilbash MH, Shah N, Kebriaei P, Shpall EJ, Champlin RE, Alousi AM. Pentostatin Therapy for Steroid-Refractory Acute Graft Versus Host Disease: Identifying Those Who May Benefit. ASH Abstract 2015, 2015. e-Pub 2015.
140. Cornell RF, Costa LJ, Kassim AA, Inns-Shelton R, Krishnan A, Mark T, Nieto Y, Gasparetto CJ, D'Souza A, Hari P, Zhang M, Huang J. Post-Transplant Therapy Is More Important Than Induction Regimen Choice in Autologous Hematopoietic Cell Transplantation (AHCT) Recipients for Multiple Myeloma (MM). ASH Abstract 2015, 2015. e-Pub 2015.
141. Sharma M, Hari P, Le-Rademacher J, Krishnan A, Nieto Y, Gasparetto C, Huang J, Scott EC, D'Souza A. Autologous Hematopoietic Cell Transplantation in Patients with High Risk Multiple Myeloma: Post- Transplant Responses Do Not Translate to Longer Survival. ASH Abstract 2015, 2015. e-Pub 2015.
142. Shah JJ, Feng L, Manasanch EE, Weber D, Thomas SK, Turturro F, Shah N, Popat UR, Nieto Y, Bashir Q, Munoz SC, Landry A, Mendoza K, Champlin RE, Qazilbash MH, Orlowski RZ. Phase I/II Trial of the Efficacy and Safety of Combination Therapy with Lenalidomide/Bortezomib/Dexamethasone (RVD) and Panobinostat in Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma. ASH Abstract 2015, 2015. e-Pub 2015.
143. Chihara D, Fanale MA, Noorani M, Westin JR, Nastoupil L, Hagemeister FB, Fayad LE, Romaguera JE, Samaniego F, Turturro F, Lee HJ, Neelapu SS, Rodriguez A, Wang M, Fowler N, Miranda RN, Hosing CM, Nieto Y, Davis RE, Oki Y. The Survival Outcome of the Patients with Relapsed/Refractory PTCL-NOS and AITL. ASH Abstract 2015, 2015. e-Pub 2015.
144. Shah N, Li L, Kaur I, McCarty J, Yvon E, Shaim H, Muftuoglu M, Liu E, Sobieski C, Orlowski RZ, Cooper LJN, Lee DA, Parmar S, Cao K, Hosing CM, Ahmed S, Nieto Y, Bashir Q, Patel KK, Bollard CM, McNiece IK, Qazilbash M, Champlin RE, Rezvani K, Shpall EJ. Infusion of Ex Vivo Expanded Allogeneic Cord Blood-Derived Natural Killer Cells in Combination with Autologous Stem Cell Transplantation for Multiple Myeloma: Results of a Phase I Study. ASH Abstract 2015, 2015. e-Pub 2015.
145. Gaballa S, Ge I, El Fakih RO, Brammer JE, Wang SA, Lee DA, Petropoulos D, Cao K, Rondon G, Chen J, Hammerstrom AE, Al-Atrash G, Korbling M, Oran B, Kebriaei P, Ahmed S, Shah N, Rezvani K, Marin D, Bashir Q, Alousi AM, Nieto Y, Qazilbash MH, Hosing CM, Popat UR, Shpall EJ, Khouri IF, Champlin RE, Ciurea SO. Results of a Two-Arm Phase II Clinical Trial Using Post-Transplantation Cyclophosphamide for Prevention of Graft-Versus-Host Disease in Haploidentical and Mismatched Unrelated Donors Hematopoietic Stem-Cell Transplantation. ASH Abstract 2015, 2015. e-Pub 2015.
146. Alousi AM, Bassett R, Chen J, Overman BJ, Hosing CM, Popat UR, Shpall EJ, Nieto Y, Qazilbash MH, Khouri IF, Kebriaei P, Ahmed S, Shah N, Rezvani K, Kondo K, Ciurea SO, Hymes SR, Neumann JL, Molldrem JJ, Plair TR, Champlin RE. A Bayesian, Phase II Randomized Trial of Extracorporeal Photopheresis (ECP) Plus Steroids Versus Steroids-Alone in Patients with Newly Diagnosed Acute Graft Vs. Host Disease (GVHD): The Addition of ECP Improves Gvhd Response and the Ability to Taper Steroids. ASH Abstract 2015, 2015. e-Pub 2015.
147. Nieto Y, Valdez BC, Thall PF, Wei W, Jones R, Hosing CM, Ahmed S, Popat UR, Shpall EJ, Qazilbash M, Gulbis AM, Anderlini P, Shah N, Bashir Q, Alousi AM, Oki Y, Hagemeister FB, Champlin RE, Andersson BS. Double Epigenetic Modulation of High-Dose Chemotherapy (HDC) with Autologous Stem-Cell Transplant (ASCT) for Patients with Refractory or Poor-Risk Relapsed Lymphoma. ASH Abstract 2015, 2015. e-Pub 2015.
148. Shah JJ, Feng L, Weber D, Thomas SK, Wang M, Turturro F, Qazilbash MH, Shah N, Bashir Q, Popat UR, Manasanch EE, Munoz SC, Landry A, Mendoza K, Nieto Y, Champlin RE, Orlowski RZ. Phase II Study of the Combination of Ixazomib with Lenalidomide As Maintenance Therapy Following Autologous Stem Cell Transplant in Patients with Multiple Myeloma. ASH Abstract 2015, 2015. e-Pub 2015.
149. Popat UR, Ray G, Bassett Jr RL, Poon MC, Valdez BC, Konoplev S, Ahmed S, Alousi AM, Andersson B, Bashir Q, Ciurea SO, Hosing CM, Jones R, Kebriaei P, Khouri IF, Kim S, Nieto Y, Olson AL, Oran B, Parmar S, Qazilbash MH, Rezvani K, Shah N, Shpall EJ, Champlin RE. Eltrombopag for Post-Transplant Thrombocytopenia: Results of Phase II Randomized Double Blind Placebo Controlled Trial. ASH Abstract 2015, 2015. e-Pub 2015.
150. Pingali SR, Saliba R, Anderlini P, Hosing CM, Khouri IF, Alousi AM, Kebriaei P, Nieto Y, Qazilbash MH, Fanale MA, Shpall EJ, Champlin RE, Popat UR. Age over 55 Years at Diagnosis Increases Risk of Second Malignancies after Auto-Transplantation for Hodgkin's Lymphoma Patients. ASH Abstract 2015, 2015. e-Pub 2015.
151. Chihara D, Fanale MA, Noorani M, Westin JR, Nastoupil L, Hagemeister FB, Fayad LE, Romaguera JE, Samaniego F, Turturro F, Lee HJ, Neelapu SS, Rodriguez A, Wang M, Fowler N, Miranda RN, Hosing CM, Nieto Y, Davis RE, Oki Y. The Survival Outcome of the Patients with Relapsed/Refractory Anaplastic Large-Cell Lymphoma. ASH Abstract 2015, 2015. e-Pub 2015.
152. Im JS, Saliba RM, Abraham SC, Rashid A, Ross W, Nieto Y, Shpall EJ, Oran B, Olson A, Ahmed S, Popat UR, Rondon G, Qazilbash MH, Shah N, Champlin RE, Alousi AM. Gastrointestinal Acuity Score (GAS): A Comprehensive Risk Score Incorporating Histologic Grade and Clinical Factors to Predict Need for Second Line Therapy, Non-Relapse Mortality, and Overall Survival in Lower Gastrointestinal Graft Vs. Host Disease. ASH Abstract 2015, 2015. e-Pub 2015.
153. Kebriaei P, Basset Jr RL, Ledesma C, Rondon G, Oran B, Ciurea SO, Alousi AM, Popat UR, Patel KK, Ahmed S, Olson AL, Bashir Q, Shah N, Jones R, Rezvani K, Nieto Y, Khouri IF, Qazilbash MH, Hosing CM, Shpall EJ, Champlin RE, Andersson BS. Clofarabine (Clo) Plus Busulfan (Bu) Is an Effective Conditioning Regimen for Allogeneic Hematopoietic Cell Transplantation (HCT) in Patients (pts) with Acute Lymphoblastic Leukemia (ALL): Long-Term Study Results. ASH Abstract 2015, 2015. e-Pub 2015.
154. Sasaki K, Shah N, Bashir Q, Hosing CM, Popat UR, Nieto Y, Parmar S, Shah JJ, Weber D, Weissinger D, Thomas SK, Orlowski RZ, Champlin RE, Qazilbash MH. Outcome of Patients with Light Chain Multiple Myeloma Compared to IgG/IgA Myeloma after Autologous Stem Cell Transplant. ASH Abstract 2015, 2015. e-Pub 2015.
155. Nieto Y, Bassett R, Anderlini P, Hosing CM, Alousi AM, Popat UR, Andersson BS, Valdez BC, Shpall EJ, Ahmed S, Qazilbash M, Guillermo M, Oki Y, Fanale MA, Hagemeister FB, Dabaja BS, Pinnix CC, Milgrom SA, Tewari P, Champlin RE, Jones R. Prospective Phase 2 Trial of High-Dose Gemcitabine/Busulfan/Melphalan (Gem/Bu/Mel) with Autologous Stem-Cell Transplant (ASCT) without Post-ASCT Maintenance, in Hodgkins Lymphoma Patients at High Risk of Post-Transplant Recurrence Comparison with a Concurrent Matched Cohort Treated with BEAM. ASH Abstract 2015, 2015. e-Pub 2015.
156. Tu S, Bilen MA, Tu ZH, General R, Ward JF, Pisters LL, General R, Chen AH, Nieto Y, Pagliaro LC, Yeung SJ, Logothetis C, Lin S, Gorlov I. Nonseminomatous germ cell tumor of the testis: Prognostic factors for a lethal phenotype. ASCO 2014, 2014. e-Pub 2014.
157. El Fakih RO, Nieto Y, Fox PS, Shah N, Parmar S, Oran B, Ciurea SO, Kebriaei P, Hosing C, Popat UR, Ahmed S, Shah JJ, Orlowski RZ, Dinh Y, Champlin RE, Qazilbash MH, Bashir Q. Autologous stem cell transplantation in dialysis-dependent myeloma patients. ASCO 2014, 2014. e-Pub 2014.
158. Ahmed S, Shpall EJ, Gulbis A, Jones R, Martinez CS, Rondon G, Rezvani K, Oran B, Olson A, Shah N, Parmar S, Popat UR, Alousi AM, Nieto Y, Hosing CM, Bashir Q, Kebriaei P, Qazilbash M, Champlin RE, Mulanovich VE. Assessment of Incidence Toxoplasma Gondii Infection and Outcomes in Allogeneic Stem Cell Patients. ASH 2014, 2014. e-Pub 2014.
159. Popat UR, Fox PS, Bassett R, Chen J, Valdez BC, Kawedia J, Ahmed S, Alousi AM, Bashir Q, Ciurea SO, Hosing CM, Jones R, Kebriaei P, Khouri IF, Nieto Y, Olson A, Oran B, Parmar S, Qazilbash MH, Shah N, Shpall EJ, Andersson BS, Champlin RE. Myeloablative Timed Sequential Busulfan Is Safe in Older Patients. ASH 2014, 2014. e-Pub 2014.
160. Shah N, Thall PF, Fox PS, Bashir Q, Shah JJ, Parmar S, Kebriaei P, Nieto Y, Popat UR, Hosing CM, Patel KK, Lin P, Shpall EJ, Orlowski RZ, Champlin RE, Qazilbash MH. Phase I/II Trial of Lenalidomide and High Dose Melphalan with Autologous Stem Cell Transplantation for Relapsed Myeloma. ASH 2014, 2014. e-Pub 2014.
161. Oran B, Cao K, Saliba RM, Hosing CM, Popat UR, de Lima M, Carmazzi Y, Alousi A, Kebriaei P, Nieto Y, Rondon G, Willis D, Shah N, Parmar S, Olson A, Moore B, Champlin RE, Rezvani K, Shpall EJ. Higher Allele Level HLA Matching Improves Prognostication after Double Umbilical Cord Blood (dUCB) Transplantation for Hematological Malignancies. ASH 2014, 2014. e-Pub 2014.
162. Nieto Y. Latest Research Developments for Managing Oral Mucositis. ASBMT 2014, 2014. e-Pub 2014.
163. Valdez BC, Zander A, Song G, Murray D, Nieto YL, Li Y, Champlin RE, Andersson BS. Synergistic Cytotoxicity of Gemcitabine, Clofarabine and Edelfosine (± DNA alkylating agent) in Lymphoma Cell Lines. ASBMT 2014, 2014. e-Pub 2014.
164. Qazilbash MH, Thall P, Fox PS, Shah N, Bashir Q, Shah J, Parmar S, Kebriaei P, Nieto YL, Dinh Y, Popat UR, Hosing C, Lin P, Shpall EJ, Orlowski RZ, Champlin RE. Phase I/II Trial of Lenalidomide and High-Dose Melphalan As Preparative Regimen for Relapsed Myeloma. ASBMT 2014, 2014. e-Pub 2014.
165. Nieto Y, Tu S, Jones RB, Tannir NM, Bassett RL, Margolin KA, Holmberg L, Champlin RE, Pagliaro LC. Phase 2 trial of bevacizumab (BEV)/high-dose chemotherapy (HDC) with autologous stem-cell transplant (ASCT) for refractory germ-cell tumors (GCT). ASCO 2014, 2014. e-Pub 2014.
166. Mian I, Milton D, Popat UR, Shah N, Nieto Y, Kebriaei P, Parmar S, Ahmed S, Shah JJ, Orlowski RZ, Qazilbash MH, Bashir Q, Champlin RE. Effect of Timing and Duration of Maintenance Lenalidomide in Myeloma Patients after Autologous Stem Cell Transplantations. ASH 2014, 2014. e-Pub 2014.
167. Afable M, Caimi PF, Hosing C, de Lima M, Khouri IF, William BM, Nieto Y, Cooper BW, Anderlini P, Campagnaro EL, Gerson SL, Lazarus HM, Champlin RE Popat UR. Brentuximab Vedotin (BV) Does Not Impair Autologous Peripheral Blood Stem Cell Mobilization and Collection in Refractory/Relapsed CD30+ Lymphoma Patients Undergoing High-Dose Chemotherapy and Autologous Stem Cell Transplant (HDC-ASCT). ASH 2014, 2014. e-Pub 2014.
168. Pingali SR, Milton D, Popat UR, Hosing CM, Bashir Q, Alousi AM, Jones R, Nieto Y, Kebriaei P, Qazilbash MH, Andersson BS, Shpall EJ, Khouri IF, Champlin RE, Ciurea SO. Transplant Outcomes of 9/10 HLA Matched Unrelated Donors (MUD) Treated with Post-Transplant Cyclophosphamide for Prevention of Graft Versus Host Disease. ASH 2014, 2014. e-Pub 2014.
169. Qazilbash MH, Thall PF, Fox PS, Kebriaei P, Bashir Q, Shah N, Andersson B, Nieto Y, Valdez B, Parmar S, Dinh Y, Hosing C, Popat UR, Shah JJ, Orlowski RZ, Champlin RE. Randomized phase III trial of busulfan plus melphalan versus melphalan alone for multiple myeloma. ASCO 2014, 2014. e-Pub 2014.
170. Shah JJ, Feng L, Manasanch EE, Weber DM, Thomas SK, Turturro F, Alexanian R, Shah N, Popat UR, Nieto Y, Bashir Q, Qazilbash MH, Champlin RE, Orlowski RZ. Phase I/Ib Trial of the Efficacy and Safety of Combination Therapy with Lenalidomide/Bortezomib/Dexamethasone (RVD) and Panobinostat in Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma. ASH 2014, 2014. e-Pub 2014.
171. Anderlini P, Saliba R, Ledesma C, Chancoco CM, Alexander TR, Alousi AM, Hosing C, Khouri IF, Nieto YL, Popat UR, Shpall EJ, Fanale MA, Oki Y, Romaguera JE, Neelapu SS, Younes A, Champlin RE. 74 Reduced-Intensity Conditioning and Allogeneic Stem Cell Transplantation For Relapsed/Refractory Hodgkin Lymphoma In The Brentuximab Vedotin Era. ASBMT 2014, 2014. e-Pub 2014.
172. Popat UR, Bassett R, Chen J, Alousi AM, Anderlini P, Ciurea SO, Hosing C, Jones RB, Kebriaei P, Khouri IF, Konoplev S, De Lima M, Nieto Y, Oran B, Qazilbash MH, Rondon G, Shpall EJ, Verstovsek S, Andersson B, Champlin RE. Allogeneic transplantation for myelofibrosis: Benefit of dose intensity. Journal of Clinical Oncology, 2013 ASCO Annual Meeting Proceedings (Post-Meeting Edition) Volume 31(No 15):7011, 2013. e-Pub 2013.
173. Nieto Y, Thall PF, Valdez BC, Hosing CM, Ahmed S, Jones RB, MD, Shah N, Anderlini P, Qazilbash MH, Popat UR, Bashir Q, Shpall EJ, Alousi A, Kebriaei P, Fox P, Bassett R, Chancoco C, Oki Y, Fanale MA, Fowler N, Hagemeister F, Romaguera JE, Champlin RE, Andersson BS. Vorinostat (SAHA) Combined With High-Dose Gemcitabine/Busulfan/Melphalan (SAHA/Gem/Bu/Mel) With Autologous Stem-Cell Transplant (ASCT) In Patients With Refractory Lymphomas. ASH 2013 Abstracts, 2013. e-Pub 2013.
174. Anderlini P, Saliba RM, Ledesma C, Chancoco CM, Alexander T, Alousi A, Hosing CM, Khouri I, Nieto Y, Popat UR, Shpall EJ, Fanale MA, Oki Y, Romaguera JE, Neelapu S, Younes A, Champlin RE. Reduced-Intensity Conditioning (RIC) and Allogeneic Stem Cell Transplantation (allo-SCT) For Relapsed/Refractory Hodgkin Lymphoma (HL) In The Brentuximab Vedotin Era: Favorable Overall and Progression-Free Survival (OS/PFS) With Low Transplant-Related Mortality (TRM). ASH 2013 Abstract, 2013. e-Pub 2013.
175. Patel K, Feng L, Oki Y, Qazilbash M, Muzzafar T, Weber DM, Fowler N, Popat UR, Thomas SK, Fanale MA, Nieto Y, Shah N, Bashir Q, Hagemeister FB, Orlowski RZ, Shah JJ. Plasmablastic Lymphoma: 28 Patient Single Institution Experience. ASH 2013 Abstracts, 2013. e-Pub 2013.
176. Nusrat M, Kazmi SM, Cornelison AM, Kebriaei P, Nieto Y, Oran B, Orlowski RZ, Parmar S, Popat UR, Shah JJ, Shah N, Champlin RE, Qazilbash MH, Bashir Q. Outcomes Among High Risk and Standard Risk Multiple Myeloma Patients Treated With High Dose Therapy and Autologous Hematopoietic Stem Cell Transplantation. ASH 2013 Abstracts, 2013. e-Pub 2013.
177. Nieto Y, Shah N, Popat UR, Jones RB, Bashir Q, Bassett R, Valdez BC, Andersson BS, Parmar S, Orlowski RZ, Shah JJ, Thomas SK, Wang M, Champlin RE, Qazilbash M. High-Dose Gemcitabine Combined With Busulfan and Melphalan (Gem/Bu/Mel) With Autologous Stem-Cell Transplant (ASCT) In Refractory and Relapsed Myeloma. ASH 2013 Abstracts, 2013. e-Pub 2013.
178. Pingali SR, Saliba RM, Smith VR, Maadani F, Adekola KUA, Popat UR, Qazilbash MH, Bashir Q, Khouri I, Kebriaei P, Ciurea SO, Anderlini P, Shah N, Nieto Y, Champlin RE, Hosing CM. Number Of Apheresis Days To Reach Target Stem Cell Dose May Be a Predictor Of Secondary Myelodysplastic Syndrome and Acute Myelogenous Leukemia. ASH 2013 Abstracts, 2013. e-Pub 2013.
179. Oran B, Poon M, Chen J, Rondon G, Ahmed S, Andersson BS, Bashir Q, Ciurea SO, Hosing CM, Parmar S, Qazilbash MH, Popat UR, Nieto Y, Alousi A, Jones RB, Rezvani K, de Lima M, Shpall EJ, Champlin RE, Kebriaei P. Comparable Outcomes After Sibling and Matched Unrelated Donor Allogeneic Hematopoietic Cell Transplantations (HCT) In Adult Acute Lymphoblastic Leukemia (ALL) With First Complete Remission (CR). ASH 2013 Abstracts, 2013. e-Pub 2013.
180. Popat UR, Oran B, Hosing CM, Kebriaei P, Rezvani K, Parmar S, Shah N, Bollard CM, Molldrem JJ, Nieto Y, Andersson BS, Alousi A, Jones RB, Cooper LJN, Qazilbash MH, Bashir Q, Ahmed S, Bosque D, Chen J, McCarty J, Rondon G, Munsell M, McNiece IK, Kaur I, Yvon E, Annandale K, Olchesky S, de Lima MJ, Champlin RE, Miller L, Paradiso L, Koh L, Zweidler-McKay PA, Shpall EJ. Ex Vivo Fucosylation Of Cord Blood Accelerates Neutrophil and Platelet Engraftment. ASH 2013 Abstracts, 2013. e-Pub 2013.
181. Ahmed S, Di Stasi A, Shpall EJ, Khouri IF, Alousi AM, Ciurea SO, Bashir Q, Qazilbash M, Jones RB, Nieto Y, Parmar S, Kebriaei P, Shah N, Rezvani K, Hosing CM, Oran B, Andreeff M, Anderlini P, Andersson BS, Champlin RE, Popat U. Development of Donor Cell Derived Leukemia After Allogeneic Stem Cell Transplant. ASH 2013 Abstracts, 2013. e-Pub 2013.
182. Shah JJ, Baladandayuthapani V, Weber DM, Thomas SK, Alexanian R, Wang M, Qazilbash MH, Champlin RE, Shah N, Bashir Q, Popat UR, Nieto Y, Ahmed S, Parmar S, Orlowski RZ. Phase II Study Of The Combination Of MLN 9708 With Lenalidomide As Maintenance Therapy Post Autologous Stem Cell Transplant In Patients With Multiple Myeloma. ASH 2013 Abstracts, 2013. e-Pub 2013.
183. Benton CB, Konopleva M, Saliba RM, Shpall EJ, Ciurea SO, Kebriaei P, Alousi AM, Popat UR, Anderlini P, Nieto Y, Parmar S, Zeng Z, Chen JJ, Rondon G, McMullin B, Wang R, Lu H, Schober WD, Woodworth GG, Gulbis A, Cool R, Qiao W, Thall PF, Andreeff M, Champlin RE. Leukemia Cell Mobilization with Plerixafor Plus G-CSF with Busulfan/Fludarabine and Allogeneic Hematopoietic Cell Transplantation in Patients with AML/MDS Is Associated with Decreased Complete Chimerism and GvHD, and Increased Risk of Relapse. ASH 2012, 2012. e-Pub 2012.
184. Alousi AM, Saliba RM, Chen J, Andersson BS, Khouri I, Qazilbash MH, Popat UR, Hosing CM, Ciurea SO, Shpall EJ, Jones RB, Kebriaei P, Nieto Y, Anderlini P, DeLima M, Rondon G, Champlin RE. A Matched Controlled Analysis of Post-Transplant Cyclophosphamide (CY) Versus Tacrolimus and Mini-Dose Methotrexate in Matched Sibling and Unrelated Donor Transplant Recipients Receiving Reduced-Intensity Conditioning: Post-Transplant CY Is Associated with Higher Rates of Acute Gvhd. ASH 2012, 2012. e-Pub 2012.
185. Hamdi A, Poon LM, Saliba RM, Rondon G, Ledesma C, Qazilbash M, Hosing CM, Jones RB, Popat UR, Nieto Y, Alousi AM, Ciurea SO, Shpall EJ, Champlin RE, Kebriaei P. Outcomes of Adults with Acute Lymphoblastic Leukemia (ALL) Following Relapse After First Allogeneic Hematopoietic Stem Cell Transplantation (HSCT). ASH 2012, 2012. e-Pub 2012.
186. Gul Z, Bashir Q, Nieto Y, Sherwani N, Parmar S, Shah N, Dinh YT, Hosing CM, Popat UR, Kebriaei P, Shpall EJ, Giralt SA, Champlin RE, Qazilbash MH. Cardiac Toxicity After High-Dose Melphalan and Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma. ASH 2012, 2012. e-Pub 2012.
187. Ciurea SO, Saliba RM, Bayraktar UD, Xie S, Rondon G, Parmar S, Kebriaei P, Montes N, Sharma M, Konopleva M, Nieto Y, Qazilbash MH, Alousi AM, Andersson BS, Hosing CM, Shpall EJ, Khouri IF, de Lima M, Champlin R. Improved Early Outcomes with T-Cell Replete (TCR) Compared with T-Cell Depleted (TCD) Haploidentical Stem Cell Transplantation (HaploSCT). ASH Annual Meeting 2011 Abstract, 2012. e-Pub 2012.
188. Anderlini P, Saliba RM, Ledesma C, Chancoco CM, Acholonu S, Valverde R, Popat UR, Hosing CM, Alousi AM, Shpall EJ, Nieto Y, Ciurea SO, Khouri I, Champlin R. Gemcitabine, Fludarabine, and Melphalan (G-FM) as Reduced-Intensity Conditioning (RIC) Regimen for Allogeneic Stem Cell Transplantation (Allo-SCT) in Relapsed and Refractory Hodgkin Lymphoma (HL). ASH Annual Meeting 2011 Abstract, 2012. e-Pub 2012.
189. Ahmed S, Chiattone A, Jones R, Sphall EJ, Farhan S, Rondon G, Nieto Y, Bashir Q, Chen J, Khouri IF, Kebriaei P, Anderlini P, Champlin R, De Lima M. Allogeneic Stem Cell Transplantation for CML in Second Chronic Phase After Blast Crisis in the Tyrosine Kinase Inhibitor Era. ASH Annual Meeting 2011 Abstract, 2012. e-Pub 2012.
190. Andersson BS, de Lima MJ, Saliba RM, Shpall EJ, Popat U, Jones R, Nieto Y, Hosing CM, Kebriaei P, Alousi, AM, Worth LL, Madden T, Gulbis A, Chen JJ, Rondon G, McAdams P, McMullin B, Andreeff M, Champlin R. Pharmacokinetic Dose Guidance of IV Busulfan with Fludarabine with Allogeneic Stem Cell Transplantation Improves Progression Free Survival in Patients with AML and MDS ; Results of a Randomized Phase III Study. ASh Annual Meeting 2011 Abstract, 2012. e-Pub 2012.
191. Popat U, Andersson BS, Bassett R, Ciurea S, Rondon G, Alousi AM, Anderlini P, Hosing C, Jones R, Kebriaei P, Nieto Y, Khouri I, Shpall EJ, Verstovsek S, Qazilbash M, de Lima MJ, Champlin R. Allogeneic Hematopoietic Stem Cell Transplantation for Myelofibrosis: PK Guided IV Busulfan Dose Intensity Results in Improved Event Free Survival. ASH Annual Meeting 2011 Abstract, 2012. e-Pub 2012.
192. Nieto Y, Thall PF, Andersson BS, Popat UR, Anderlini P, Valdez BC, Shpall EJ, Qazilbash M, Alousi AM, Chancoco C, Hosing CM, Kebriaei P, Bashir Q, Shah N, Khouri I, Ciurea SO, McMullin B, Rondon G, Champlin R, Jones R. High-Dose Infusional Gemcitabine (Gem) Combined with Busulfan (Bu) and Melphalan (Mel) (GemBuMel) with Autologous Stem-Cell Transplant (ASCT) in Patients with Refractory Lymphoid Malignancies. ASH Annual Meeting 2011 Abstract, 2012. e-Pub 2012.
193. Khouri IF, Saliba RM, Valverde R, Samuels BI, Korbling M, Alousi AM, Anderlini P, Bashir Q, De Lima M, Hosing C, Kebriaei P, Nieto Y, Popat UR, Qazilbash M, Neelapu S, Fowler NH, Samaniego F, Wang L, Champlin R, Macapinlac HA. Nonmyeloablative Allogeneic Stem Cell Transplantation with/ or without 90yttrium Ibritumomab Tiuxetan (90YIT) Is Curative for Relapsed Follicular Lymphoma: Median 9 Year Follow-up Results. ASH Annual Meeting 2011 Abstract, 2012. e-Pub 2012.
194. Konopleva M, Zhihong Z, Wang RY, Thall P, McCormick G, Lu H, Chen JJ, Shpall EJ, Ciurea SO, Kebriaei P, Alousi AM, Popat U, Anderlini P, Nieto Y, Parmar S, McMullin B, Rondon G, Schober WE, Gulbis A, Cool R, Lin E, Andreeff M, Champlin R. A Phase I/II Trial of Plerixafor/G-CSF Combined with IV Bu/Flu Conditioning Regimen In AML/MDS Patients Undergoing Allogenic Stem Cell Transplantation. Blood (ASH Annual Meeting Abstracts) 116, 2010. e-Pub 2010.
195. Tang X, de Lima M, Wei W, Chiattone A, Thall P, Jeffrey M, Rondon G, Chen JJ, Shpall EJ, Jones R, Nieto Y, Alousi AM, Champlin RE, Andersson BS. Early Mixed Chimerism After Allogeneic Stem Cell Transplantation with the Reduced-Toxicity IV Busulfan-Fludarabine (BuFlu) Regimen Does Not Independently Affect Long-Term Prognosis for Patients with AML/MDS. Blood (ASH Annual Meeting Abstracts) 116, 2010. e-Pub 2010.
196. de Lima M, Robinson S, McMannis J, Alousi AM, Saliba RM, Munsel M, Kberiaei P, Hosing C, Parmar S, Cooper L, Shah N, Staba Kelly S, Rondon G, Fernandez-Vina M, Maewall I, Bosque D, Bollard CM, Chen JJ, McNiece KI, Komanduri KV, Nieto Y, Jones R, Andersson BS, Popat U, Champlin RE, Simmons PJ, Shpall EJ. Mesenchymal Stem Cell (MSC) Based Cord Blood (CB) Expansion (Exp) Leads to Rapid Engraftment of Platelets and Neutrophils. Blood (ASH Annual Meeting Abstracts) 116, 2010. e-Pub 2010.
197. Alousi A, Andersson BS, Saliba RM, Botnick W, Rondon G, Shpall EJ, de Lima M, Popat U, Hosing C, Kebriaei P, Khouri I, Qazilbash MH, Anderlini P, Nieto Y, Ciurea SO, Jones R, Champlin R. Reduced Intensity Conditioning Combined with Post-Transplant Cyclophosphamide for Graft Vs. Host Disease Prophylaxis In Older-Aged or Medically Frail Patients with Advanced Hematological Malignancies. Blood (ASH Annual Meeting Abstracts) 116, 2010. e-Pub 2010.
198. Nieto Y, Anderlini P, Popat U, Liu P, Andersson BS, Shpall EJ, Kebriaei P, Hosing C, Alousi AM, Qazilbash MH, So C, Parmar S, Champlin RE, Jones R. Gemcitabine, Busulfan and Melphalan (GemBuMel) Is a New High-Dose Chemotherapy (HDC) Regimen with High Activity In Refractory Hodgkin's Lymphoma (HL) Patients Receiving An Autologous Stem-Cell Transplant (ASCT): A Contemporaneous Comparison with BEAM and Busulfan/Melphalan (BuMel). Blood (ASH Annual Meeting Abstracts) 116, 2010. e-Pub 2010.
199. Sharma M, Ravandi F, Chiattone A, Kebriaei P, Popat U, Giralt S, Bashir Q, Qazilbash MH, Nieto Y, Yuen C, Parmar S, Kantarjian H, Cortes J, Kadia T, Borthakur G, Champlin RE, de Lima M. Treatment of FLT3-ITD Positive AML Relapsing After Allogeneic Hematopoietic Stem Cell Transplant (HSCT) with Sorafenib. Blood (ASH Annual Meeting Abstracts) 116, 2010. e-Pub 2010.
200. Chiattone A, Andersson B, Bashir Q, Landau D, Rondon G, Nieto Y, Al Atrash G, Giralt S, Champlin RE, De Lima M. Treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) relapsing after allogeneic hematopoietic cell transplantation (HCT). ASCO Meeting Abstracts 28(No 15_suppl (May 20 Supplement)):65, 2010. e-Pub 2010.
201. Popat U, Rondon G, Alousi A, Anderlini P, Andersson B, Hosing C, de Lima M, Ciurea S, Giralt S, Kebriaei P, Nieto Y, Khouri I, Qazilbash MH, Jones R, Champlin R. Allogeneic Hematopoietic Stem Cell Transplantation for Myelofibrosis. Blood (ASH Annual Meeting Abstracts) 114(22):900, 2009. e-Pub 2009.
202. de Padua Silva L, Patah P, Saliba RM, Szewczyk N, Gilman L, Glbis A, Neumann J, Walker J, Petropoulos D, LaSala R, Shaz Mir KA, Nieto Y, Khouri I, Giralt S, Champlin RE, De Lima M. Polyoma (BK) Viruria Prior to Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) from Donors Other Than Matched Siblings: A Prospective Evaluation of Hemorrhagic Cystitis (HC) Incidence. Blood 112(11):25, 2008. e-Pub 2008.
203. Popat U, Saliba R, de Padua Silva L, Andersson BS, Alousi AM, Anderlini P, de Lima M, Okoroji GJ, Hosing CM, Jones RB, Kebriaei P, Khouri I, Hosing C, Korbling M, Alousi A, Rondon G, Andersson BS, Nieto Y, Ciurea S, Komanduri K, Champlin RE, Shpall E. Busulfan and Fludarabine Conditioning Regimen Negates the Impact of Comorbidity Score on Nonrelapse Mortality in Patients with AML/MDS. Blood 112(11):297, 2008. e-Pub 2008.
204. Jabbour E, De Lima M, de Padua Silva L, Giralt S, Cortes J, Qazilbash M, Rondon G, Ciurea S, Jones R, Nieto Y, Korbling M, Couriel D, Kantarjian H, Champlin R. Long-Term Efficacy of Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in Patients (pts) with Advanced Chronic Myeloid Leukemia (CML) Post Imatinib Failure. Blood 112(11):360, 2008. e-Pub 2008.
205. Popat U, de Lima MJ, Ativitavas T, Rondon G, de Padua Silva L, Koca E, Zhang W, Alousi A, Anderlini P, Giralt SA, Hosing CM, Jones R, Kebriaei P, Khouri I, Nieto Y, Qazilbash MH, Andersson BS, Champlin R. Allogeneic Transplantation (HCT) for Myelodysplastic Syndrome:Recent MDACC Experience. Blood 112(11):413, 2008. e-Pub 2008.
206. De Lima M, McMannis JD, Saliba R, Worth L, Kebriaei P, Popat U, Qazilbash M, Jones R, Giralt S, de Padua Silva L, Cooper L, Petropoulos D, Lee D, Kelly S, Thall P, Robinson S, Khouri I, Hosing C, Korbling M, Alousi A, Rondon G, Andersson BS, Nieto Y, Ciurea S, Komanduri K, Champlin RE, Shpall E. Double Cord Blood Transplantation (CBT) with and without Ex-Vivo Expansion (EXP): A Randomized, Controlled Study. Blood 112(11):63, 2008. e-Pub 2008.
207. De la Cruz S, Aramendia JM, Espinós J, Fernandez-Hidalgo O, Santisteban M, Arbea L, Aristu J, Garran C, Martinez-Monge R, Martinez-Regueira F, Nieto Y. Phase II trial of sequential dose-dense epirubicin/cyclophosphamide (E/C) followed by docetaxel/capecitabine (D/X) as adjuvant or neoadjuvant chemotherapy for patients with HER2-negative breast cancer (BC). Journal of Clinical Oncology 26(15S):39s, 2008. e-Pub 2008.
208. Ramos CA, Saliba RM, Giralt S, Khorshid O, de Padna L, Andersson BS, Nieto YL, Popat UR, Qazilbash MH, Qureshi S, Zhang W, Champlin RE, de Lima M. The Impact of Resolved Hepatitis B Infection On Allogeneic Hematopoietic Stem Cell Transplantation For Hematological Malignancies. Biology of Bone and Marrow Transplantation 14(2):8, 2008. e-Pub 2008.
209. Popat U, Saliba R, Ablawat S, Okoroji GJ, Alousi A, Korbling M, Nieto Y, Qazilbash M, Shpall EJ, Khouri I, Giralt S, Champlin R, Hosing C. Incidence and Factors Influencing Stem Cell Mobilization In Patients With Non-Hodgkin's Lymphoma (NHL) And Hodgkin's Disease (HD). Biology of Bone and Marrow Transplantation 14(2):37, 2008. e-Pub 2008.
210. Ramos CA, Saliba RM, Khorshid O, de Padua L, Giralt S, Andersson BS, Ueno NT, Shpall EJ, Khouri IF, Hosing C, Alousi A, Nieto Y, Qureshi SR, Champlin RE, de Lima M. Hepatitis C (HC) Virus Infection Is Associated with Worse Survival after Allogeneic Hematopoietic Stem Cell Transplantation (alloSCT) for Hematological Malignancies. Blood 110(11):23a, 2007. e-Pub 2007.
211. Nieto Y, Rifon J, Perez-Calvo J, Zafra A, Zufia L, Viudez A, Viteri S, Sayan O, Hernandez M, Aldaz A. Phase I trial of gemcitabine (GEM) infused at fixed-dose rate (FDR) with high-dose docetaxel/melphalan/carboplatin (GEM-DMC) and autologous stem-cell transplant (ASCT). Journal of Clinical Oncology 25(18S):680s, 2007. e-Pub 2007.
212. Giralt SA, Saliba RM, Mendoza F, Parikh G, Qureshi S, Zhang W, Popat UR, Qazilbash MH, Khouri I, Hosing C, Alousi A, Anderlini P, Andersson B, Jones RB, Shpall EJ, Kebriaei P, Nieto Y, Ueno N, Champlin RE, de Lima M. Pretransplant Values of C Reactive Protein (CRP) and Brain Natriuretic Peptide (BNP) as Predictors of Transplant Outcomes in Patients with Acute Myelogenous Leukemia or Myelodysplastic Syndromes (AML/MDS) Undergoing Allogeneic Stem Cell Transplantation (AlloSCT). Blood 110(11):590a, 2007. e-Pub 2007.
213. Popat UR, Rondon G, Alousi AM, Anderlini P, Andersson BS, de Lima MJ, Giralt SA, Hosing CM, Kebriaei P, Jones RB, Nieto YL, Shpall EJ, Verstovesek S, Qazilbash MH, Champlin RE. Myelofibrosis and Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation (RISCT). Blood 110(11):900a, 2007. e-Pub 2007.
214. Patah P, Fernandez-Vina M, Stastny P, Liu P, Cano P, Pesoa S, Shpall EJ, Giralt SA, Khouri I, Anderlini P, Alousi A, Padua L, Ramos C, Rondon G, Nieto YL, Champlin RE, de Lima M. Mismatches in Low Expression HLA Class II Loci and MIC-A in Unrelated Donor Hematopoietic Stem Cell Transplantation (HSCT). Blood 110(11):590a, 2007. e-Pub 2007.
215. Sayar O, Aldaz A, Zufia L, Viudez A, Rifon J, Nieto Y. New model to Gemcitabine and its metabolites. Proceedings of the 2007 Meeting of the Population Approach Group in Europe (PAGE), Kobenhavn, Denmark, 2007. e-Pub 2007.
216. Yang H, Robinson SN, Nieto Y, Giralt SA, Jones RB, Decker WK, Xing D, Steiner D, Champlin RE, Ng J, Thomas MW, de Lima M, Shpall EJ. Ex Vivo Graft Purging and Expansion of Autologous Mobilized Peripheral Blood Progenitor Cell (PBPC) Products from Patients with Multiple Myeloma (MM). Blood/ASH Annual Abstract 110(Suppl 11):237a, 2007. e-Pub 2007.
217. Aldaz A, Sayar O, Zufia L, Viúdez A, Rifón J, Nieto Y. Comparison between NONMEM and NPAG to gemcitabine modeling. Proceedings of the 2007 Meeting of the Population Approach Group in Europe (PAGE), Kobenhavn, Denmark, 2007. e-Pub 2007.
218. Gonzalez-Cao M, Viteri S, Chopitea A, Nieto Y, Gonzalez A, Redondo P, Idoate M, Ballesteros AI, Aquerreta D, Martin-Algarra S. Bevacizumab and weekly taxol combination in previously treated metastatic melanoma patients. Annals of Oncology 17(Suppl 9):161, 2006. e-Pub 2006.
219. Santisteban M, De la Cruz S, Sola JJ, Aramendía JM, Espinós J, Garrán C, Martinez-Regueira F, Zornoza G, Fernández-Hidalgo O, Nieto Y. Sequential doxorubicin plus vinorelbine (AV) followed by docetaxel plus carboplatin (DC) as neoadjuvant chemotherapy for advanced breast cancer (BC). Annals of Oncology 17(Suppl 9):86, 2006. e-Pub 2006.
220. Nieto YL, Woods J, Jones RB, Shpall EJ, Bearman SI, Baron AE, Nawaz S. Prognostic analysis of intratumor microvessel density (MVD) and vascular endothelial growth factor (VEGF) in high-risk primary breast cancer (HRPBC) patients (PTS) receiving high-dose chemotherapy (HDC). Journal of Clinical Oncology 23(Suppl):16S, 2005. e-Pub 2005.
221. Storme G, Nieto Y, Vinh-Hung V, Hortobagyi GN. Lymph node ratio as a prognostic factor in node-positive breast cancer. European Journal of Cancer 3(2 Suppl):76-77, 2005. e-Pub 2005.
222. Ueno NT, Cserni G, Wallace AM, Janni W, Royce M, Nieto Y, Vinh-hung V. Lymph node ratio as a prognostic factor in metastatic breast cancer. Breast Cancer Research and Treatment 94(Suppl 1):S131, 2005. e-Pub 2005.
223. Nieto Y. Prognostic studies in patients with high-risk primary breast cancer (HRPBC) receiving high-dose chemotherapy. Breast Cancer Research S22(Suppl 1):S13-S14, 2005. e-Pub 2005.
224. Epenetos AA, Ceriani R, Peterson J, Cagnoni PJ, Nieto YL, Jones RB. Phoenix-A humanised 90Y-conjugated monoclonal antibody for the treatment of relapsed breast cancer. Journal of Clinical Oncology 22(14S):35a, 2004. e-Pub 2004.
225. Nieto YL, Patton N, Hawkins T, Spearing R, Bearman SI, Rabinovitch R, Zeng C, Barón A, McSweeney PA. Low incidence of acute GVHD using tacrolimus (TAC) and mycophenolate mofetil (MMF) after matched sibling donor (MSD) non-myeloablative stem-cell transplants (NST) conditioned with Fludarabine (FLU)/total body irradiation (TBI). Blood 104:5065, 2004. e-Pub 2004.
226. McSweeney PA, Abhyankar S, Petersen F, Devetten M, Arcaroli J, Zeng C, Baron A, Hardiman P, McGuirk JP, Bearman SI, Nieto YL, Foran J, Pulsipher M, Pavletic S. Tacrolimus and Mycophenolate Mofetil for GVHD Prevention After Unrelated Donor Transplants. Blood 102:717a, 2003. e-Pub 2003.
227. Rabinovitch R, Cersonsky N, Slat-Vasquez V, Wolf D, Nieto Y, Bearman S, Shpall EJ, Jones R, McSweeney P. Acute toxicity of low-dose total body irradiation (200 cGy) as conditioning for allogeneic hematopoietic cell transplantation. Radiology 225:456, 2003. e-Pub 2003.
228. Abbot B, Kaiser J, Madinger, Bearman SI, McSweeney P, Nieto YL. Amphotercin B-Lipid Complex (ABLC) for Antifungal Prophylaxis in Patients Receiving High-Dose Steroids for GVHD. Blood 102:431b, 2003. e-Pub 2003.
229. McSweeney PA, Abhyanar S, Foran J, Arcaroli J, Baron A, Zeng C, Devetten M, Nieto YL, Bearman S, McGuirk J, Hardiman P, Niehus J, Pavletic S. Favorable early transplant outcoms Using Tacrolimus and Mycophenolate Mofetil for GVHD Prevention After Matched Sibling Allografting. Blood 102:714a, 2003. e-Pub 2003.
230. Nieto Y, Shpall EJ, Si B, McSweeney PA, Jones RB. Long-term analysis of high-risk primary breast cancer patients enrolled in prospective trials of high-dose chemotherapy (HDC) and autologus hematopoietic progenitor cell transplant (AHPCT). Biology Blood Marrow Transplant 9:72a, 2003. e-Pub 2003.
231. Nieto Y, Jones RB, Bearman SI, McNiece IK, McSweeney PA, Shpall EJ. Prognostic analysis of the early lymphocyte recovery in patients with advanced breast cancer receiving high-dose chemotherapy (HDC) with an autologous hematopoietic progenitor cell transplant. Biology Blood Marrow Transplant 9:72a, 2003. e-Pub 2003.
232. Nieto Y, Nawaz S, Bearman SI, Shpall EJ, McSweeney PA, Jones RB. Overexpression of epidermal growth factor receptor (EGFR) adds prognostic value to HER2 status in patients (pts) with high-risk primary breast cancer (HRPBC). Proceedings ASCO 22:15a, 2003. e-Pub 2003.
233. Medeiros BC, Nieto Y, Bearman SI, Shpall EJ, Jones RB, Rabinovitch R, Cagnoni PJ, McSweeney PA. Fatal Aplasia and Graft Rejection after Nonmyeloablative Allografting. Blood 100:416a, 2002. e-Pub 2002.
234. Rabinovitch R, Cersonsky N, Slat-Vasquez V, Wolf D, Nieto YL, Bearman SI, Shpall EJ, Jones RB, McSweeney P. Acute toxicity of low-dose total body irradiation (200cGy) as conditioning for allogeneic hematopoietic cell transplantation. Radiology 225, 2002. e-Pub 2002.
235. Shpall EJ, Quinones R, Giller R, Zeng C, Baron AE, Jones RB, Bearman SI, Nieto Y, Freed B, Madinger N, Hogan CJ, Slat-Vasquez V, Russell P, Blunk B, Schissel D, Hild E, Malcolm J, Ward W, McNiece IK. Transplantation of ex vivo expanded cord blood. Biol Blood Marrow Transplant 8(7):368-376, 2002. e-Pub 2002. PMID: 12171483.
236. Bearman SI, Nieto Y, Sweetenham J, Cagnoni PJ, Slat-Vasquez V, Shpall EJ, Jones RB, Mc Sweeney PA. Sequential Autologous and Allogeneic Stem Cel Transplantation for Hematologic Malignancies. Blood 100:622a, 2002. e-Pub 2002.
237. McSweeney PA, Abhyankar S, Becker C, Baron A, Foran J, McGuirk JP, Hardiman P, Picken S, Zeng C, Bearman S, Bierman P, Nieto YL, Cagnoni PJ, Pavletic SZ. Low incidence of Early Transplant Mortality Using Tacrolimus and Mycophenolate Mofetil For GVHD Prevention. Blood 100:419a, 2002. e-Pub 2002.
238. Rosinski S, Mc Niece I, Shpall E, Clough N, Russell P, McDermott J, Nieto YL. Peripheral T cell levels correlate with outcome in patients undergoing autologous stem cell transplant. Experimental Hematology 30(6 (Suppl 1)):S111, 2002. e-Pub 2002.
239. Nieto Y, Vredenburgh JJ, Shpall EJ, Bearman SI, McSweeney PA, Cagnoni PJ, Elias A, Rabinovitch R, Matthes S, Razook C, Chao N, Jones RB. Pilot phase II study of concurrent administration of trastuzumab and high-dose chemotherapy (HDCT) in advanced HER2+ breast cancer. Proceedings ASCO 21:416a, 2002. e-Pub 2002.
240. McSweeney PA, Bearman SI, Jones RB, Nieto Y, Cagnoni PJ, McNiece IK, Slat-Vasquez V, Ward W, Shpall EJ. Nonmyeloablative hematopoietic cell transplants using cord blood. Blood 98:666a, 2001. e-Pub 2001.
241. Nieto YL, Nawaz S, Jones RB, Shpall EJ, Cagnoni PJ, McSweeney PA, Beaudet J, Razook C, Matthes S, Bearman SI. Prognostic Analysis of a Phase II Clinical Trial of High-Dose Chemotherapy (HDC) with Autologous Stem-Cell Transplant (ASCT) for Patients with Metastatic Breast Cancer (MBC) with No Evidence of Disease (NED). Proceedings ASCO 20:8a, 2001. e-Pub 2001.
242. Beaudet J, Jones RB, Shpall EJ, Bearman SI, Baron A, Zeng C, Slat-Vasquez V, Nieto YL, McSweeney P, Cagnoni PJ. Long Term Follow-Up of 114 Patients with Chemosensitive Stage IV Breast Cancer Treated with High-Dose Chemotherapy (HDC) and Autologous Stem Cell Support (ASCS). Proceedings ASCO 20:11a, 2001. e-Pub 2001.
243. Si B, Cagnoni PJ, Nieto Y, Slat-Vasques, Shpall EJ, Jones RB, McSweeney PA. High-dose chemotherapy and autologous transplantation followed by nonmyeloablative allogeneic transplantation; Separating cytoreduction from adoptive immunotherapy. Blood 96(11):410a, 2000. e-Pub 2000.
244. McNiece I, Candia J, Jones RB, Bearman SI, Cagnoni PJ, Nieto YL, Murphy J, Shpall EJ. Long-term engraftment in breast cancer patients who received ex vivo expanded PBPC. Blood 96(11):840a, 2000. e-Pub 2000.
245. Shpall EJ, Quinones R, Giller R, Jones RB, Bearman SI, Cagnoni PJ, Nieto YL, McSweeney P, Murphy J, Hogan C, Mc Niece I. Transplantation of adult and pediatric cancer patients with cord blood progenitors expanded ex vivo. Blood 96(11):207a, 2000. e-Pub 2000.
246. Nieto Y, Cagnoni PJ, Shpall EJ, Bearman SI, McSweeney P, Matthes S, Holter S, Razook C, Russell P, Cook B, Yerushalmi R, Jones RB. Phase I Trial of Docetaxel (DTX) (Taxotere) with Peripheral Blood Progenitor Cell (PBPC) Support, with Melphalan (MEL) and Carboplatin (CB), in Refractory Advanced Cancer. Proceedings ASCO 19:56a, 2000. e-Pub 2000.
247. Zhang L, Webb T, Glueck D, Barón A, Murphy J, Cagnoni P, Nieto Y. Power and death: Sample size calculations and survival after potentially toxic treatment. Proceedings of the 2000 Meeting of the International Biometrics Society, 2000. e-Pub 2000.
248. Shpall EJ, Quinones R, Jones R, Bearman S, Cagnoni P, Giller R, Nieto Y, McSweeney P, McNiece I. Transplantation of adult and pediatric cancer patients with ex vivo expanded cord blood. Experimental Hematology 28(Suppl 1):88, 2000. e-Pub 2000.
249. McNiece I, Hogan C, Jones R, Bearman S, Cagnoni P, Nieto Y, Shpall EJ. Do stem cells contribute to short term engraftment in transplant patients?. Experimental Hematology 28(Suppl 1):89, 2000. e-Pub 2000.
250. Nieto Y, Cagnoni PJ, Shpall EJ, Xu X, Bearman SI, Jones RB. Validated predictive model for relapse after high-dose chemotherapy (HDC) with autologous stem-cell support (ASCS) for high-risk primary breast cancer (HRPBC). Biology of Blood and Marrow Transplant 5:112, 1999. e-Pub 1999.
251. Roman-Unfer S, Potter T, Quinones R, McNiece IK, Smith M, Steele A, Stoltz J, Cagnoni PJ, Bearman SI, Jones RB, Nieto Y, Shpall EJ. The effect of sequential ex vivo cytokine exposure on the generation of dendritic cells from mobilized CD34+ blood progenitor cells. Biology of Blood and Marrow Transplant 5:114a, 1999. e-Pub 1999.
252. Nieto Y, Nawaz S, Cagnoni PJ, Shpall EJ, Bearman SI, Jones RB. Overexpression of Her2/neu, but not p53 mutations, is a poor prognostic factor in high-risk primary breast cancer treated with high-dose chemotherapy and autologous stem-cell transplant. Journal of Clinical Oncology 18:77a, 1999. e-Pub 1999.
253. Casado A, Martín M, García-Carbonero I, Llorente L, López-Martín JA, Esteban C, Oruezábal M, Rodríguez-Lescure A, Ayala F, Nieto Y, Alonso JL, Portugal T, Alvarez J, Vidart J, Herráiz MA, Díaz-Rubio E. DICEP (HD-DICEP) chemotherapy with or without peripheral blood stem cell support (PBSCS) as consolidation treatment of patients with advanced epithelial ovarian cancer. Proceedings ASCO 18:373a, 1999. e-Pub 1999.
254. Hogan C, Shpall EJ, Candia J, Jones R, Bearman S, Cagnoni P, Nieto Y, Murphy J, McNiece I. Ex vivo expansion of PBPC maintains SCID repopulating cells and provides rapid and durable engraftment in breast cancer patients. Blood 94(10 (Suppl 1)):554a, 1999. e-Pub 1999.
255. Shpall EJ, Jones RB, Bearman SI, Cagnoni PJ, Quinones R, Giller R, Nieto Y, Yerushalmi R, Cook B, McSweeney P, McNiece I. Transplantation of cancer patients with cord blood progenitors which are expanded ex vivo. Blood 94(10 (Suppl 1)):554a, 1999. e-Pub 1999.
256. Cagnoni PJ, Ceriani RL, Cole W, Johnson T, Quaife R, Nieto Y, Matthes SM, Shpall EJ, Bearman SI, Taffs S, Peterson J, Blank E, Jones RB. Phase I study of high-dose radioimmunotherapy with 90-Y-hu-BrE-3 with autologous stem cell support (ASCS) in patients with metastatic breast cancer. Bone Marrow Transplant 23(Suppl 1):S38, 1999. e-Pub 1999.
257. McNiece I, Jones R, Bearman S, Cagnoni P, Nieto Y, Shpall EJ. Transplantation of ex vivo expanded PBPC after high dose chemotherapy results in decreased neutropenia. Experimental Hematology 27(Suppl 1):124, 1999. e-Pub 1999.
258. McNiece I, Jones R, Bearman S, Cagnoni P, Nieto Y, Murphy J, Shpall EJ. Rapid engraftment of neutrophils using ex vivo expanded PBPC correlates with total nucleated cells and not CD34 cells. Blood 94(10 (Suppl 1)):554a, 1999. e-Pub 1999.
259. García-Carbonero I, Casado A, Martín M, López-Martín JA, Oruezábal M, Nieto Y, Alonso JL, Portugal T, Álvarez J, Díaz-Rubio E. DICEP high dose (HD-DICEP) chemotherapy with or without peripheral blood stem cell support as consolidation treatment of patients (pts) with advanced epithelial ovarian cancer (AOC). European Journal of Cancer 35(Suppl 4):S237, 1999. e-Pub 1999.
260. Shpall EJ, Quinones R, Jones R, Bearman S, Cagnoni P, Giller R, Nieto Y, McNiece I. Transplantation of cancer patients receiving high dose chemotherapy with ex vivo expanded cord blood cells. Experimental Hematology 27(Suppl 1):117, 1999. e-Pub 1999.
261. Cagnoni PJ, Ceriani RL, Cole W, Johnson T, Quaife R, Nieto Y, Matthes SM, Shpall EJ, Bearman SI, Taffs S, Peterson J, Blank E, Jones RB. High-dose radioimmunotherapy for metastatic breast cancer with 90Y-huBrE-3: A phase I study with autologous stem-cell support. Breast Cancer Research and Treatment 50(3):249, 1998. e-Pub 1998.
262. Shpall EJ, Quinones R, Hami L, Jones RB, Bearman SI, Cagnoni PJ, Giller R, Nieto Y, Roman-Unfer S, McNiece I. Transplantation of cancer patients receiving high dose chemotherapy with ex vivo expanded cord blood cells. Blood 92(10 (Suppl 1)):126a, 1998. e-Pub 1998.
263. McNiece I, Hami L, Jones RB, Bearman S, Cagnoni PJ, Nieto Y, Shpall EJ. Transplantation of ex vivo expanded PBPC after high dose chemotherapy results in decreased neutropenia. Blood 92(10 (Suppl 1)):126a, 1998. e-Pub 1998.
264. Shpall EJ, Briddell R, Hami L, Gringer A, Jones RB, Bearman SI, Cagnoni PJ, Quinones R, Giller R, Nieto Y, Roman-Unfer S, Ross M, McNiece I. Transplantation of leukemia patients receiving high dose chemotherapy with ex vivo expanded cord blood cells. Proceedings of the Annual Meeting of the American Society of Bone Marrow Transplant (ASBMT), Miami, Florida, 1998, 1998. e-Pub 1998.
265. Roman-Unfer S, Potter T, Quinones R, McNiece I, Hami L, Steele A, Stolz J, Franklin W, Cagnoni P, Bearman S, Jones R, Nieto Y, Shpall E. Ex vivo generation of dendritic cells from fresh and frozen mobilized CD34+ blood progenitor cells. Proceedings of the Annual ASBMT Meeting, Miami, FL, 1998, 1998. e-Pub 1998.
266. Casado A, Martín M, García-Carbonero I, Pérez Segura P, Alonso Romero JL, Ayala F, Nieto Y, Díaz-Rubio E. High dose DICEP chemotherapy with or without peripheral blood stem cell support as consolidation treatment in young adults with high risk Ewing’s sarcoma and primitive neuroectodermal tumors. Preliminary results. Proceedings ASCO 17:520a, 1998. e-Pub 1998.
267. Nieto Y, Cagnoni PJ, Bearman SI, Shpall EJ, Matthes SM, Dunbar SE, Jones RB. Central nervous system toxicity secondary to taxol-containing high-dose chemotherapy. Proceedings AACR 39:325a, 1998. e-Pub 1998.
268. Cagnoni PJ, Matthes SM, Baron AE, Dunbar SE, Day T, Nieto Y, Jones RB. Pharmacokinetics of BCNU in melphalan-pretreated Sprague-Dawley rats. Proceedings AACR 39:524a, 1998. e-Pub 1998.
269. Cagnoni PJ, Ceriani RL, Cole W, Johnson T, Quaife R, Nieto Y, Matthes SM, Shpall EJ, Bearman SI, Taffs S, Peterson J, Blank E, Jones RB. Phase I study of high-dose radioimmunotherapy with 90-Y-hu-BrE-3 followed by autologous stem cell support in patients with metastatic breast cancer. Proceedings of the 7th Conference on Radioimmunodetection and Radioimmunotherapy of Cancer, Princeton, New Jersey, 1998. e-Pub 1998.
270. Nieto Y, Cagnoni PJ, Xu X, Jones RB, Shpall EJ, Murphy J, Bearman SI. Predictive model for relapse after high-dose chemotherapy with peripheral blood progenitor cell support for high-risk primary breast cancer. Proceedings ASCO 17:119a, 1998. e-Pub 1998.
271. Nieto Y, Cagnoni PJ, Shpall EJ, Bearman SI, Ross M, Sedlacek S, Jones RB. High-dose chemotherapy (HDC) with autologous stem cell transplant (ASCT) for inflammatory breast cancer. Breast Cancer Research and Treatment 46(1):72, 1997. e-Pub 1997.
272. Cagnoni PJ, Nieto Y, Shpall EJ, Matthes SM, Dunbar SE, Bearman SI, Ross M, Jones RB. Pulmonary toxicity secondary to paclitaxel-containing high-dose chemotherapy. Proceedings ASCO 16:232a, 1997. e-Pub 1997.
273. Nieto Y, Cagnoni PJ, Bearman SI, Shpall EJ, Ross M, Jones RB. High-dose chemotherapy with cisplatin, cyclophosphamide and BCNU (CCB), followed by autologous hematopoietic progenitor cell support for inflammatory breast cancer. Proceedings ASCO 16:124a, 1997. e-Pub 1997.
274. López-Martín JA, Martín M, Casado A, Nieto Y, Ayala F, Alonso JL, Valero J, Portugal T, Pérez P, Díaz-Rubio E. FlexiFAC in High-Risk and Metastatic Breast Cancer: The Impact of Scheduling. Breast Cancer Research and Treatment 37(Suppl):74, 1995. e-Pub 1995.
275. López-Martín JA, Martín M, Casado A, Nieto Y, Ayala F, Alonso JL, Portugal T, Valero J, Pérez P, Díaz-Rubio E. Control of High-Dose-Chemotherapy-Induced Emesis: One More Reason for Continuing Antiemetic Research. Supportive Care in Cancer 3(5), 1995. e-Pub 1995.
276. Martín M, López-Martín JA, Casado A, Rodríguez-Lescure A, Nieto Y, Ayala F, Alonso JL, Portugal T, Valero J, Díaz-Rubio E. FlexiFAC: an active chemotherapy regimen for advanced breast cancer [Spanish]. Proceedings of the 5th Congress of the Spanish Society of Medical Oncology (SEOM), 1995. e-Pub 1995.
277. Nieto Y, Alonso JL, Casado A, González JL, Martín M, López-Martín JA, Rodríguez-Lescure A, Ayala F, Sastre J, Vidart JA, Herráiz MA, Díaz-Rubio E. A phase II study of high-dose cisplatin, bleomycin, and methotrexate (PBM) as neoadjuvant chemotherapy for bulky unresectable locally advanced squamous cervical cancer. Proceedings of the 5th International Congress on Anti-Cancer Chemotherapy, Paris, France, 1995. e-Pub 1995.
278. López-Martín JA, González JL, Portugal T, Begara F, Rodríguez-Lescure A, Ayala F, Nieto Y, Alonso JL, Valero J, Casado A, Martín M, Resel L, Díaz-Rubio E. Efficacy of M-VAC in the multimodal treatment of invasive bladder cancer. Proceedings of the 19th Congress of the European Society for Medical Oncology (ESMO),, 1994. e-Pub 1994.
279. López-Martín JA, González JL, Portugal T, Begara F, Rodríguez-Lescure A, Nieto Y, Ayala F, Valero J, Alonso JL, Casado A, Martín M, Resel L, Díaz-Rubio E. M-VAC in invasive bladder cancer: Efficacy and toxicity in the elderly. Proceedings of the 2nd International Conference on Geriatric Oncology, 1994. e-Pub 1994.
280. Palmeiro R, Martín M, González JL, Casado A, Domínguez S, Ibáñez G, Rodríguez-Lescure A, López-Martín JA, Nieto Y, Ayala F. Body mass index in relation to some risk factors of breast cancer. Proceedings of the XVI International Congress of the Union Internationale Contre le Cancer (UICC),, 1994. e-Pub 1994.
281. Martín M, Díaz-Rubio E, Casado A, López JA, Rodríguez-Lescure A, Ayala F, Nieto Y. FlexiFAC: A modified schedule for breast cancer. Proceedings ASCO 13:107a, 1994. e-Pub 1994.
282. Popat U, Jr RB, Thall P, Alousi A, Alatrash G, Bashir Q, Hosing C, Im JS, Kebriaei P, Marin D, Mehta R, Nieto Y, Olson A, Oran B, Valdez B, Qazilbash M, Champlin R, Shpall E, Andersson B. Myeloablative fractionated busulfan conditioning regimen with sorafenib for allogeneic stem cell transplant in AML: Results of a phase 1/2 study. 2025 ASCO Annual Meeting.
283. Srour S, Tannir N, Jazaeri A, Campbell M, Nieto Y, Haymaker C, Yuan Y, Salih I, Yang Y, Doppler V, Garibal J, Escande M, Yang Q, Kushner J, Koo J, Gurses S, Hong D, Fu S, Meric-Bernstam F, Naing A. Safety and efficacy of HLA-G–targeted CAR T cells (IVS-3001) in patients with advanced HLA-G–positive solid tumors: Clinical trial in progress. 2025 ASCO Annual Meeting.

Book Chapters

1. Ramdial, JL, Jankowski, ML, Nieto, Y. Hematopoietic Cell Transplantation for Germ-Cell Tumors and Other Adult Solid Tumors, 395-402, 2023.
2. Veltri, L, Nieto, Y. Hematopoietic cell transplantation for germ cell tumors and other adult solid tumors. In: Hematopoietic Cell Transplantation for Malignant Conditions. Elsevier, 279-287, 2019.
3. Nieto, Y, Shpall, E. Autologous Hematopoietic Cell Transplantation for Breast Cancer and Germ-cell Tumors. In: Thomas’ Hematopoietic Cell Transplantation: Stem Cell Transplantation. 5, 739-750, 2015.
4. Ahmed, S, Nieto, Y. Late Effects after Autologous Hematopoietic Stem Cell Transplantation. In: Blood and Marrow Transplantation Long-Term Management: Prevention and Complications. John Wiley & Sons, Ltd, 31-42, 2013.
5. Ahmed S, Nieto Y. Late Effects after Autologous Hematopoietic Stem Cell Transplantation. In: Blood and Marrow Transplantation Long-Term Management: Prevention and Complications, 31-42, 2013.
6. Nieto, Y, Shpall, E. Hematopoietic Cell Transplantation for Breast Cancer, 931-947, 2009.
7. Nieto Y, Shpall EJ. Hematopoietic Cell Transplantation for Breast Cancer. In: Thomas' hematopoietic Cell Transplantation. 4. Blackwell Publishing, 931-47, 2009.
8. Nieto Y. DNA-Binding Agents. In: Cancer Chemotherapy & Biological Response Modifiers. Annual 22. Elsevier BV, 163-203, 2005.
9. Nieto Y, Shpall EJ. Hematopoietic Progenitor Cell Transplantation for Breast Cancer. In: Stem Cell Transplantation for Hematologic Malignancies. Humana Press, 99-132, 2004.
10. Nieto Y. Pharmacodynamics of High-Dose Chemotherapy. In: Side-Effects of Cancer Chemotherapy on Gastrointestinal Tract. Kluwer Academic Publishers, 2003.
11. Nieto Y. DNA-Binding Agents. In: Cancer Chemotherapy & Biological Response Modifiers. Annual 21. Elsevier BV, 171-209, 2003.
12. Nieto Y, Jones RB. DNA-Binding Agents. In: Cancer Chemotherapy & Biological Response Modifiers. Annual 20. Elsevier BV, 197-225, 2002.
13. Nieto Y, Jones RB. DNA-Binding Agents. In: Cancer Chemotherapy & Biological Response Modifiers. Annual 19. Elseveier Science, 197-225, 2002.
14. Cagnoni PJ, Nieto Y, Jones RB. High-Dose Chemotherapy Conditioning Regimens for Autologous or Allogeneic Hematopoietic Stem Cell Transplantation Support. In: Hematopoietic Stem Cell Transplantation. Churchill Livingstone, 382-402, 2000.
15. McNiece I, Jones R, Cagnoni P, Bearman S, Nieto Y, Shpall EJ. Ex Vivo Expansion of Hematopoietic Cells. In: Cell Therapy. Springer-Verlag, 171-183, 2000.
16. Nieto Y, Shpall EJ. Ex Vivo Stem Cell Expansion. In: Hematopoietic Stem Cell Transplantation. Churchill Livingstone, 355-363, 2000.
17. Nieto Y, Shpall EJ. High-Dose Chemotherapy for Breast Cancer. In: Advances in Breast Cancer Management. Kluwer Academic Publishers, 77-114, 1999.
18. Nieto Y, Shpall EJ. Clinical Results of Autologous Bone Marrow Transplantation for Solid Tumors. In: Hematology, Basic Principles and Practice. 3rd edition. Churchill Livingstone, 1597-1609, 1999.
19. Roman-Unfer S, Cook B, Nieto Y, Shpall EJ. Negative and Positive Stem Cell Selection. In: High-Dose Cancer Therapy: Pharmacology, Hematopoietins, Stem Cells. 3rd. Lippincott Williams & Wilkins, 331-353, 1999.
20. Shpall EJ, Jones RB, Si B, Cagnoni PJ, Nieto YL, McNiece IK. Peripheral Blood Stem Cell Transplantation in Breast Cancer. In: Baillieres Best Pract Res Clin Haematol, 219-232, 1999.
21. Nieto Y. Hormonal Therapy [Spanish]. In: Guide for Prescription in Medical Oncology. 2nd. IMC, 1998.
22. Roman-Unfer S, Jones RB, Bearman SI, Cagnoni PJ, Nieto Y, Shpall EJ. Autologous Hematopoietic Progenitor Cell Transplantation. In: Cellular Support for the Oncology Patient. Fenwal Baxter, 1998.
23. Nieto Y, Cagnoni PJ, Shpall EJ. High-Dose Chemotherapy in Gynecologic Malignancies. In: Gynecologic Oncology. Kluwer Academic Publishers, 277-285, 1998.
24. Nieto Y, Shpall EJ. CD34+ Blood Stem Cell Transplantation. In: Blood Stem Cell Transplantation. Martin Dunitz Publishers, 187-201, 1998.
25. Shpall EJ, Cagnoni PJ, Bearman SI, Ross M, Nieto Y, Jones RB. Peripheral Blood Stem Cell Harvesting and CD34-Positive Cell Selection. In: Blood Stem Cell Transplantation. Kluwer Academic Publishers, 143-157, 1997.
26. Nieto Y. Narcotic Analgesic Drugs [Spanish]. In: Pain in the Cancer Patient. ELA, 1996.
27. Nieto Y, López-Martín JA. Toxicity from Chemotherapy [Spanish]. In: San Carlos University Hospital Textbook for Residents. 3rd edition, 1996.
28. Nieto Y, Ayala J. Palliative Care of the Terminally Ill Patient [Spanish]. In: San Carlos University Hospital Textbook for Residents. 3rd edition, 1996.
29. Nieto Y, Díaz-Rubio E. Hormonal Therapy [Spanish]. In: Guide for Prescription in Medical Oncology. IMC, 1995.
30. Nieto Y, Díaz-Rubio E. Treatment of Breast Cancer: Review [Spanish]. In: Health News - Madrid Health Department. Madrid Health Department, 145-159, 1994.
31. Nieto Y. High-Dose Chemotherapy: Basis and Biological Rationale for Treatment. In: Molecular Biology in Cancer. Thomson Reuters.
32. Nieto Y, Shpall E. Autologous Hematopoietic Cell Transplantation For Breast Cancer And Germ-Cell Tumors. In: Thomas’ Hematopoietic Cell Transplantation, 5th edition.

Letters to the Editor

1. Marcoux, C, Pasyar, S, Milton, D, Khan, HN, Tanner, MR, Bashir, Q, Srour, S, Saini, N, Lin, P, Ramdial, JL, Nieto, Y, Neupane, N, Lee, HC, Patel, K, Tang, G, Aljawai, YM, Kebriaei, P, Thomas, SK, Orlowski, R, Shpall, E, Champlin, RE, Qazilbash, MH, Pasvolsky, O. Impact of body mass index on outcomes of multiple myeloma patients undergoing upfront autologous stem cell transplant. British Journal of Haematology 206: 763-765, 2025.
2. Malek, A, Al-Juhaishi, T, Milton, D, Ramdial, JL, Daher, M, Olson, AL, Srour, S, Al-Atrash, G, Oran, B, Mehta, RS, Khouri, IF, Bashir, Q, Shah, N, Ciurea, SO, Rondon, G, Maadani, F, Hosing, C, Marin, D, Kebriaei, P, Rezvani, K, Nieto, Y, Anderlini, P, Alousi, AM, Faisal, MS, Qazilbash, MH, Popat, UR, Champlin, RE, Shpall, E, Mulanovich, VE, Ahmed, S. Outcomes of toxoplasmosis after allogeneic hematopoietic stem cell transplantation and the role of antimicrobial prophylaxis. Bone marrow transplantation 59: 699-704, 2024.
3. Merryman, RW, Rhoades, J, Xiong, K, Redd, R, Antel, K, An, HH, McDonough, MM, Guerrero, L, Crnjac, A, Sridhar, S, Blewett, T, Cheng, J, Dahi, PB, Nieto, Y, Joyce, R, Chen, YB, Herrera, AF, Armand, P, Murakami, MA, Adalsteinsson, VA. Comparison of whole-genome and immunoglobulin-based circulating tumor DNA assays in diffuse large B-cell lymphoma. HemaSphere 8, 2024.
4. Pasvolsky O, Saliba RM, Masood A, Mohamedi AH, Tanner MR, Bashir Q, Srour S, Saini N, Ramdial J, Nieto Y, Lee HC, Patel KK, Kebriaei P, Thomas SK, Weber DM, Orlowski RZ, Shpall EJ, Champlin RE, Qazilbash MH. Impact of gender on outcomes of patients with multiple myeloma undergoing autologous Haematopoietic stem cell transplant. Br J Haematol 201: e37-e41, 2023.
5. Jallouk AP, Gouni S, Westin J, Feng L, Mistry H, Steiner RE, James J, Noorani M, Horowitz S, Puebla-Osorio N, Fayad LE, Iyer SP, Hawkins M, Flowers CR, Ahmed S, Nastoupil LJ, Kebriaei P, Shpall EJ, Neelapu SS, Nieto Y, Strati P. Axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma patients in complete metabolic response. Haematologica 108: 1163-1167, 2023.
6. Popat UR, Andersson BS, Bassett R, Kawedia J, Valdez BC, Alousi AM, Al-Atrash G, Bashir Q, Hosing CM, Im JS, Kebriaei P, Marin D, Nieto Y, Oran B, Olson A, Qazilbash MH, Srour SA, Shpall EJ, Champlin RE, Mehta RS. Myeloablative fractionated busulfan conditioning regimen with post-transplant cyclophosphamide in HLA matched and haploidentical transplantation: results of a phase II study. Haematologica 107: 2496-2500, 2022.
7. Patel R, Ma J, Bashir Q, Delgado R, Rondon G, Popat UR, Hosing CM, Nieto Y, Kebriaei P, Alousi AM, Daher M, Mehta R, Srour S, Weber DM, Thomas SK, Lee HC, Patel KK, Orlowski RZ, Shpall ES, Champlin RE, Saini N, Qazilbash MH. Black multiple myeloma patients undergoing upfront autologous stem cell transplant have similar survival outcomes compared to Whites: A propensity-score matched analysis. Am J Hematol 96: E455-E457, 2021.
8. Srour SA, Milton DR, Bashir Q, Nieto Y, Saini N, Daher M, Ramdial J, Im J, Hosing C, Delgado R, Manasanch E, Lee HC, Thomas S, Kaufman G, Patel K, Popat U, Weber D, Orlowski R, Shpall E, Champlin RE, Qazilbash MH. Melphalan dose intensity for autologous stem cell transplantation in multiple myeloma. Haematologica 106: 3211-3214, 2021.
9. Manasanch EE, Berrios D, Fountain E, Claussen CM, Chuang T, Kaufman G, Amini B, Bashir Q, Nieto Y, Qazilbash M, Patel K, Thomas SK, Weber DM, Berkova Z, Toruner G, Lin P, Feng L, Lee HC, Orlowski RZ, Kunacheewa C. Gene expression profiling predicts relapse-free and overall survival in newly diagnosed myeloma patients treated with novel therapies. Br J Haematol 192: e115-e120, 2021.
10. Saini N, Marin D, Ledesma C, Delgado R, Rondon G, Popat UR, Bashir Q, Hosing CM, Nieto Y, Alousi AM, Qazilbash MH, Ciurea S, Shpall E, Khouri I, Kantarjian H, Jabbour E, Ravandi F, Champlin RE, Kebriaei P. Impact of TKI's post-allogeneic transplant in Philadelphia positive acute lymphoblastic leukemia. Blood 136: 1786-1789, 2020.
11. Kawedia JD, Handy VW, Shigle TL, Gulbis AM, Nieto Y, Andersson BS. Letter to the Editor Regarding "Harmonization of Busulfan Plasma Exposure Unit (BPEU): A Community-Initiated Consensus Statement". Biol Blood Marrow Transplant 26: e232-e234, 2020.
12. Saini NY, Patel RD, Varma A, Bashir Q, Delgado R, Rondon G, Mukherjee A, Popat U, Hosing C, Nieto Y, Kebriaei P, Weber DM, Thomas SK, Lee HC, Manasanch EE, Orlowski RZ, Champlin RE, Qazilbash MH, Patel KK. Outcomes of autologous stem cell transplantation in Waldenström's macroglobulinemia. Ann Hematol 98: 2233-2235, 2019.
13. Saini NY, Patel RD, Varma A, Bashir Q, Delgado R, Rondon G, Popat U, Hosing C, Nieto Y, Kebriaei P, Weber DM, Thomas SK, Lee HC, Manasanch EE, Orlowski RZ, Champlin RE, Qazilbash MH, Patel KK. Long-term durable efficacy of autologous stem cell transplantation in POEMS syndrome. Am J Hematol 94: E72-E74, 2019.
14. Saini NY, Patel R, Varma A, Bashir Q, Delgado R, Rondon G, Popat UR, Hosing CM, Nieto Y, Kebriaei P, Alousi AM, Ahmed S, Weber DM, Thomas SK, Lee HC, Manasanch EE, Patel KK, Orlowski RZ, Champlin RE, Qazilbash MH. Melphalan based autologous transplant in octogenarian multiple myeloma patients. Am J Hematol 94: E2-E5, 2019.
15. Strati P, Chihara D, Oki Y, Fayad LE, Fowler N, Nastoupil L, Romaguera JE, Samaniego F, Garg N, Feng L, Wesson ET, Ruben CE, Stafford MD, Nieto Y, Khouri IF, Hosing C, Horowitz SB, Kamble RT, Fanale MA. A phase I study of romidepsin and ifosfamide, carboplatin, etoposide for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma. Haematologica 103: e416-e418, 2018.
16. Oliver NT, Nieto YL, Blechacz B, Anderlini P, Ariza-Heredia E, Torres HA. Severe hepatitis C reactivation as an early complication of hematopoietic cell transplantation. Bone Marrow Transplant 52: 138-140, 2017.
17. Varma A, Saliba RM, Torres HA, Afrough A, Hosing C, Khouri IF, Nieto Y, Shah ND, Parmar S, Bashir Q, Ahmed S, Jones RB, Kebriaei P, Olson AL, Shpall EJ, Alousi AM, Qazilbash MH, Champlin RE, Popat U. Outcomes in hepatitis C virus seropositive lymphoma and myeloma patients after autologous stem cell transplantation. Bone Marrow Transplant 51: 999-1001, 2016.
18. Karuturi M, Younes A, Fayad L, Kwak L, Pro B, Shah J, Oki Y, Simien R, Liboon MJ, Hutto T, Feng L, Horowitz S, Nieto Y, Anderlini P, Alousi A, Popat U, Medeiros LJ, Miranda R, Fanale M. ICE (Ifosfamide, Carboplatin, Etoposide) with or without Bortezomib in Patients with Relapsed/Refractory Hodgkin Lymphoma: Results of a Randomized Phase II Trial. Leuk Lymphoma 57: 445-447, 2016.
19. Cornelison AM, Saliba RM, Afrough A, Dinh Y, Nieto Y, Bashir Q, Shah N, Parmar S, Hosing C, Popat U, Shpall E, Champlin R, Qazilbash MH. Autologous hematopoietic stem cell transplantation in light chain amyloidosis (AL) with renal involvement. Bone Marrow Transplant 51: 307-309, 2016.
20. Shah N, Thall PF, Fox PS, Bashir Q, Shah JJ, Parmar S, Lin P, Kebriaei P, Nieto Y, Popat UR, Hosing CM, Cornelison A, Shpall EJ, Orlowski RZ, Champlin RE, Qazilbash MH. Phase I/II trial of lenalidomide and high dose melphalan with autologous stem cell transplantation for relapsed myeloma. Leukemia 29: 1945-8, 2015.
21. Gul Z, Bashir Q, Cremer M, Yusuf SW, Gunaydin H, Arora S, Slone S, Nieto Y, Sherwani N, Parmar S, Shah N, Dinh YT, Hosing CM, Popat UR, Kebriaei P, Shpall EJ, Giralt SA, Champlin RE, Qazilbash MH. Short-term Cardiac Toxicity of Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma. Leuk Lymphoma 56: 533-535, 2015.
22. Robertson, KB, Barron, MA, Nieto, Y. West Nile virus infection in bone marrow transplant patients. Bone marrow transplantation 34: 823-824, 2004.
23. Nieto Y, Cagnoni PJ, Jones RB. Standard versus High-Dose Therapy in 10+ Breast Cancer. Journal of Clinical Oncology 16: 810, 1998.
24. Nieto Y, Cagnoni P, Jones R, Garcia-Carbonero R, Paz-Ares L, Colomer R, Cortes-Fumes H. Standard versus high-dose therapy in 10+ breast cancer. Journal of Clinical Oncology 16: 810-811, 1998.
25. Alonso JL, Nieto Y, López JA, Martín M, Díaz-Rubio E. Ifosfamide Encephalopathy and Methylene-Blue: A Case Report. Annals of Oncology 7: 643-644, 1996.